

MANAGEMENT REPORT

January-December 2023

Annual Report according to IFRS

Report Date: 31.12.2023

Name of the trading company: ANTIBIOTICE S.A.

Head Office:

Iasi, 1 Valea Lupului St.

Phone number:

0232/209000, Fax 0232/209633

Fiscal registration code:

RO 1973096

Order number in the Trade Register:

J22/285/1991

Regulated market on which the issued securities are traded:

Bucharest Stock Exchange

Subscribed and paid up capital:

67,133,804 LEI

Main characteristics of the securities issued by the company:

Nominative shares, nominal value: 0.10 LEI

Contents

- Antibiotice in 2023 3
- Antibiotice, Romanian tradition and continuity..... 4
- Antibiotice, a profitable company for investors i..... 4
 - Pillar 1: Strategic adaptation of human resources..... 7
 - Implementation of modern human resources management 8
 - Modernization of organizational culture **Error! Bookmark not defined.**
 - Pillar 2: Strategic adaptation of the product portfolio 11
 - Research-Development, an ongoing concern 14
 - In-licensing activity..... 16
 - Promotion activity..... **Error! Bookmark not defined.**
 - Pillar 3: Business sustainability through the continuous improvement of the Integrated Management System (quality, environment, occupational health and safety) 17
 - Pillar 4: Performance management 19
 - Strengthening the domestic business **Error! Bookmark not defined.**
 - Expanding the business internationally in the ATB territories and other territories..... 22
 - Price - a strategic element..... 23
 - Management of financial flows and operational expenses **Error! Bookmark not defined.**
 - Applying the principles of business consolidation **Error! Bookmark not defined.**
 - Investments – a support for the future..... 33
 - Pillar 5: Improvement of the Corporate Governance Systems 35
- Antibiotice, a company involved in a sustainable development of the community..... 41

Antibiotice in 2023

- Net turnover increased by 25% compared to the previous year in the domestic and international markets;
- Net turnover in the domestic market increased by 29% compared to the previous year, strengthening our company's profitability in terms of structure;
- Net turnover in the foreign market increased by 18% compared to the previous year;
- In Romania, Antibiotice is the leader in terms of quantity (indivisible units) in the total market on the following pharmaceutical forms: ointments (20.7%), suppositories and pessaries (35.8%) and powders for injection (57.0%) and the leader in terms of value on the segments of generic prescription medicines and non-RX medicines sold in hospitals, with a 14.0% market share.
- Our company recorded a 81.09 milioane lei net;
- The value of the share increased from 0.57 lei on January 1, 2023 to 1.39 lei on December 31, 2023;
- Our company attracted non-reimbursable funds amounting to 85 million lei for a production facility that produces sterile products, solutions and topicals;
- A co-financing in value of 4.1 million lei was obtained for developing a green energy production facility;
- Our company signed a financing agreement, in the form of a loan granted through the InvestEU facility, for implementing the Investment Program of Antibiotice SA, parte of the Business Plan "The Future Together";
- Total investments in value of 98.05 million lei for consolidating and strategically developing our business.

Antibiotice, Romanian tradition and continuity

Antibiotice is the most important manufacturer of generic medicines with Romanian capital, unique producer of active substances biosynthetically processed, with a 68-year experience in the pharmaceutical industry.

Our company's portfolio comprises 168 products from 11 therapeutic classes, consisting both of prescription-only medicines as well as of non-prescription medicines, food supplements, dermatocosmetics, medical devices, veterinary medicinal products, biocides, active substances and biofertilizers.

Antibiotice has its own production facility organized in 3 manufacturing divisions: Topical Products Division, Solid Oral Products Division, Sterile Products & APIs Division, including 8 flows for: sterile penicillin powders for injection; penicillin capsules; non-beta lactam capsules; cephalosporin capsules; tablets; ointments, creams, gels; suppositories; pessaries; active substances obtained by biosynthesis. Antibiotice S.A. concluded also manufacturing contracts with ten partner sites.

Our company holds internationally recognized certifications and authorizations: authorizations granted by the Food and Drug Administration (the US drug regulatory agency) for Nystatin and for injectable penicillins, Certificate of Suitability with European Pharmacopoeia (CEP) for Nystatin, Good Manufacturing Practice (GMP) for all the manufacturing flows, Good Laboratory Practice (GLP) Certificate and Good Clinical Practice (GCP) Certificate for the Center for Clinical Studies, WHO prequalification and WHO certification for the range of essential antituberculosis medicines.

Antibiotice, a profitable company for investors

Since 1997, the shares issued by Antibiotice have been listed in the PREMIUM category of the Bucharest Stock Exchange (BVB), under the ATB symbol.

The first transaction was recorded on April 16, 1997, at a reference price of 0.3500 LEI/share.

Currently, in the Bucharest Stock Exchange market, the Antibiotice shares are included in the following stock indices:

- BET-Plus which includes the Romanian companies listed on the BVB market that meet the minimum selection criteria on liquidity and value of the shares included in free float, except for financial investment companies;
- BET-BK (since 18.09.2023) used as a benchmark by fund managers, but also by other institutional investors and calculated as a weighted price index with the free-float capitalization of the most traded companies listed on the BVB regulated market.

Starting with December 4, 2023, the Antibiotice (ATB) shares have been included in the MSCI Frontier IMI si MSCI Romania IMI (Investable Market Indices), in the category Small Cap. With the inclusion of Antibiotice SA in these indices, Romania's presence increases from 22 to 23 companies in the MSCI Frontier IMI and MSCI Romania IMI indices.

In 2023, the minimum price of the ATB share had the value of 0.5400 LEI and increased up to maximum value of 1.5500 LEI/share.




During 2023, a number of 49,531,258 shares were traded, in value of 41.12 million lei (8.3 million EURO, 8.95 million USD), with an average price of 0.8301 lei/share.



Stock market capitalization of Antibiotice on December 31, 2023 was 936,517 thousand lei.



Antibiotice Shareholding - 31.12.2023



Ownership breakdown:

- Legal persons - 86.7086 %
- Natural persons - 13.2914 %

Antibiotice S.A. shares - (ATB)/Regular Market

	2019	2020	2021	2022	2023
Number of shares	671,338,040	671,338,040	671,338,040	671,338,040	671,338,040
Stock market capitalization (thousand LEI)*	341,040	326,270	406,831	379,977	936,517
Stock market capitalization (thousand EUR)*	71,370	66,935	82,211	76,803	188,260
Stock market capitalization (thousand \$)*	79,873	82,163	93,022	81,987	208,309
Valoare totala tranzactionata (milioane lei)	15	14	44	8	41
Total traded value (million LEI)	30,364,292	27,085,005	80,534,368	14,651,742	49,531,258
Opening price (LEI/share)	0.4800	0.5120	0.4940	0.6060	0.5660
Maximum price (LEI/share)	0.5260	0.5550	0.6080	0.6100	1.5500
Minimum price (LEI/share)	0.4500	0.4130	0.4800	0.4800	0.5400
Price at the end of the period (LEI/share)	0.5080	0.4860	0.6060	0.5660	1.3950
Average price (LEI/share)	0.4851	0.5079	0.5913	0.5408	0.8301
Earnings/share (LEI/share)***	0.0459	0.0418	0.0446	0.0574	0.1214
Gros dividend/share (LEI/share)**	0.029879738	0.00330631	0.0031980923	0.00792224	0.045842443
Dividend yield****	6.2%	6.5%	0.65%	1.31%	8.1%
Dividend distribution rate*****	65%	8.4%	7.2%	13.8%	37.8%

* Calculation based on the share price in the last trading day of that year

** Proposed dividend

*** Calculation of the earnings per share is based on the net profit of each year

**** Dividend per share/price of the share in the first trading day of each year

***** Dividend distribution rate = (total number of shares x gross dividend per share/total net profit)

During 2023 a number of 49,531,258 shares in value of 41,116,948.60 million lei (8,288,763.40 million EURO, 8,949,596.51 million USD) were traded, with an average price of 0.8301 lei/share.

In 2023, our company paid dividends for the financial years 2019, 2020, 2021 and 2022, in value of 4,617,419.12 lei, as follows:

Dividend history 2019 - 2020- 2021-2022

Period	Net dividends							
	Due	Paid				Unclaimed dividends 31.12.2023		Date on which the payment of dividends ceases
		Lei			% (total paid)	lei	%	
		Until 31.12.2022	01.01 ÷ 31.12.2023	Total				
0	1	2	3	4	5	6	7=6/1	8
2019	19,811,039.75	18,214,252.34	13,552.12	18,227,804.36	92.01	1,583,235.39	7.99	20.09.2023
2020	2,208,009.98	2,020,069.54	3,238.65	2,023,308.19	91.63	184,702.23	8.37	Payment in progress
2021	2,136,257.01	1,949,195.32	4,908.57	1,954,103.89	91.47	182,153.11	8.53	Payment in progress
2022	5,025,047.00	-	4,595,719.78	4,595,719.78	91.46	429,327.22	8.54	Payment in progress

Payment of the dividends for the fiscal years 2019, 2020, 2021 and 2022 has been made through the Central Depository Bucharest and, implicitly, through the CEC Bank - the Paying Agent. Dividends are available to the shareholders for the entire payment period, they are recognized by the legislation as income, after the approval of the shareholders.

The activity of Antibiotice S.A. is guided by the following principles:

- principle of strategic planning;
- principle of identifying the activities by operating divisions: Oral Solid Products Division, Sterile Products & APIs Division, Topical Products Division;
- principle of good governance and performance management;
- principle of budget decentralization.

The main management and organization tool of our company for the period 2023-2030 is the **"Business Plan - The Future Together"**, approved by the Management Board.

The actions carries out during 2023, based on each supporting pillar of the **"Business Plan - The Future Together"**, i.e.:

- Pillar 1: Strategic adaptation of human resources;
- Pillar 2: Strategic adaptation of the produc portfolio;
- Pillar 3: Business sustainability through a continuous improvement of the Integrated Management System (Quality, Environment, Occupational Health and Safety);
- Pillar 4: Performance management;
- Pillar 5: Improving the Corporate Governance Systems.

have led to results that create the conditions for achieving the company's long-term planned objectives.

Pillar 1: Strategic adaptation of human resources

In 2023, strategic adaptation of human resources consisted in developing and implementing strategies to motivate and retain valuable employees and strategies to

attract new employees with skills adapted to the pharmaceutical industry, in line with the labor market trends.

In carrying out these steps, we aimed at ensuring qualified staff and developing policies to motivate our employees and create a work environment that fosters performance and competitiveness.

The main objectives, included in the Business Plan, are:

- improving staff retention;
- monitoring and supporting performance as part of our company's development strategy;
- conducting training programs for developing employees' skills.

Performance indicators for each pillar	UM	2023		
		Planned	Achieved	Achievement degree
Average number of hours of continuing professional training / employee	no. of hours	40	43,62	109.05%
Average number of employees / year	No. of employees	1350	1352	99.85%
Work productivity*	thousand lei	422	466	110.42%
Sustainability policies**		100%	100%	100%

* determined as operational income/average number of employees;

**ensuring diversity in the organizational climate - equal opportunities, gender, health status assessment of employees.

Implementing the modern human resource management

- Analysis and redefinition of organizational structures in our company, adapted to modern human resources principles, correlated with the need for business growth in the period 2025-2030, as well as with the market trends or other legal regulations.

In April 2023, in order to achieve an optimal internal organizational structure, the following actions were implemented:

- Setting of the **Executive Unit "Strategic Planning & Performance Management"**;
- Setting of the **Executive Unit "Research-Development & Portfolio Management"**.

- Adaptation of motivational packages in order to attract and retain valuable employees (key positions) and increase the degree of retention.

In 2023, salary increases were granted in relation to the inflation rate. Through a dynamic increase in wages, Antibiotice SA aims to align itself with the increasing trends of the average net income both nationally and especially in the pharmaceutical industry and to reach the targets of the Business Plan „The Future Together”.

From the perspective of the fiscal facilities provided in the current legislation, the motivational system is grouped by elements, as follows:

- Up to 33% of the employee's basic salary - facility granted: private health insurance;

In 2023, the number of health insurance packages was extended from 250 to 580 (41% of the staff) considering the following eligibility criteria:

- the specific working conditions, according to the provisions of the Collective Labour Contract;
- persons with rare professions difficult to be formed and recruited on the labor market;
- inclusion in the categories of strategic staff.
- The 5% limit granted for social expenses from the value of the staff expenses: staff transport, social allowances for family events, prizes awarded on legal holidays.

Employee retention rate was 95.83% in 2023, similar to the level recorded last year.

- Management of the professional career of employees and succession plans/staff reserves
During 2023, essential actions were taken for creating the succession plan and identifying the staff reserve according to the potential determined by the annual evaluation of the employees' performances.
- Carrying out training programs and developing employees' skills
For 2023, an average number of 40 hours of professional training/employee was planned, with 43.62 hours/employee being achieved, including training hours in areas where there are legal training requirements, with internal lecturers, with external suppliers and on the e-Learning platform.
The 2023 Annual Training Plan for developing the skills of employees with external suppliers was part of the project **Academy a+** and was adapted to the training requests and needs identified for activity structures and employees.
- Promoting the platform **Academy a+** as a management tool for knowledge management in the company.
Academy a+ has two components: Technical College a+ and Business School a+.
Specific actions:
 - ✓ **Collaboration with the university environment** materialized in 2023 through:
 - concluding collaboration protocols with 5 academic institutions from Iasi: Alexandru Ioan Cuza University, University of Medicine and Pharmacy Grigore T. Popa, Gheorghe Asachi Technical University, Ion Ionescu de la Brad University of Life Sciences, and Petru Poni Institute;
 - running of the 8th edition of the Performa+ project - following the promotion actions organized in collaboration with the relevant faculties, 35 candidates were selected for participation from the 81 applicants. They were registered in the database for future selections for vacant positions;
 - participation in events organized for promoting our company and for guiding the young graduates in their careers.
 - ✓ **Our collaboration with the pre-university environment included:**
 - didactic visits carried out in the three editions of the "Different Week" program for a number of 500 students from theoretical and professional education;
 - collaboration contracts were initiated with three high schools in order to ensure internships for students in the 2023-2024 school year, for the following qualifications: operator in the medicine and cosmetic industry, laboratory technician, mechatronic and automation technician, mechanical maintenance and repair technician.
 - Within the **Technical College a+**:
 - following the second edition, within the program of identification and multidisciplinary professional training of those registered, 10 of the 16 participants were evaluated and employed with an employment contract for an indefinite period.

- the 3rd edition of the internship-based multidisciplinary professional identification and training program started. The program started in 2023, with 11 internship contracts, which will be completed during 2024.
- ✓ Projects to attract European funds for organizing the internships in high school and university education - our company identified the opportunity of a new call for projects to attract funds through the Management Authority for the Education and Employment Program (PEO) - "Promoting the development of high-quality, flexible tertiary study programs correlated with the requirements of the labor market - STUDENT/PUPILS INTERNSHIPS. Two projects were drafted: one for higher education and one for secondary education, their submission being established by the contracting authority in 2024.

Modernization of organizational culture

Organizational culture of our company sets the way in which employees work together, interact with clients and partners, the way in which they are motivated, involved and perceived in the pharmaceutical market. It helps to define the organization's values and objectives which can contribute to stimulating a sense of loyalty and trust among staff members. In addition, it can be used as a tool to attract and retain quality talents, as well as to help establish an attractive brand image and identity. Ultimately, having a strong company culture can lead to higher levels of productivity, improved morale and a positive work environment.

The pillars of communication within the organizational culture are:

- Pillar 1 - Antibiotice, a company worth working for - the actions carried out within this pillar aim at the loyalty, cohesion and collaboration of employees through motivation and involvement.

In 2023, the following projects were carried out: leisure and socialization workshops (Club a+ Montan, handmade workshops), workshops for the development of communication skills and feedback in each structure, the organization of year-end events: Awards to the most deserving employees based on clear evaluation criteria, participation of approximately 710 employees in an operetta performance at the Vasile Alecsandri National Theatre.

- Pillar 2 - Living healthy in a healthy company refers to the health of employees and the way it is maintained through dedicated projects.

In 2023, the projects carried out were: sports activities, actions dedicated to World Mobility Week, health monitoring program for colleagues involved in activities that require physical effort, screening program for the early detection of breast cancer, as well as healthy nutrition campaigns held through Club a+ and in the Bistro where our employees have a daily meal.

- Pillar 3 - Antibiotice, a friendly and responsible brand creates a friendly and open work environment for employees, implementing also social, environmental protection, health and education projects for the community.

The projects implemented in 2023 were: first aid courses for employees, the Friendship Relay (for our employees' children, on the occasion of June 1st), Connect with Nature - tree planting project, Donate Blood - put your soul for life, Power deeds - charitable actions to help disadvantaged people, access to the Bistro - Meal Break.

- Pillar 4 - Romanian tradition and continuity - Antibiotice believes in the concepts and values that entire generations of people have carried in the same noble mission with a Hippocratic spirit.

- Pillar 5 - Antibiotice, a company oriented towards knowledge and performance - Promotes the culture of continuous learning within the organization by providing access to online training resources, workshops and mentoring sessions to support the continuous growth of professional competencies.

Pillar 2: Strategic adaptation of product portfolio

Antibiotice has in its portfolio 168 products, from 11 therapeutic classes:

- Medicines for human use:
 - prescription medicines (Rx)
 - non-prescription medicines (OTC)
- food supplements;
- dermatocosmetics;
- medical devices,
- active substances based on biotechnologies derived from streptomycines noursei for pharmaceutical use (compacted nystatin, micronized nystatin and standard nystatin);
- medicines for veterinary use,
- biocides for surface and hand disinfection;
- biofertilizers.

Prescription medicines (Rx) are grouped by therapeutic classes (ATC1) and are intended for pathologies with increased incidence and treatment of chronic conditions.

The main therapeutic classes by which the prescription product portfolio is identified are:

- Anti-infectives dor systemic use (including the drugs intended for the treatment of tuberculosis);
- Dermatological preparations;
- Cardiovascular system;
- Digestive tract and metabolism.

NonRx products are grouped by portfolio concepts for a more efficient communication to the target audience:

- Nutriensa,
- Cold & Flu;
- Derma+;
- Quality of life (Family Health, Women's Health and Men's Health);

These include dietary supplements, medical devices, dermatocosmetics, OTCs and OTXs (Rx products with OTC behavior being released from the pharmacy without a medical prescription).

The products in our current portfolio are carefully monitored, taking actions to adapt them to national requirements and international regulations, through the analysis of therapeutic trends, medical guidelines, new effectiveness and safety studies.

Taking into account the Rx/Non-Rx classification, the sales of finished products, in 2023 versus 2022, were as follows:

Sales in the domestic + international market	Value 2022	Value 2023	Variation (2023-2022)
FINISHED PRODUCTS (Mil.LEI)			
RX	478,5	577,6	99,1
NON RX	153,6	164,1	10,4
Total	632,1	741,6	109,5

Rx products recorded in 2023 a value of 577.6 million lei, up 21% compared to 2022. Non-prescription products (non-Rx) recorded an increase of 7% compared to the previous year, thus sales amounting to 164.1 milioane lei.

As regards the sales data by division, taking into account both finished products and active substances, the following were recorded:

Sales in the domestic + international market (Mil.LEI)	Value 2022	Value 2023	Variation (2023-2022)
Sterile Products & APIs Division	320.0	378.4	58.4
Oral Solid Products Division	170.0	199.4	29.4
Topical Products Division	142.1	163.8	21.7
Total	632.1	741.6	109.5

Presentation of the product portfolio by division, at the end of 2023:

Oral Solid Products Division

The oral solid portfolio comprises **70 products**, being enriched with 5 new products in 2023:

- **Equilibra® Plus tablets**, dietary supplement under the umbrella brand Nutriensa®, a complex combination of organic magnesium and vitamin B6, which contributes to the restoration of the body's energy and normal functioning of the nervous system.
- **Remiflu® granules for oral solution in sachet**, an OTC medicine under the Cold & Flu concept, a triple combination of paracetamol, chlorpheniramine maleate and ascorbic acid, indicated for improving the main symptoms of ailments.
- **Faguria tablets**, a food supplement under the Cold & Flu concept, a combination of Manuka honey, Icelandic lichen extract, colloidal silver, panthenol and essential oils recommended for improving the symptoms of upper respiratory tract diseases.
- **Faguria spray**, a medical device under the Cold & Flu concept, a combination of Manuka honey, Icelandic lichen extract, colloidal silver, panthenol and essential oils recommended for improving the symptoms of upper respiratory tract diseases.
- **Lejer anti-gas capsules**, a medical device under the Nutriensa range, which contains simethicone, intended for abdominal and intestinal comfort.

Aiming to harness the current portfolio of **Oral Solid Products Division** in a more efficient way, by securing the planned sales and also by identifying new opportunities, our company:

- took actions with a positive impact on profitability (price repositioning, redefining of its commercial policy);
- analyzed and identified opportunities as certain markets to assimilate new products;
- made line extensions, proposed new products (to enrich some ranges containing products for the same indication);
- evaluated the internationalization potential of the products.

Compliance with legislative requirements

- prohibition of the use of titanium dioxide capsules for the food supplements - it assumed the development of the manufacturing test stage and preparation of the

notification file with the new type of capsules for the products Lejer® and Fezivit® C capsules;

- analyzes regarding falling within the established limits for nitrosamine concentrations - the analyzes were carried out according to the methods established according to the plan, and analyzes to assess the risk of the appearance of nitrosamines were also completed;
- Law no. 81/2022 which regulates the granting of commercial advantages and promotion budgets for a series of food supplements, limiting the level of advantages granted on the producer-distributor-pharmacy line.

The sales recorded by the oral solid product portfolio in 2023 amounted to **199.46 million lei**, up 17% compared to the previous year. The first 3 classes, i.e. Anti-infectives for systemic use, Cardiovascular System and Digestive Tract covered 94% of the sales value recorded by the Oral Solid Products Division. The products that supported the increases are prescription medicines: Eficef® range, Amoxicilina® range, Nolet®, Piafen®, Bisotens®.

FINISHED PRODUCTS Therapeutic class (Mil.LEI)	Value 2022	Value 2023	Variation (2023-2022)
Anti-infectives	90.0	122.2	32.2
Cardiovascular system*	36.6	37.1	0.5
Digestive tract	23.4	27.6	4.2
Total	150.0	186.9	36.9

* Including ATC code B

Topical Products Division

The Topical Products Division's portfolio includes a diversified range of products: medicines for human use, medicines for veterinary use, dermacosmetics and biocides.

Medicines for human use cover a wide range of pathologies with increased incidence and prevalence: dermatological, muscular and osteoarticular, venous, ocular, genito-urinary, digestive tract disorders and symptoms of colds and flu.

The topical product portfolio includes **58 products**. In 2023, it was enriched with 4 new topicals under the concept Derma+: an OTC medicine and 3 dermatocosmetics.

- **Zinba® ointment**, a topical anti-infective OTC medicine intended for the prevention and treatment of a wide spectrum of bacterial skin infections.
- **Tinero® AZ range contains *Cleansing foam, Moisturizing cream with sun protection factor and Treatment serum***. The new dermatocosmetics line provides a complete daily care routine and is intended to improve the symptoms of rosacea, a chronic inflammatory disease. The new line contributes to developing the dermatocosmetics portfolio, a market segment in which the Antibiotice has proposed itself to become one of the first choices among Romanian brands, until 2030.

Non-prescription topical products reinforce the Derma+ portfolio, thus ensuring a product structure adapted to the new consumption trends, to different target audiences.

The sales structure by the main therapeutic classes for this division is presented below:

FINISHED PRODUCTS Therapeutic class (Mil.LEI)	Value 2022	Value 2023	Variation (2023-2022)
Dermatological preparations	62.6	71.4	8.8
Musculoskeletal system	20.4	23.6	3.2
Antihemorrhoid preparations and venous circulation	15.9	18.6	2.7
Other classes	43.2	50.2	7.0
Total	142.1	163.8	21.7

The products that had a significant contribution to the recorded increases are Nidoflor[®], Flucinolol N, Clotrimazol, Clafen[®] Rapid, Saliform[®] range, Hemorzon[®] range, Fluxiv[®] tonic cream, Paracetamol range, Kanamicina and Zifex[®] range.

Sterile Products & APIs Division

The Sterile Products & APIs Division's portfolio has 40 products, finished products and active substances. The finished product portfolio comprises anti-infectives for systemic use, beta-lactam penicillins, cephalosporins, carbapenems, polymyxins, glycopeptides as well as reconstitution of parenteral solutions.

The important objectives of the product portfolio strategy are to consolidate the leading status in the antibacterial anti-infectives class and enrich it with therapeutically essential medicines. In this regard, the current portfolio has been expanded with 3 other anti-infective products: Vancomicina Atb[®] 500 mg, 1g powder for concentrate for infusion solution and Cefazolina Atb[®] 1g powder for injection/infusion solution.

Sales structure of the products from the portfolio of this division in 2023

FINISHED PRODUCTS Therapeutic class (Mil.LEI)	Value 2022	Value 2023	Variation (2023-2022)
Anti-infectives	242.4	291.4	49.0
Hospital solutions*	0.9	1.0	0.1
Total	243.3	292.4	49.1

* Distilled water and saline

The products with a significant contribution in sales are: Amoxiplus[®] range, Ampiplus[®] range, Cefort[®], Colistin[®], Perasin[®] range.

Development of our company's product portfolio is achieved by assimilating the products both through our own research and development activity and through in-licensing, in compliance with the therapeutic trends and the company's development strategy.

Research-development, an ongoing concern

Antibiotice has a modern Research-Development Center whose main objective is to develop medicines, food supplements, medical devices and dermacosmetics.

Complexity of research and development activities determines the multi-year development of new product and/or product update projects for internationalization.

In 2023, the Research-Development Center carried out new product development projects for the three divisions of the company, on the following therapeutic classes:

dermatology, genitourinary system, anti-infectives, digestive tract, central nervous system and musculoskeletal system.

Considering the multi-year specificity of research and development projects, in 2023, our research specialists continued 24 projects started in the previous year and initiated 16 new projects. A number of 8 projects were completed in 2023 and handed over to the department responsible for authorizing/notifying them.

The research projects will develop the portfolios of our company's divisions, as follows:

Topical Products Division:

- 13 projects started in 2022 continued in the reporting period: 6 dermatocosmetics, 4 medical devices, 2 OTCs and 1 Rx. The technological transfers to the manufacturing site were carried out for 4 dermatocosmetics and for 1 medical device in order to prepare the commercial batches of these products.
- In the second half of 2023, 10 projects for topical products were started: 6 dermatocosmetics and 4 sterile topicals.

Proiectele de produse topice sterile fac parte din proiectul „Capacitatea de productie, ambalare si depozitare produse sterile, solutii si topice”, proiect care are ca obiectiv consolidarea pozitiei Antibiotice SA pe piata genericelor, prin diversificarea portofoliului de produse topice sterile.

The projects of sterile topical products are part of the project "Production, packaging and storage facility for sterile products, solutions and topicals", whose objective is to strengthen the position of Antibiotice SA in the generics market by diversifying the sterile topicals portfolio.

The estimated sales value for these products between 2024-2026 is 47 million lei.

Oral Solid Products Division:

- 9 projects started in 2022 continued in the reporting period: 7 products in the form of tablets (2 Rx, 1 OTC and 4 food supplements) and 2 products in the form of capsules (1 Rx and 1 food supplement).
- In 2023, the development actions for three projects in the food supplements category were completed, with a view to their notification.
- During the year, 3 other new product projects in the food supplements category were substantiated. Two of these projects started in the first half of 2023, and the third one started in the third quarter of the year.

The estimated sales value between 2024-2026 for the products belonging to the Oral Solid Products Division under development is 30 million lei.

Sterile Products and APIs Division:

- 2 projects started in 2022 continued in the reporting period: both of them are prescription medicines : 1 injectable product and 1 suspension for oral use;
- The estimated sales value for these products is 49 million lei between 2024-2026.

- In the second half of 2023, our specialists initiated the first 3 projects for developing new products such as sterile injectable solutions (prescription medicines, Rx), these being part of the project "Production, packaging and storage facility for sterile products, solutions and topicals", a project whose objective is to strengthen the position of Antibiotice SA in the generics market by diversifying the sterile product portfolio with injectable solutions.

As an integral part of the Research & Development Center, the Clinical Studies Center carried out in 2023 clinical studies stages for the products from the portfolios of the following divisions:

- Oral Solid Products Division - bioequivalence study stages for 3 new Rx products;
- Topical Products Division - clinical study stages for 2 topical products, studies required in the international authorization process, of which:
 - a. a new Rx product; pharmaceutical form: pessaries;
 - b. one product having a MA in Romania (OTC), proposed for internationalization; pharmaceutical form: cream.

A third, observational, post-marketing study for a prescription product from the Topical Products Division, has been in progress, with the aim of supporting its promotion among medical specialists.

In 2023, a clinical bioequivalence study was carried out for a solid oral product with prolonged release for a partner from Greece, based on a collaboration contract. The study will be completed in the first half of 2024.

In parallel with the studies mentioned above, taking into account the requirements of the regulatory authorities in the pharma field at national and international level, in the Research laboratories, activities were carried out to determine nitrosamine impurities for the products in the company's portfolio, these analyzes being necessary to maintain the marketing authorizations.

In 2023, development stages of new analytical methods for the active substance Nystatin were completed, which come to support the quality of this product and implicitly to strengthen the company's position in the world market of this active substance.

Efficacy studies for ecological biofertilizers were carried out in the field. In parallel with the experimentation in the field, a research project has been carried out in collaboration with the "Ion Ionescu de la Brad" University of Life Sciences, which aims to determine the characteristics of these two products. These actions will support the positioning of the products in the market of biofertilizers.

In-licensing activity

To complete the portfolio, according to the strategies established by the Business Plan "The Future Together", in 2023, our company concluded partnerships for 28 products, in the following structure:

- ✓ 20 products for human use, from the following therapeutic classes:
 - 10 anti-infectives
 - 3 cardiovasculars
 - 4 products for digestive tract and metabolism
 - 1 product for cold & flu
 - 1 product for nervous system
 - 1 product from the genitourinary system and sexual hormones class
- ✓ 8 products for veterinary use intended for pets (dogs and cats) that will go on sale in the first quarter of 2024 under the VetAria+ brand.

Out of the 28 contracted products, 15 products will be launched in the market in 2024.

Promotional activity

Promotion of the products from our company's portfolio aims at increasing and consolidating the brands' awareness and targets both health professionals and general public.

Communication to health professionals aims to strengthen partnerships with them, identify prescription habits and treatment practices, as well as access alternative promotion channels.

In 2023, we communicated to health professionals through direct promotion visits made by the team of medical representatives and also through participation in national congresses and conferences. These events were organized by the main Romanian professional, academic and scientific societies and associations of the following medical specialties: Anesthesia and Intensive Care, Infectious diseases, Cardiology, Dermatology, Obstetrics-Gynecology, Urology, Otorhinolaryngology, Gastroenterology, Pneumology, Family Medicine and Pharmacy.

The promotional actions focused mainly on promoting the products newly assimilated in the portfolio, along with actions aimed at consolidating the market shares of the products from the company's portfolio.

Communication to the general public

In order to develop our portfolio and increase the brands' awareness, we carried out integrated media communication campaigns to the general public.

Media campaigns strengthen our partnerships with the main distributors for the purchase of products and ensures the distribution of the products in an extensive number of pharmacies, boosting the purchase of products.

The integrated communication campaigns to the general public run through the TV, radio and social media channels.

The TV campaigns were carried out for the following brands: Silithor[®], Clafen[®] rapid, Simbiflora[®] range. Radio campaigns promoted the products of the Nutriensa range (Equilibra[®], Fluxiv[®], Imunofix[®], Lejer[®], Silithor[®], Simbiflora[®] range, Soriso[®], Sprinten[®]) and Clafen[®] rapid. Online promotion was carried out through the dedicated websites (Nutriensa, Cutaden Bebe, Tiner), Facebook pages (Nutriensa, Cutaden Bebe, Tiner), Instagram (Nutriensa, Cutaden Bebe, Tiner), Tik Tok (Tiner). To inform potential consumers about the four new products, Tiner[®] AZ range and Zinba[®], communication actions were carried out in pharmacies and online.

The 36 products promoted in 2023 recorded sales by 15% higher than in the previous year.

Pillar 3: Business sustainability through the continuous improvement of the Integrated Management System (quality, environment, occupational health and safety)

Internationally certified quality

In 2023:

- the National Agency for Medicines and Medical Devices of Romania conducted an inspection for GCP-GLP recertifying the Bioanalytical Laboratory within the Clinical Studies Center (25-27.01.2023).
- Antibiotice SA received from the National Agency for Medicines and Medical Devices of Romania the approval to operate as a distributor of medical devices.
- Antibiotice SA received from the National Agency for Medicines and Medical Devices of Romania the approval for registering the company as a manufacturer, importer and distributor of active substances which will be used as raw materials for medicines for human use.
- The National Veterinary Sanitary & Food Safety Authority conducted an inspection for Good Manufacturing Practice recertifying the following manufacturing

flows: sterile veterinary products (injectables and ointments) and non-sterile veterinary products - ointments (27-28.02.2023).

- TÜV Rheinland Romania conducted the surveillance audit 1 regarding the certification of the Integrated Management System, ISO 9001, ISO 14001, ISO 45001 (04-05.12.2023).
- The National Environmental Guard - CJ Iasi carried out an inspection (29.09 - 16.10.2023) to verify the compliance with the provisions of the Integrated Environmental Authorization. An inspection Report was concluded and the measures established following the previous controls were carried out. No violations of the applicable legal requirements were found.

In August 2023, Annex 1 to the (EU) GMP guideline entered into force, which provides for new regulations regarding the manufacture of medicines. Antibiotice started a series of activities to comply with the new requirements imposed by this guideline.

Audits were carried out at the suppliers of raw materials/primary packaging materials/finished products which ended without the identification of critical non-conformities, being accepted as authorized suppliers for Antibiotice.

50 quality agreements were initiated, evaluated or completed with the manufacturers of active substances, finished products and Nystatin.

Environmental responsibility

The environmental protection activity manages the prevention of pollution and the continuous improvement of environmental performance, acting in order to comply with the requirements of the legislation.

In 2023, the Water Management Authorization no. 20/30.03.2021 issued by the Prut Barlad Water Basin Administration, as well as Integrated Environmental Authorization no. 3/29.09.2021 issued by the Iasi Environmental Protection Agency were maintained.

Quality of environmental factors (water, air, soil, groundwater)

In order to monitor the quality of environmental factors, our own laboratory and laboratories of the third parties made analyses on the quality of water entering the pre-treatment plant and discharged into the municipal sewerage system. For the emissions/imissions of pollutants in the air, determinations were made according to the requirements of the Integrated Environmental Authorization, throughout the year 2023.

No exceedances of the maximum allowed concentrations established by the Integrated Environmental Authorization and Water Management Authorization were recorded.

Antibiotice is a company responsible for environmental protection while proactively ensuring the compliance with product safety requirements. An equipment was installed and put into operation, which has the role of reducing the emissions of odors specific to the biosynthesis process (the action is in progress and its effectiveness is to be evaluated).

As regards the climate change, Antibiotice carried out a rigorous assessment of the associated risks and a detailed TCFD-compliant report was completed. (Task Force on Climate-Related Financial Disclosures (TCFD)).

Waste management

Antibiotice continuously improves the waste management system to ensure a sustainable and efficient approach. Thus, the completion of the waste warehouse contributed to reducing our impact on the environment, promoting more sustainable practices and a more efficient management of resources.

A series of measures from the Waste Management Plan were implemented in the Waste Warehouse, such as setting up selective collection areas and placing specific equipment for reducing the volume of waste.

Recyclable waste was sold based on contracts to the authorized economic operators. Non-recyclable waste was incinerated in our own installation, disposed of at the municipal waste landfill, or taken over by authorized operators.

Also, the global objectives regarding the recovery of packaging waste for the products introduced on the national market were fulfilled through the contract concluded with an authorized organization implementing extended producer liability obligations (OIREP). Our company did not register outstanding payment amounts to the Environmental Fund Administration.

Occupational Health and Safety

In order to comply with the legislative provisions on the protection of employees' health, the following were drawn up and implemented: the 2023 Prevention and Protection Plan, Annual Training Program in the field of Occupational Health and Safety, Annual Program for Periodic Medical Examination, Annual Monitoring Program for Exposure to Noxes.


There was no incident or work accident reported during the analyzed period.

Pillar 4: Performance Management

Performance management is supported by the strategic planning concept, by preparing management plans compliant with our company's activities, interconnected and monitored in order to achieve the specific and general objectives of the company.

Through the methods of strategic planning of all activities and operational monitoring, our company's management aims to follow monthly, quarterly and annually the progress made by each executive, operational or support unit.

The following presentation refers to the retail and hospitals sales in the domestic and international markets in 2023. In the portfolio structure, sales in the domestic and international market in 2023, compared to the values from the same period of the previous year, are presented as follows:



The increase in sales was based on the company's repositioning actions for the products in the portfolio, on encouraging the rational consumption, as well as on the market context, marked by an increased incidence of acute respiratory diseases, including bacterial super-infections.

In the reporting period, the sales structure was the following:

- 654 million lei - finished products, representing 88% of total sales;
- 86 million lei - active substances, representing 12% of total sales.

Business consolidation in the domestic market

Evolution of the pharmaceutical market in Romania¹

In 2023, the value of medicines released to the patients from Romania was 29.96 billion lei, higher by 16.2% compared to 2022. Consumption of medicines increased by 2.4% in 2023, a number of 722.6 million boxes being released from the pharmacies.

Evolution of the generic pharmaceutical market - prescription and non-prescription medicines

Of the total pharmaceutical market in Romania, 44.5% (in terms of value) is represented by the segment of generics, prescription and non-prescription medicines. In the analyzed period, the generics market registered a 14.0% value increase, from 11.7 billion lei to 13.3 billion lei. In terms of quantity, it increased by 1.4%, with a number of 530.0 million boxes released from pharmacies in 2023 compared to 522.7 million boxes in 2022.

Prescription drugs (Rx) represented 43.4% of total value sales in 2023 and 48.9% of total generic drug consumption (reported as number of boxes). These recorded a 18.7% increase in value, from 4.9 billion lei in 2022 to 5.8 billion lei in 2023 and a 4.8% increase in terms of quantity, from 247.1 to 259.1 million boxes in 2023.

Non-prescription drugs (non-RX) recorded a 10.7% value increase (from 6.8 billion lei to 7.5 billion lei in 2023) and dropped by 1.7% in terms of quantity, from 275.6 million boxes in 2022 to 271.0 million boxes in 2023.

By market segments, the sales situation in the market developed as follows:


- **hospital** - the sales increased by 13.3%, from 1.03 billion lei in 2022 to 1.16 billion lei in 2023. In the analyzed period, consumption increased by 9.4% from 22.8 to 25.0 million boxes;
- **national pharmacy chains** - the sales increased by 11.0%, from 4.23 billion lei in 2022 to 4.69 billion lei in 2023. In terms of quantity, a slight decline of 0.7% was recorded compared to 2022, from 196.8 million boxes in 2022 to 195.3 million boxes in 2023;
- **independent pharmacies and minichains** - the sales increased by 16.1%, from 6.43 billion lei in 2022 to 7.46 billion lei in 2023. In terms of quantity, a 2.2% increase was recorded in 2023 compared to 2022, from 303.2 to 309.8 million boxes.

Antibiotice in the Romanian pharmaceutical market ²

¹ According to the data source CEGEDIM Sell Out Romania 2023

In 2023, in the domestic market, Antibiotice:

- recorded sales in value of 522.0 million lei, higher by 17.4% compared to 2022;
- in terms of consumption (number of boxes), it ranked 4th in the segment of prescription generic medicines and non-RX (a 5.4 % market share);
- quantitative leader (IU) in the total market on the following pharmaceutical dosage forms: ointments (20.7%), suppositories and pessaries (35.8%) and powders for injection (57.0%);
- ranked 2nd, as number of boxes with capsules in the total market (9.9%);
- leader in terms of value in the segment of generic medicines, prescription and non-RX medicines sold in hospitals, with a 14.0 % market share.
- Antibiotice has consolidated its sales on the portfolio of anti-infectives for systemic use, developing also the therapeutic classes where it holds important positions in the domestic market: dermatological preparations, cardiovascular system and digestive tract.



Prescription medicines (Rx) represented 85.9% from the total value sales in 2023 and 86.3% from the total consumption of medicines (reported as number of boxes). During the analyzed period, they recorded a 20.7% value increase, from 371.6 million lei in 2022 to 448.6 million lei in 2023 and a 6.7% increase in terms of quantity, from 23.0 la 24.6 million boxes.

Non-prescription medicines (non-RX) recorded a 0.3% value increase (from 73.1 million lei in 2022 to 73.4 million lei in 2023) and a decrease in consumption from 4.4 to 3.9 million boxes.

By **market segments**, the Antibiotice sales situation presented itself as follows:

- **hospital** - the sales recorded a significant value increase of 19.9%, %, from 135.8 million lei in 2022 to 162.9 million lei in 2023. Consumption recorded in this segment as number of boxes increased slightly compared to the previous year, from 1.54 to 1.58 million boxes;

² According to the data source CEGEDIM Sell Out Romania 2023

- **national pharmacy chains** - the value sales increased by 15.2 % in 2023 compared to the previous year (from 111.5 to 128.4 million lei). The number of boxes released by pharmacies increased by 4.2%, i.e.10.0 million boxes in 2023.
- **independent pharmacies and minichains** - the value sales increased by 16.9% in 2023 compared to the previous year (from 197.4 to 230.7 million lei). The number of boxes released by pharmacies increased by 3.9% (from 16.24 to 16.88 million boxes).


In 2023, the promotion actions developed by Antibiotice led to the consolidation of the quantitative market shares for the promoted brands: Eficef® (a product ranked 1st in terms of value - part of our company's anti-infectives portfolio), Zifex Duo® pessaries and Zifex Complex® pessaries - from the class of Genitourinary products, and the brands SimbiFlora®, Lejer® and Imunofix® from the Nutriensa range.

Internationalization of business in the ATB territories and other territories

In 2023, the international sales revenues were 218.4 million lei, higher by 18% compared to the value recorded in 2022 (184.5 million lei) and by 5.5% compared to the planned sales (207 million lei).

As regards their structure, our company's revenues from the sale of finished products represented 61% of the export value:

- finished products: 132.3 million lei, higher by 20.3% compared to 2022 (109.5 million lei)
- active substances: 86.1 million lei, higher by 13,7% compared to 2022 (75.7 million lei).



The upward trend of sales of finished products was mainly determined by:

- a consolidated sales growth in the company's traditional markets: US, Vietnam, UK, Denmark, Norway and Republic of Moldova - sterile beta-lactam antibiotics;
- doubling the volumes sold, for a series of antibiotics and cardiovascular medicines in the territories where the company has representative offices and its own promotion and sales teams: Vietnam, Republic of Moldova and Serbia;
- accessing new markets in the EU (Hungary, Poland) and Georgia with a portfolio of products carefully selected according to the current and future consumption

potential of the market, selling price, the area targets set in the territorial expansion plan.

Statistical milestones, relevant for 2023:

- 92 finished products traded (SKU);
- 63% of the exported volumes of finished products were capsules and tablets;
- 30 territories where our company exported, of which 12 in the EU;

In the US, our company consolidated a 7 million USD business, by selling 6 sterile beta-lactam antibiotics, being an important supplier for the health system in this country.

The significance of Antibiotice has been growing year by year in Europe, from about 5 million Euro (2020-2021) to over 10 million Euro in 2023. Our company's presence has been constantly increasing in the traditional territories, while accessing new markets, especially in the European Union within some regional partnerships.

In the Asia area, our sales in the Vietnamese market recorded an 3% advance compared to the period January-December 2022 and reached 7 million USD by launching 3 new products for treating hypercholesterolemia and by an increased demand for oral antibiotics.


In the **Republic of Moldova**, the second territory where we have our own representative office, **we consolidated sales** of 1.3 million Euro, notable being the upward trend for the products in the focus and promotion actions of the local representative office.

The **export of active substances** based on biotechnologies derived from streptomyces noursei for pharmaceutical use followed the growth trend recorded in the recent years, consolidating the position of the active substance Nystatin in the world market.

In 2023, the sales increased by about 14% compared to the previous year, Nystatin being exported to over 55 countries. The sales aimed both at strengthening our presence in the strategic territories and at conducting development projects in various countries from Europe, North America and South America.

Price - a strategic element

In 2023, the average price in the **generic market, RX si non-RX**, was 1.19 lei/IU, up 11.3% compared to the previous year (1.07 lei/IU). In terms of sales channels, the price structure was as follows: **hospital** 5.78 lei/IU, of which the injectable products registered a price of 9.59 lei/IU, up 11.5% compared to last year. **Independent and mini-chain pharmacies (MLFI)** 1.13 lei/IU (up 11,9% compared to 2022), and **national chains** 1.08 lei/ IU (up 10.4% compared to 2022).



The average price of the **Antibiotice** portfolio in terms of international units (IU) was 1.51 lei/IU in 2023, higher by 16.0% (1.30 lei/IU in 2022).

Positioning strategy of products in the market is the starting point for the entire marketing mix, implicitly for the product and price policy. The applied market segment strategies and promotion concepts led to an efficient harness of the portfolio in the terms of structure compared to the planned average price, with a 108.8% achievement degree.

As regards the sales channels, in 2023, the price structure of the Antibiotice portfolio was as follows: **hospital** 4.74 lei/IU, from which injectable products recorded a price of 9.90 lei//IU (up +17.2% compared to the last year); **mini-chain and independent pharmacies** 1.24 lei/IU (up 14.6% compared to 2022); **chain pharmacies** 1.02 lei/IU (up 18.0% compared to 2022).

On the retail segment, the focus on the development projects of the non-Rx brands from the range Quality Life - Nutriensa generated a 13.6% increase of the average unit price compared to 2022, from 0.87 lei/IU to 0.99 lei/IU.

Development of the product range Quality Life - Cold & Flu by introducing new pharmaceutical forms: granules for oral solution in sachets (REMIFLU), oral spray (Faguria) and drops (Faguria), as well as the price increase of the products from the current portfolio led to the increase of the average unit price of the range Quality Life - Cold & Flu by +35.3%, from 0.78 lei/IU in 2022 to 1.06 Lei/ IU in 2023.

The launch of the Tinerio dermatocosmetics range, with a selling price above the portfolio average: Tinerio AZ® serum and Tinerio AZ® cream as well as price repositioning at the competition level for the products in the current portfolio led to a 6.7% increase of the average selling price of the products under the Derma+ concept, from 19.47 lei/IU in 2022 to 20.77 lei/IU in 2023.

Management of financial flows and operational expenses

The effect of all the activities carried out in 2023 is summarized in the Individual Financial Statements prepared in accordance with the International Financial Reporting Standards ("IFRS") adopted by the European Union. In 2023, our company made corrections on the retained earnings and restated the related indicators from the Individual Financial Statements of 2022.

Comprehensive Income Statement

A. Compared to the planned value of **total revenues** of 580.5 million lei, our company recorded in 2023, **total revenues** amounted to 640.73 million lei, by 10% higher than the planned value (580.5 million lei) Compared to the value achieved in 2022, they were 23% higher.

Operating income recorded a value of 629.3 million lei, by 11% higher compared to the planned value and by 23% higher than the value recorded in 2022. The favorable evolution of these revenues was determined by the positive trend of revenues from contracts with clients (turnover).

The revenues from contracts with clients (turnover) achieved in 2023 were in value of 600.78 million lei, by 7% higher than planned (560.51 million lei) and by 24% higher compared to the value recorded in 2022 (483.72 million lei).

In structura cifrei de afaceri:

- revenues from the sale of products made on our own sites represented 80%. Their value was 482.09 million lei, by 12% higher than planned (430.89 million lei) and by 24% higher compared to the value recorded in anul 2022 (387.5 million lei);
- revenues from the sale of products made on partner sites represented 19.5%. Their value was 117.38 million lei, by 9% lower than planned (129.26 million lei) and by 23% higher compared to the value recorded in 2022 (95.16 million lei).

In 2023, income included from an accounting point of view in the category of **other operating revenues** recorded a value of 1.42 million lei. Of these, 0.52 million lei represented income from the prescription, according to legal requirements, of the shareholders' right to collect the distributed dividends and 0.56 million lei represented income from the revaluation of tangible assets.

Indicators	31.12.2023	31.12.2023	31.12.2022	31.12.2022	31.12.2023/	31.12.2023/	31.12.2023/
		(planned)	(reported)	(restated)	31.12.2023	31.12.2022	31.12.2022
					(planned)	(audited)	(restated)
A. Total revenue, of which:	640,726,948	580,496,000	522,227,008	527,524,478	10%	23%	21%
1. Operating income	629,266,367	569,215,000	511,528,738	516,826,208	11%	23%	22%
1.1 Revenues from contracts with clients (turnover), of which:	600,780,825	560,512,328	483,724,186	483,724,186	7%	24%	24%
income from the sale of products made on their own websites	482,092,932	430,890,988	387,506,130	387,506,130	12%	24%	24%
income from the sale of products made on partner sites	117,383,457	129,264,340	95,160,681	95,160,681	-9%	23%	23%
Income from the provision of services	1,304,436	357,000	1,057,375	1,057,375	265%	23%	23%
1.2 Other operating revenues	1,424,282	687,500	2,033,372	7,330,842	107%	-30%	-81%
1.3 Income from subsidies	270,907	0	302,979	302,979	-11%	-11%	-11%
1.4 Changes in stocks of finished products and production in progress	13,408,502	(2,352,000)	11,689,110	11,689,110	470%	15%	15%
1.5 Income from immobilization projects	13,381,851	10,367,072	13,779,091	13,779,091	29%	-3%	-3%
2. Financial income	11,460,581	11,281,000	10,698,270	10,698,270	2%	7%	7%
Income from exchange rate differences	11,456,207	11,280,000	10,696,833	10,696,833	2%	7%	7%
Income from bank interest	4,374	1,000	1,437	1,437	337%	204%	204%
B. Total expenses, of which:	549,202,704	530,489,000	480,323,777	461,914,504	4%	14%	19%
1. Operating expenses:	532,733,136	516,550,000	465,028,352	446,619,079	3%	15%	19%
Expenses with raw materials and consumables	157,104,754	148,579,891	125,990,448	125,990,448	6%	25%	25%
Expenditure on products made on partner sites	61,063,703	64,731,374	51,126,807	51,126,807	-6%	19%	19%
Electricity expenses	13,741,049	16,084,629	11,505,725	11,505,725	-15%	19%	19%
Natural gas expenses	9,620,298	15,209,204	9,111,618	9,111,618	-37%	6%	6%
Drinking water and sewerage expenses	1,972,935	2,075,193	1,409,136	1,409,136	-5%	40%	40%
Staff costs	156,053,526	140,245,178	122,940,724	125,766,529	11%	27%	24%
Other operating expenses (*)	105,301,309	102,981,000	120,674,339	96,401,539	2%	-13%	9%
Depreciation and adjustments for the depreciation of fixed assets, net	27,875,560	26,643,531	22,269,554	25,307,276	5%	25%	10%
2. Financial expenses	16,469,567	13,939,000	15,295,425	15,295,425	18%	8%	8%
Expenses from exchange rate differences	12,323,961	10,345,000	11,704,137	11,704,137	19%	5%	5%
Bank interest expenses	4,145,607	3,594,000	3,591,288	3,591,288	15%	15%	15%
Operating result	96,533,232	52,665,000	46,500,386	70,207,129	83%	108%	37%
Financial result	(5,008,986)	(2,658,000)	(4,597,156)	(4,597,156)	88%	9%	9%
Gross profit	91,524,246	50,007,000	41,903,231	65,313,721	83%	118%	40%
Expenses with profit tax and deferred tax	10,435,650	8,009,000	3,389,803	13,841,684	30%	208%	-25%
Net profit	81,088,596	41,998,000	38,513,427	51,472,037	93%	111%	58%

Through the research-development activity carried out in 2023, **revenues of 13.2 million lei from the production of intangible assets** were recorded. The methodology was certified by an expert appointed by the Ministry of Research, Innovation and Digitization.

From the financial activity, **financial income** of 11.46 million lei was recorded in 2023, represented by income from exchange rate differences and interest income.

B. The effort made to achieve total revenues determined **total expenses** of 549.20 million lei, 4% higher compared to the planned value of 530.49 million lei and 14% higher compared to the value of 480.32 million lei recorded in 2022. The treatment of the level of some elements of expenses from 2022 determined total expenses of 462.2 million lei. In the structure of total expenses, **operational expenses** amounted to 532.73 million lei, higher than planned (516.55 million lei) and higher than the value recorded in 2022 (465.03 million lei).

Expenses with the raw materials were in value of 141.83 million lei, by 7% higher than planned, being in correlation with the production structure, adapted to meet the consumption needs of the domestic and international markets.

- **Expenses for products made on other sites** amounted to 61 million lei, by 6% lower than planned and by 19% higher compared to the value recorded in 2022, being correlated with the sales structure.

- **Expenses for electricity, natural gas, drinking water** amounted to de 25.33 million lei, lower than planned, i.e. 33.4 million lei. The favorable difference between the planned and achieved level is the result of optimizing the specific technological processes that determined a lower quantitative consumption of utilities, with a value influence of 2.4 million lei. Utility tariffs, below than estimated, determined an influence of 5.6 million lei.
- **Personnel expenses** - adaptation of the salary system and employee motivation to the labor market, structure of the professions in the company and inflation rate determined personnel expenses in the amount of 156.05 million lei (which includes the provision for the participation of employees in the profit and for unused vacations).

The structure of expenses includes **other operating expenses**, described below:

- expenses with the transport of goods and services in value of 4.2 million lei, performed for the transport of finished products free to destination, sold in the domestic and international market.
- **expenses with services performed by third parties**, in the amount of 14.14 million lei which included sales support services, drug serialization, market studies in the pharma field, equipment qualifications, equipment maintenance, customs services, physical-chemical analyzes (nitrosamine analyses), participation in congresses.
- **maintenance and repair expenses** in the amount of 2.5 million lei necessary to maintain the production equipment in optimal condition, consolidation of some constructions, maintenance and repair of the car fleet.
- **expenses with taxes and fees**, in the amount of 47.6 million lei, of which:
 - claw-back tax has a 77% share. Its value was 37 million lei, higher than planned, i.e. 34 million lei and higher than the value recorded in the previous year, i.e. 31.3 million lei, being correlated with the increased level of sales in the Romanian market. Claw back tax is regulated by GEO no. 77/2011 on the establishment of some contributions for the financing of some expenses in the field of health, paid quarterly to the State Budget for prescription drugs included in the national health programs, with or without personal contribution, used in outpatient treatment based on medical prescription through open-circuit pharmacies, for those used in hospital treatment, supported by the Unique National Health Insurance Fund and by the budget of the Ministry of Health.

Indicators	31.12.2023	31.12.2023 (planned)	31.12.2022 (reported)	31.12.2022 (restated)	31.12.2023/3 1.12.2023 (planned)	31.12.2023/ 31.12.2022 (reported)	31.12.2023/ 31.12.2022 (restated)
Shipping costs	4,199,124	4,944,010	4,171,593	4,171,593	-15%	1%	1%
Expenses with services performed by third parties	14,141,264	22,295,618	14,176,126	14,176,126	-37%	0%	0%
Repair work expenses	2,545,491	2,793,111	1,959,716	1,959,716	-9%	30%	30%
Expenses with other taxes and fees	47,588,521	39,794,138	38,256,584	38,256,584	20%	24%	24%
Protocol, advertising and publicity expenses	24,162,131	30,276,093	23,271,794	21,390,637	-20%	4%	13%
Insurance premium expenses	2,818,950	2,231,860	1,962,310	1,962,310	26%	44%	44%
Consultancy expenses	106,912	0	0	0			
Other general expenses, of which:	3,986,392	4,100,259	11,585,068	11,585,068	-3%	-66%	-66%
Professional training expenses	955,676	1,000,000	554,862	554,862	-4%	72%	72%
Representation expenses in the territories	1,039,541	1,403,359	2,496,617	2,496,617	-26%	-58%	-58%
Expenses with bank commissions	504,921	475,218	582,729	582,729	6%	-13%	-13%
Environmental protection expenses	1,485,956	1,221,682	1,124,096	1,124,096	22%	32%	32%
Losses from receivables and various debtors	0	0	4,382,606	4,382,606			
Other operating expenses	299	0	2,444,159	2,444,159			
Rent expenses	595,149	420,231	293,025	293,025	42%	103%	103%
Travel expenses	1,643,571	1,691,013	824,117	824,117	-3%	99%	99%
Expenses with post and telecommunications fees	562,380	564,573	544,524	544,524	0%	3%	3%
Expenses with sponsorships and donations	1,059,242	450,000	450,214	450,214	135%	135%	135%
Expenses with compensations, fines and penalties	5,608	20,094	25,075	25,075	-72%	-78%	-78%
Gains from the disposal of tangible and intangible assets	0		103,546	103,546			
Expenses from revaluation of fixed assets	1,459,611						
Expenses regarding the adjustment of the value of current assets	8,285,010	0	29,561,510	29,561,510		-72%	-72%
Income from the adjustment of the current assets value	7,858,047	6,600,000	9,477,775	28,747,361	19%	-17%	-73%
Expenses regarding provisional risks and expenses		4,500,000	6,679,335	3,853,530	-100%	-100%	-100%
Income from the cancellation of provisions for risks and expenses		4,500,000	3,905,130	3,905,130	-100%	-100%	-100%
Total	105,301,309	102,981,000	120,378,087	96,401,539	2%	-13%	9%

- fees for registration and maintenance of product certification at the regulatory authorities, with a 14% share;
- local taxes and fees (buildings, land, means of transport), with a 4.5% share.
- **protocol, advertising and publicity expenses** amounted to 24.2 million lei. Of these, the amount of 23.04 million lei represented expenses for advertisement and publicity, the main categories of promotion activities being:
 - promotion campaigns to the general public (TV, radio, online), which represented 45% of the total;
 - campaigns for promoting the non-Rx products in partnership with distributors that take place both through the national pharmacy chains and mini-chains and independent pharmacies, which represented 34% of the total;
 - promotion in media publications, brochures and magazines intended for the general public, making and supporting presentations produced by health professionals in scientific events, which represented 11% of the total;
 - providing product samples and personalized promotional materials (for brand promotion and communication, within the actions carried out to increase the visibility and awareness of the products, as well as for increasing the loyalty of the target audience), which represented 5.5 % of the total;

- scientific promotion/participation in congresses, which represented 1 % of the total;
- **expenses with insurance premiums** in value of 2.8 million lei, included:
 - optional insurance granted to employees based on performance criteria (28%);
 - insurance of internal and external receivables (21%);
 - insurance for vehicles in the fleet (21%);
 - insurance of products during domestic and international transport (14%);
 - civil liability insurance for the consumption of medicines by patients, mandatory for sales in the US market (8.7%).
- **professional training expenses** in the amount of 0.96 million lei, close to the budgeted level and above the value recorded in the similar period of the previous year, necessary for maintaining/improving the professional level of our employees.
- **expenses of representation in territories** in the amount of 1.04 million lei, lower compared to the planned level and the one recorded in the previous year. The sale of products in the Antibiotice territories involves concluding contracts with partners in the respective areas to manage the registration of products with the authorities and to mediate sales in the market;
- **environmental protection expenses**, in value of 1,49 million lei were represented by the values paid to the electricity supplier for the green certificates that hold the main share, as well as the environmental fees paid to the authorized suppliers for waste recycling;
- **travel expenses** amounted to 1.64 million lei, a value similar to the planned level and above the level recorded in 2022. The diverse activities carried out by our company, in line with specific legal regulations, involves traveling to the authorities, to business partners both in the country and abroad for consolidating and developing new partnerships, attending conferences and international events in the field of pharma and training courses.
- **expenses with donations and sponsorships**, in value of 1 million lei were represented by the amounts allocated to social responsibility projects in which the company has been actively involved, with a view to sustainable development.

Financial expenses recorded in 2023 amounted to 16.5 million lei (represented by expenses from exchange rate differences and interest expenses).

The combined effect of operational revenues and expenses determined a value of the **operational result** of 96.53 million lei.

Financial result - financial income correlated with the level of financial expenses generated a negative financial result of 5 million lei. The unfavorable impact is from the amount of interest expenses, the income and expenses from exchange rate differences being approximately at the same level.

Gross profit amounted to 91.52 million lei, higher than the planned level (50 million lei) and higher than the value recorded in 2022 (41.9 million lei).

Net profit amounted to 81.09 million lei, higher than the planned level (42 million lei) and than the value recorded in 2022 (38.5 million lei), a combined effect of:

- increasing the sales in the international market by accessing new territories with products that define the Antibiotice strategic portfolio;
- optimizing the sales structure of anti-infectives for systemic use and dermatological preparations in the domestic market;
- renegotiating partnerships with distributors, in each market segment - hospital, national chains, mini-chains and independent pharmacies, in order to improve market share and profitability;
- increasing the sales in an optimal structure both in the hospital and retail segments.

Statement of Financial Position

Analysis of the patrimonial asset

At the end of 2023, Antibiotice S.A. recorded assets of 1.139 million lei. The fixed assets had a 65% share while the current assets had a 35% share.

Compared to the previous year, fixed assets increased by 39%, a positive result of the investment process in 2023 and of the revaluation of fixed assets (land, buildings and special constructions) performed by an authorized third party for accounting reporting purposes.

The land and buildings are at the revaluated value (without accumulated depreciation and depreciation losses).

For the data comparability, revaluation was also carried out for the lands, buildings and special constructions in the patrimony on 31.12.2022, proceeding with the restating of the indicators from the 2022 individual financial position statement.

Investments in intangible assets (research and development projects, purchases of product licenses, software licenses) over the depreciation value, determined their increase compared to the level at the beginning of 2023. For 2022, the value of intangible fixed assets was restated by correcting the depreciation expenses for an element of intangible fixed asset.

Value of stocks registered an increase correlated with the global context that determined the extension of supply times. Stocks of raw materials, materials and finished products were correlated with the manufacturing and sales plans.

Stocks of raw materials and finished products made on our own sites and on the sites of our partners were monitored and correlated with the stock standards.

In correlation with the increase in turnover in the domestic and international markets, receivables increased. To counteract the commercial risks, the company concluded insurance policies for receivables from the domestic market and international markets. For 2022, the level of receivables was restated with the amount of adjustments for the depreciation of receivables, calculated by applying the simplified approach of IFRS 9 "Financial instruments".

Analysis of current and long-term debts

At the end of 2023, our company recorded long-term debts in the amount of 101.74 million lei, comprised of:

- balance of the loan for financing the investment activity;
- balance of subsidies for investments that will be recognized as income as the investments financed from them are amortized;

- deferred profit tax liabilities, recognized according to IAS 12, "Profit tax". The company restated the amount of deferred profit tax liabilities from 2022.

Indicators	31.12.2023	31.12.2022	31.12.2022	31.12.2023/3	31.12.2023/
	(audited)	(reported)	(restated)	1.12.2022	31.12.2022
				(reported)	(restated)
Assets					
Fixed assets					
Tangible assets	692,361,541	496,810,361	599,898,910	39%	15%
Intangible assets	45,526,698	35,795,943	32,758,221	27%	39%
Total fixed assets	737,888,239	532,606,304	632,657,131	39%	17%
Current assets					
Stocks	160,214,484	122,494,428	142,659,974	31%	12%
Trade and similar receivables	235,771,990	196,402,918	204,033,217	20%	16%
Prepaid expenses	3,489,615	3,243,331	3,243,331	8%	8%
Cash and cash equivalents	1,807,930	1,727,454	1,727,454	5%	5%
Total current assets	401,284,019	323,868,131	351,663,976	24%	14%
Total assets	1,139,172,258	856,474,435	984,321,107	33%	16%
Equity and liabilities					
Equity					
Subscribed capital	67,133,804	67,133,804	67,133,804	0%	0%
Revaluation reserves	225,417,959	111,164,239	197,758,620	103%	14%
Legal reserves and other reserves	324,877,598	305,594,766	305,594,766	6%	6%
Retained earnings	229,534,759	157,537,792	170,496,402	46%	35%
Total equity	846,964,120	641,430,601	740,983,592	32%	14%
Long-term liabilities					
Bank loans and debts	36,750,203	46,973,501	46,973,501	-22%	-22%
Subsidies for investments - non-current portion	1,586,415	1,857,322	1,857,322	-15%	-15%
Deferred tax liabilities	63,401,227	30,871,210	57,817,259	105%	10%
Total long-term liabilities	101,737,845	79,702,033	106,648,082	28%	-5%
Current liabilities					
Trade and similar liabilities	150,780,362	86,067,391	99,391,828	75%	52%
Bank loans	29,552,092	34,008,116	34,008,116	-13%	-13%
Debts from taxes and current charges	9,831,550	8,280,670	2,983,200	19%	230%
Subsidies for investments - current portion	306,289	306,289	306,289	0%	0%
Provisions		6,679,335			
Total current liabilities	190,470,293	135,341,801	136,689,433	41%	39%
Total liabilities	292,208,138	215,043,834	243,337,515	36%	20%
Total equity and liabilities	1,139,172,258	856,474,435	984,321,107	33%	16%

Current liabilities recorded a value of 190.47 million lei at the end of 2023, of which the bank loans were 29.55 million lei and included the balance of the operational credit in the amount of 18.86 million lei (by 18.7% lower compared to the level recorded at the end of the previous year) and the loan rates for financing the investment activity due within 12 months, in the amount of 10.69 million lei.

The **commercial debts** chapter includes balances of partners that were overdue.

Debts from current taxes and fees were represented by the amounts owed to the State Budget due on 25.01.2024 (the contribution to the Solidarity Fund regulated by Law no. 448/2006 regarding the protection and promotion of the rights of disabled persons, 0.14 million lei) and the clawback tax due for the fourth quarter (9.69 million lei). At the end of 2023, Antibiotice did not register outstanding obligations to the state budget.

The cash flow prepared by the indirect method was determined starting from the gross profit, corrected with the influences of non-monetary operations (depreciation, provisions, adjustments of current assets) and with the variation of the working capital elements. Our company's ability to generate cash from the operational activity emerges from its analysis, contributing to the financing of the investment process and the repayment of debts to the banks.

The overall picture of 2023, synthesized through economic and financial indicators, reflects the increase in profitability, a steady financial balance, creating the conditions for a long-term resilient business:

No.	Indicators	31.12.2023 audited	31.12.2023 planned	12/31/2022 reported	-lei- 12/31/2022 restated
1	Current assets	401,284,019	339,500,000	323,868,131	351,663,976
2	Short-term bank debts	29,552,092	32,700,000	34,008,116	34,008,116
3	Total bank debts	66,302,295	69,673,501	80,981,617	80,981,617
4	Net accounting assets (equity)	846,964,120	722,690,874	641,430,601	740,983,592
5	Current liquidity (Current assets/Short-term bank liabilities)	13.58	10.38	9.52	10.34
6	Total bank liabilities/EBITDA	0.53	0.96	0.91	0.84
7	Total bank liabilities/Equity	0.08	0.10	0.13	0.11
8	Total debts	292,208,138	200,809,126	215,043,834	243,337,515
9	Total assets	1,139,172,258	923,500,000	856,474,435	984,321,107
10	Indebtedness (Total Debts/Total Assets)	25.7%	21.7%	25.1%	24.7%
11	Earnings before interest, taxes, depreciation, and amortization (EBITDA)	124,835,756	72,709,327	89,098,327	96,276,955

The growth trend in 2023 in the domestic and international markets and the improvement of profitability led to the consolidation of the net accounting asset, its value being 846.96 million lei, higher compared to the value recorded on 31.12.2022.

Current liquidity, determined as the ratio between current assets and short-term bank liabilities, at a level of 13.58 indicates the maintenance of the short-term financial balance, being on the rise compared to the previous year. The company has the ability to honor the current obligations on account of its most liquid assets.

The **degree of indebtedness** (25.7%) reconfirms the financial autonomy of the company as a result of a responsible debt policy, adequate to the volume of activity while maintaining a satisfactory profit margin.

The total bank debts reported at the EBITDA level registered a level of 0.53, being within the parameters agreed by the financial institutions (maximum allowed level of 3.5). Also, the indicator total bank debt relative to equity registered a level of 0.08, being within the parameters agreed by the financial institutions (maximum accepted level of 1).

Applying the principles of business consolidation

The synthesis of the main diagnostic indicators recorded highlights the financial balance and continuous concern for business efficiency.

Intermediate management balances

No.	Indicators	31.12.2023 audited	31.12.2023 planned	31.12.2022 reported	-lei-			
					12/31/2022 restated	31.12.2023/3 1.12.2023 planned	31.12.2023/3 1.12.2022 reported	31.12.2023/3 1.12.2022 restated
1	Income from contracts with clients, turnover	600,780,825	560,512,327	483,724,186	483,724,186	7%	24%	24%
2	Raw material expenses	141,828,708	133,083,345	109,740,746	109,740,746	7%	29%	29%
3	Material expenses	15,276,046	15,496,655	16,249,702	16,249,702	-1%	-6%	-6%
4	Expenditure on finished products made on other sites	61,063,703	64,731,000	51,126,807	51,126,807	-6%	19%	19%
5	Gross margin	409,402,722	355,216,327	332,075,131	332,075,131	15%	23%	23%
6	Gross margin (%)	65%	62%	65.2%	65.2%	4%	0%	0%
7	Added value	330,793,331	253,752,009	259,211,240	261,092,397	30%	28%	27%
8	Operating result (EBIT)	96,533,232	52,665,000	46,500,386	69,910,878	83%	108%	38%
9	Financial result	-5,008,986	-2,658,000	-4,597,156	-4,597,156	88%	9%	9%
10	Pre-profit tax	91,524,246	50,007,000	41,903,230	65,313,721	83%	118%	40%
11	Current and deferred income tax expenses	10,435,650	8,009,000	3,389,803	13,841,684	30%	208%	-25%
12	Net result	81,088,596	41,998,000	38,513,427	51,472,037	93%	111%	58%
13	Earnings before interest, taxes, depreciation, and amortization (EBITDA)	124,835,756	72,709,000	89,098,327	96,276,955	72%	40%	30%

Gross margin reflects the performance of the company's sales and production activity. This indicator is superior both to the similar period of the previous year and compared to the planned value due to the efficient correlation of production, sales and stock levels, as well as due to making the purchases of raw materials and consumables more efficient.

The added value indicator reflects what the company adds to the economic circuit through its own activity. The activity carried out during the reference period led to a value by 30% higher than the planned one and by 28% higher compared to the value of the previous year.

EBITDA, which reflects profit before interest, taxes, depreciation and amortization, showed an upward trend.

Investments - a support for the future

In 2023 our company made investments amounting to **98.05 million lei**. The recorded value exceeded the planned value, by supplementing the budget for the 2023 Investment Program, from 77.80 million lei to 99.02 million lei. The addition of 21.21 million lei was substantiated by the replanning of some investment objectives from 2024 in 2023, because the investment objective „Production, packaging and storage facility for sterile products, solutions and topicals”, was approved through the state aid scheme established by GD 807/2014. The value of this investment amounted to 200 million lei.

I. Investments for strategic development, respectively investments for developing the product portfolio

The new product development program aims to expand the portfolio and ensure competitive pharmaceutical products for the national and foreign markets.

1. Development of the product portfolio, in value of 16.60 million lei

In 2023, our company continued investments in research and development projects in order to obtain new, quality, safe, efficient and competitive products. The Research-Development Center carried out new product development projects for the three divisions, on the following therapeutic classes: dermatology (29%), genitourinary

system (23%), anti-infectives (19%), digestive tract (13%), central nervous system (10%) and musculoskeletal system (10%). We continued also the projects for developing the product portfolio through cooperation with international partners.

2. Investments in new production sites

The contracting procedure was started for the design and execution of 3 new manufacturing flow. Se estimeaza incheierea contractelor de proiectare si executie in primul semestrul al anului 2024. The design and execution contracts are estimated to be concluded in the first semester of 2024.

II. Investments for business consolidation

In 2023 we made investments of **81.45 million lei** for consolidating our business.

1. Investments in information technology, telecommunications and digitization of processes, in value of 8.31 million lei

Within the digitization and computerization plan, Antibiotice prioritized the acquisition of software for making more efficient the activities in the fields of human resources, quality assurance, research, but also for securing data and information throughout the company. Also, in 2023, the feasibility stage was completed for an ERP system that will be implemented in 2024.

2. Adapting the infrastructures for the utilities supply and distribution, storage of raw materials and finished products, transport and connection to the national road system to the development trends of the industrial site, in the amount of 51.42 million lei

In 2023, the expansion of the existing storage capacity of raw materials was completed, in the perspective of increasing and diversifying production. Also, our company signed the contract and started the construction of a warehouse for modern finished products, adapted to cope with the estimated production until 2030. Stages of the projects for modernizing the utilities production and distribution facilities were scheduled.

Implementing "green energy" projects and reducing utilities consumption represent important components. Thus, a photovoltaic plant with an installed power of 3.7 MWh started to be implemented. Contracts were signed and the condensate recovery projects were executed. Lighting systems were replaced by modern LED systems.

3. Investments in the Integrated Management System (Quality, Environment, Sustainability, Occupational Health and Safety), worth 10.77 million lei
The increased accuracy of laboratory analysis methods and revision of monographs from pharmacopoeias required investments in equipment for maintaining the quality standards of manufactured products and complying with legal requirements to protect the environment and employees.

4. Investments for modernizing the existing sites and equipment, worth 10.95 million lei

In order to upgrade the medicine manufacturing flows in the three divisions, in 2023 we followed the required procedures for the purchase of equipment, installations and laboratory equipment.

Attracting financing sources for investments

The state aid for financing new production and storage capacities

On May 17, 2023, following the call for projects financed by GD 807/2014 for the establishment of state aid schemes aimed at stimulating investments with a major impact on the economy, Antibiotice SA obtained the agreement for financing the project „The production, packaging and storage facility for sterile products, solutions and

topicals”. The total value of the project is 200.1 million lei, of which the state aid is worth 85 million lei. This investment is part of the Business Plan „The Future Together”.

Financing the green energy production

On June 06, 2023, Antibiotice SA obtained from the Ministry of European Projects and Investments a financing through the National Recovery and Resilience Plan (PNRR) for the "2.5 MW PHOTOVOLTAIC PLANT". The approved financing was 4 million lei.

Consulting grant awarded by the European Investment Bank

Antibiotice SA benefits from the expertise of the European Investment Bank (EIB) in the process of planning the future strategy for 2030. In April 2023, our company signed the consulting agreement in the form of a grant, which is to be implemented by the EIB through its own experts.

Financing agreement with the European Investment Bank

In November 2023, our company signed a financing agreement in the form of a loan granted through the InvestEU facility, for achieving the Investment Program of Antibiotice SA, part of the Business Plan „The Future Together”.

Pillar 5: Improving the Corporate Governance System

Antibiotice SA is a public company, which complies with the Government Emergency Ordinance (GEO) no. 109/2011 on the corporate governance of public enterprises. Management of the company is organized to meet the expectations of shareholders in terms of competitiveness, profitability and long-term value generation. A well-defined, traceable decision-making system is ensured and the delegation of attributions and competences are made in proportion to the prerogatives granted and the existing control system.

The basic pillars of the corporate governance system of Antibiotice SA can be found on the company's website at <https://www.antibiotice.ro/investitori-php/corporate-governance/>. These are the following:

- Corporate Governance Code
- Code of Ethics
- General Meeting of Shareholders
- Management Board
- Advisory Committees
- Executive Management
- Internal audit, Inventory Financial Control and Risk Management

Corporate Governance Code

The good governance practices in the company are based on the Corporate Governance Code which outlines the general framework of the Management Board's activity and is an important tool for obtaining sustainable performance, ensuring the accuracy and transparency of the company's decision-making process, through equal access of all shareholders to the relevant information about Antibiotice SA. Built according to the principles and recommendations of the Corporate Governance Code of the Bucharest Stock Exchange (BVB), the Corporate Governance Code of Antibiotice approved by the Management Board in January 2017 and updated in November 2021, includes, among other things, information about the responsibilities of management

structures, justa reward and motivation, relations with investors, risk management system and internal control.

Code of Ethics

Antibiotice's Code of Ethics is the basis of an organizational culture that meets the integrity standards and complies with the specific legislation in force. Integrity, professionalism, responsibility and transparency are the fundamental ethical values assumed by our company. Any violation of the Code of Ethics is considered an ethical incident, failure to comply with the Code of Ethics may lead to disciplinary sanctions. Compliance with the provisions of the Code of Ethics is mandatory for all structures in the company's organizational chart (employees, executive management and Management Board members). The Code of Ethics is made known to every new employee or administrator and can be consulted online.

General Meeting of Shareholders

General Meeting of Shareholders represents the highest decision-making body of our company, where shareholders participate directly and take decisions on the distribution of profit, election of the members of the Management Board, appointment of the financial auditor and setting of the remuneration for the Management Board members.

In 2023, the Management Board convened three Ordinary General Meetings and two Extraordinary General Meetings, the decisions of which can be found on the company's website at: <https://www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/>

Management Board

The Management Board of Antibiotice SA is responsible for the good governance of the company, being the highest form of management (with the exception of the decisions made by the General Meeting of Shareholders, as provided by law). The duties of the Management Board are described in our company's Articles of Association and in the relevant internal regulations, available on the company's website, in the Corporate Governance section.

During 2023, the President of the Management Board convened 11 meetings of the Management Board in which the results obtained in implementing the strategy according to the business plan, performance criteria and income and expenses budget were analyzed.

The Management Board of ANTIBIOTICE S.A. can be found at the web address <https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/>

Advisory Committees

The Management Board exercises a part of its responsibilities through the three advisory committees: Nomination and Remuneration Committee, Audit Committee, Commercial Policy Committee. Starting with 18.10.2023, the Risk Management Committee replaced the Commercial Policy Committee. The specialized advisory committees carry out investigations, analyses, elaborate recommendations and periodically submit reports on their activity to the Management Board.

The Advisory Committees can be found at the address <https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/>

The duties and responsibilities of the advisory committees can be found on the company's website at: <https://www.antibiotice.ro/en/investors/corporate-governance/documente-de-guvernanta/>

Executive management

Antibiotice S.A. is represented by the General Director, according to the prerogatives established by law and the company's Articles of Association. The Management Board has the authority to represent the company in relations with the appointed directors.

The management team a Antibiotice S.A., on 31.12.2023 can be consulted at: <https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/>

Risk Management

The risk management process in our company meets the legal and regulatory requirements in force for identifying, evaluating, managing and reporting the risks arising from all its activities.

The main goal is to identify the risks to which the organization is exposed, so that they can be anticipated and managed without affecting the efficient fulfillment of the organization's objectives.

Antibiotice objectives on risk management:

- to understand the risks to which our company is exposed as well as their general and specific causes;
- to improve the risk profile of our company by managing the process of identifying, evaluating and managing risks and by implementing the control measures needed to maintain exposure to risk within the tolerable area.

The responsibilities related to risk management are fulfilled by the Risk Management Department together with the risk officers and Antibiotice employees.

Specific risks were identified in each organizational structure within Antibiotice S.A. The Risk Management Department annually analyzes and prioritizes the significant risks which may affect the achievement of the general objectives, by establishing the risk profile and tolerance limit, approved by the company's management. This department prepares also the "Plan for implementing the measures to control the significant risks in the company".

The cyclical review of the main risks involves an assessment of their likelihood of occurrence and their potential consequences in order to confirm the level of exposure and evaluate the strategies for managing them.

The Internal Audit Office carries out an annual risk management assessment, making recommendations for improvement, where necessary, and the findings are presented to the Audit Committee.

In 2021, the General Risk Register was prepared and approved, with the aim of minimizing the significant risks with an impact on the objectives, to which the company is exposed. Relevant risks were synthesized according to their magnitude using impact and probability.

Antibiotice SA is exposed to a variety of risks specific to the pharma industry, including: business risks (economic, legislative, generated by partners), financial risks (currency, liquidity, interest rate, commercial), legislative risks, operational risks (personnel, IT and information security), integrity risks, cyber risks, occupational health and safety risks, environmental risks, and last but not least, the risks generated by climate change.

Business risk represents the possibility that an event or an action will negatively affect the company's ability to fulfill its assumed objectives or proposed strategies. Geopolitical and macroeconomic aspects; increase in the inflation rate; energy crisis; interruptions in the supply chain; raw materials crisis; increase in the price of raw materials due to the reduction in the number of producers, implementation of the European GMP requirements, application of the environmental policy; increase in the price of energy and methane gas; increase in transport costs; the change of conditions on the local market (decrease in consumption, decrease in prices, entry of new competitors), are just a few circumstances of the emergence of business risks.

Among the measures that can mitigate these risks, the following measures were considered: renegotiation of prices and contracts; development on regulated markets (US, Europe) that have high price levels; commercial relations with several suppliers; authorization of at least one more source of raw materials where it is economically justified; meetings with partners to secure the source while maintaining a constant and proactive contact with them; informing partners regarding the organization of production in campaigns to reduce costs, manufacturing times and revision period; correlation of the quarterly purchase plan with the production plan; creation of safety stocks for certain raw materials.

Financial risks reflect the impact that financial sources and/or resources have on the company: liquidity risk, currency risk, interest rate risk, commercial (non-payment) risk. Circumstances favorable to the emergence of financial risks: fiscal unpredictability (clawback tax); increase in the inflation rate; increase in the prices of raw materials and utilities; fluctuation of the currency exchange rate which is reflected both in the costs of imported raw materials and in the prices of finished products for export; increase in the monetary policy interest rate; increase of the ROBOR index.

To reduce the impact of financial risks, a series of measures were taken, such as: optimizing the rotation speed of the distribution stocks, ensuring demand for the products from the Antibiotice portfolio and improving the collection period of receivables from distributors, improving relations with our suppliers; organizing a rigorous management of costs in the company to identify measures to optimize and reduce them; ensuring an optimal balance of receipts and external payments; coverage of external payments from receipts from abroad through a permanent analysis of receipts and payments, so as to achieve the best possible correlation between the currency and time of payment/collection; reducing the value used from operational credits, reducing the level of crediting to an optimal level for covering the temporary gap between the receipts and the mandatory payments to be made; permanent analysis

of the structure of assets and liabilities to determine the dependence on interest rate changes.

Legislative risks

Pharmaceutical market is a regulated market, with clear legislative requirements elaborated for controlling the quality and therapeutic efficiency of the medicines present in the market and for avoiding counterfeiting.

Our effort for complying with these provisions is reflected in additional costs related to updating the documentation, and complying with the latest quality standards.

Our company's strategy of managing these risks involves a permanent concern for obtaining international certifications for the manufacturing flows, updating the authorization documentation for the products in the portfolio, continuous monitoring of international legislative changes, constantly adapting our policies, rules and procedures to the all these changes.

Operational risk is the risk of loss that results either from the use of some inadequate processes, persons or internal systems that did not perform their function properly, or from external events such as those arising from legal and regulatory requirements and from generally accepted standards regarding organizational behavior.

Operational risks can materialize in equipment failures, human errors, faulty operational processes which can lead to unplanned shutdowns.

Our company constantly monitors the operational risks in order to take measures to maintain them at an acceptable level that does not threaten its financial stability, interests of creditors, shareholders, employees, partners.

Human Resources risks

The lack on the labor market of candidates properly trained in the pharmaceutical field; loss of specialists due to retirements but also due to voluntary departures, establishment of new companies in the pharmaceutical field which attract the existing staff; labor migration due to socio-economic conditions, impossibility of rewarding performance at the level of some competitors; restrictive regulations regarding the increase of the salary budget, are just a few circumstances of the occurrence of human resources risks.

Among the measures to reduce the impact generated by this risk, we mention: the search for internal training solutions through assigned mentors; continuation and expansion of collaboration programs with university institutions; scholarships and practice opportunities; implementation of professional training projects for employment; permanent analysis of the organizational climate, identification of financial and non-financial motivation opportunities to keep the staff in the organization; implementation of projects for the management of career plans; improvement of the system of compensations and benefits to increase the attractiveness of the employer brand.

Failure to comply with the law which could have a negative impact on the environment and the company's reputation.

In order to monitor the risk, a series of measures were taken such as: maintaining and improving the environmental management system according to ISO 14001 and carrying out internal audits for verifying the compliance with the requirements of the standard; compliance with operating procedures; staff training; compliance with the maintenance program, monitoring the legislative changes and harmonizing them with the existing ones; preparation and reaction in emergency situations.

The risks arising from climate change represent one of the most important global challenges today. Antibiotice focuses on evaluating the company's potential vulnerabilities to climate change, impact on the environment and mitigation actions that will ensure a transition to a low-carbon emissions environment. In acest sens Antibiotice carried out a rigorous assessment of the associated risks and the detailed report according to the Task Force on Climate-Related Financial Disclosures (TCFD) was completed.

Cyber Risk Management

Antibiotice S.A. is classified as an operator of essential services in the national economy and has the obligation to comply with the national strategy on the security of networks and IT systems, according to the Law no. 362/2018 on ensuring a high common level of network and IT systems. An important component of corporate governance is cyber threat risk management to which the set of rules on the security of the IT system is added for compliance with the legal requirements. Continuous monitoring of internal IT infrastructure highlights any missing or inadequate protection and defense measure, allowing security teams to implement the necessary mitigation controls and prioritize risk remediation.

During 2023, 23 system procedures were developed and are being implemented. These procedures regulate the way in which the company works and ensures the cyber security according to the requirements of the National Cyber Security Directorate, the national authority with attributions in monitoring the way the Law no. 362 of December 28, 2018 on ensuring a high common level of security of network and information systems ("NIS Law") is applied.

Integrity Risk Management

Antibiotice has adhered to the National Anti-Corruption Strategy 2016-2020 and 2021-2025, having an organizational integrity agenda in accordance with the GD no. 1269/2021 on the approval of the National Anti-Corruption Strategy.

Our company's Integrity Plan includes measures to prevent and combat acts of corruption and procedures to ensure ethics and integrity in all its activities.

During 2023, no integrity incidents were recorded.

In 2023, the procedure for receiving, examining and solving reports on violations of the law was developed and implemented, drawn up according to the provisions of Law no. 361/2022 on the protection of public interest whistleblowers. According to this procedure, any employee as well as any of the administrators, shareholders, volunteers, interns or persons who work under the supervision or management of the trading company, hereinafter referred to as whistleblowers in the public interest, who have obtained or know information regarding possible cases of violations of the laws in the company or made by it have the right to report it to the company's Ethics and Integrity Board.

In 2023, no reports regarding possible violations of the law were registered in the commercial company.

Following the entry into force of Law no. 202/2002, on equal opportunities and treatment between men and women, our company developed and implemented the policy in the field of workplace harassment and equal opportunities. This way, Antibiotice undertakes to provide a safe environment for its employees based on the principle of exclusion from discrimination on any basis.

During 2023, there were no incidents of discrimination against employees on any topic.

Antibiotice - a company involved in the sustainable development of the community

Antibiotice is involved in promoting the growth and development of the community in which it operates, being actively engaged in projects that meet its needs, investing funds for a positive impact.

The main directions of involving in the community are centered around four pillars:

- health
- education
- environment
- social matters

Health

„Donate blood! Put your soul to life!”

Over 140 Antibiotice employees donated blood in the two editions of the campaign "Donate blood! Put your soul for life!", organized in April and October 2023, by the *Antibiotice - Science and Soul* Foundation, in partnership with the Regional Blood Transfusion Center (CRTS) Iasi.

"Treat antibiotics with care for a care-free future!"

On the occasion of the World Antimicrobial Awareness Week (WAAW) from November 18-24, 2023, Antibiotice supported international initiatives and ran the information campaign *"Treat antibiotics with care for a care-free future!"*. The campaign started with training sessions on good practices in administration intended for medical and pharmacist students from five university centers (Iasi, Bucuresti, Cluj-Napoca, Oradea and Timisoara) and included training sessions for resident doctors from Iasi and Bucharest, actions and information campaigns addressed to the general public were held.

"Plus for Life"

Antibiotice recognizes the critical importance of first aid training in saving lives, and health education plays a vital role in increasing the chances of survival before professional medical help arrives. In a remarkable initiative, 100 Antibiotice employees and their children participated in the fourth edition of the first aid course that took place between October 30-31, 2023 in the Sports Hall of Club a+.

"Health Cup at Club a+"

On the occasion of World Health Day, Club a+ organized the first edition of the Health Cup between April 7-9, 2023. For three days, Antibiotice employees exercised, learned about how to feed themselves when practicing sports so that, at the end, they could all be counted among the winners.

Education

„Science and Soul Scholarships"

Now in its 22nd edition, the "Science and Soul Scholarships" is the longest involvement program run by the *"Antibiotice - Science and Soul"* Foundation. Through this initiative, Antibiotice actively collaborates with the "Pro Ruralis" Association to provide valuable support for five deserving students from rural areas every year.

Environment

"We plant oxygen in the community"

On March 31, 2023, 150 Antibiotice employees planted 600 maples and poplars in the western area of our company's industrial site. The activity took place within the fourth edition of the project *"We plant oxygen in the community"* in order to expand the green area on the Antibiotice site.

"Give an hour for Earth. Connect with nature!"

On Saturday, March 25, 2023, on the occasion of Earth Hour, between 20:30 and 21:30, Antibiotice symbolically turned off the lights, in the thirteenth consecutive participation of the company in this action.

"European Mobility Week"

Antibiotice actively participated in the European Mobility Week, held between September 16-22, 2023. About 50 Antibiotice employees participated in the internal campaign entitled "By car sharing, nature wins" choosing to leave their cars at home and opt for car-sharing instead.

The first campaign to collect expired medicines carried out by Antibiotice

Between October 27 and November 3, 2023, our company carried out the internal campaign to collect expired medicines "Be responsible, don't treat the environment with medicines!". At the end of the campaign, 95 kg of expired medicines were collected from our company's employees. Launched on the National Day of Sustainability on October 27, the project aimed to raise our employees' awareness on the importance of proper collection of expired medicines.

Social area/matters

"The power of deed", an Easter charity program

The *"Antibiotice - Science and Soul"* Foundation started the "Power of Deed" initiative, through which 100 vulnerable elderly people from the city of Iasi and Miroslava commune, received packages with traditional Easter products from the volunteers of the *"Antibiotice - Science and Soul"* Foundation. Also, within the *"Respect for the elderly"* program, whose beneficiaries are former employees of Antibiotice, currently retired with advanced age and in poor health, the Foundation offered, on the occasion of the holidays, help for 50 people who worked "a life" in Antibiotice.

Magic and fun for children in the Friendship Park a+

In 2023, on the occasion of International Children's Day, the Friendship Park a+ in the vicinity of the Antibiotice became a place of fun, good cheer and party for 150 children of employees and from the community.

Antibiotice, partner at the INIMO 2023 Festival

Antibiotice supported as a partner, the INIMO Festival 2023 which took place between August 18-20, 2023 in Iasi. The purpose of the event was to raise funds for 10,000 children without material possibilities in order to prepare for school.

"Give from the heart! Be Santa Claus"

100 children from needy families felt the joy and emotion of Christmas during the 11th edition of the project "Give from the heart! Be Santa Claus" organized on December 19, 2023 at the Antibiotice headquarters.

Also, during this festive period, 100 retired people, former Antibiotice employees, received food packages from Antibiotice as part of the 4-year-old project, "Respect for the Elderly".

In 2023, Antibiotice S.A.:

- achieved a turnover amounting to 600.78 million lei, higher by 24% compared to the value recorded in 2022 (483.72 million lei);
- recorded a gross profitability in value of 91.52 million lei, a result of the measures applied in 2023 for increasing the sales and for managing operational and financial expenses.
- recorded a level of indebtedness of 26% by optimizing collections and reducing the terms of collection of receivables in the pharmaceutical market with a favorable effect in reducing credits for financing the working capital, simultaneously with reducing the commercial debts and, implicitly, the total debts.

This report is elaborated on the basis of the data from the individual financial statements prepared in accordance with the International Financial Reporting Standards, which were submitted, according to the legal requirements, to the statutory audit carried out by S.C. Deloitte Audit S.R.L.

General Director,
Ioan NANI, Economist

Executive Financial Director,
Paula COMAN, Economist

The state of compliance with the provisions of the new Corporate Governance Code of BVB ¹ on December 31 2023	Compliance YES / NO	
Section A - Responsibilities		
<p>A.1. All the companies must have an internal regulation of the Council that includes terms of reference/responsibilities of the Council and the key management functions of the company, and which applies, among other things, the General Principles of this Section.</p>	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/
<p>A.2. The provisions for managing conflicts of interest should be included in the Council Regulation.</p>	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/
<p>A.3. The Council must consist of at least five members.</p>	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/
<p>A.4. Most members of the Council must not have executive functions. In the case of Premium Category companies, not less than two non-executive members of the Council must be independent. Each independent member of the Council shall make a declaration at the time of his nomination for election or re-election and when any change of his status occurs, indicating the elements on the basis of which he is considered to be independent in terms of his character and judgment.</p>	YES	The Administrative Board has four independent members
<p>A.5. Other relatively permanent commitments and professional obligations of a member of the Board, including executive and non-executive positions in the Board of Nonprofit Companies should be disclosed to shareholders and potential investors prior to the nomination and during their term of office.</p>	YES	https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/
<p>A.6. Any member of the Council must provide to the Council information on any report with a shareholder directly or indirectly owning shares representing more than 5% of all voting rights.</p>	YES	https://www.antibiotice.ro/en/news-release-and-current-reports/
<p>A.7. The company must designate a secretary of the Council responsible for supporting the work of the Council.</p>	YES	
<p>A.8. The statement concerning the Corporate Governance provides information whether an evaluation of the Council has taken place under the chairmanship of the President or the nomination committee and, if so, will summarize the key measures and the resulting changes. The society must have a</p>	YES	Fulfillment of performance criteria and objectives for the year.

policy/guidance on the Council's assessment of the scope, criteria and frequency of the assessment process.		
The state of compliance with the provisions of the new Corporate Governance Code of BVB ¹ on December 31 2023	Compliance YES / NO	
A.9. The statement concerning the Corporate Governance should contain information on the number of the Council and committee meetings over the past year, the administrators' participation (in person and in their absence) and a report by the Council and committees upon their activities.	YES	https://www.antibiotice.ro/en/investors/financial-information/annual-reports/
A.10. The corporate governance statement should include information on the exact number of independent members of the Council.	YES	The Administrative Board has four independent members
A.11. The Board of the Premium Companies must establish a nomination committee made up of non-executive members, who will direct the nomination procedure of new members to the Council and will make recommendations to the Council. Most members of the nomination committee must be independent.	YES	https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/
Section B - The Risk management and internal control system		
B.1. The Council should set up an audit committee in which at least one member should be a non-executive and independent. In the case of Premium Category companies, the audit committee must be composed of at least three members and the majority of the members of the audit committee must be independent.	YES	https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/
B.2. The chairman of the audit committee must be an independent non-executive member.	YES	
B.3. Within its responsibilities, the audit committee must carry out an annual assessment of the internal control system.	YES	
B.4. The assessment should take into account the effectiveness and coverage of the internal audit function, the degree of adequacy of the risk management and internal control reports submitted to the Council's audit committee, the promptness and effectiveness with which the executive management addresses the deficiencies or weaknesses identified in the audit Internal and the submission of relevant reports to the Council.	YES	

The state of compliance with the provisions of the new Corporate Governance Code of BVB ¹ on December 31 2023	Compliance YES / NO	
B.5. The Audit committee should assess the conflicts of interest in relation to the transactions of the company and its subsidiaries with the affiliated parties.	YES	
B.6. The audit committee must assess the effectiveness of the internal control system and the risk management system.	YES	
B.7. The Audit Committee should monitor the application of the general standards and the generally accepted legal standards and internal audit standards. The audit committee must receive and assess the internal audit team reports.	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reports/
B.8. Whenever the Code mentions reports or analyzes initiated by the Audit Committee, they must be followed by periodic reports (at least annually) or ad hoc reports to be submitted to the Council.	YES	https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/
B.9. No shareholder may be granted preferential treatment over other shareholders in connection with transactions and agreements concluded between the company and shareholders and their affiliates.	YES	https://www.antibiotice.ro/en/investors/financial-information/annual-reports/
B.10. The Council should adopt a policy to ensure that any company transaction with any of the companies with which it has close relationships with a value equal to or greater than 5% of the company's net assets (according to the latest financial report) is approved by the Council following a mandatory opinion of the audit committee.	YES	https://www.antibiotice.ro/wp-content/uploads/2015/06/Corporate-Governance-Code-1.pdf
B.11. The internal audits should be performed by a separate structural division (internal audit department) within the company or by hiring an independent third party.	YES	https://www.antibiotice.ro/wp-content/uploads/2015/06/Corporate-Governance-Code-1.pdf
B.12. In order to ensure the main functions of the internal audit department, it must report functionally to the Council through the audit committee. For administrative purposes and within the management's responsibility to monitor and mitigate risks, it must report directly to the General Director.	YES	https://www.antibiotice.ro/wp-content/uploads/2015/06/Corporate-Governance-Code-1.pdf
Section C - Fair reward and motivation		

The state of compliance with the provisions of the new Corporate Governance Code of BVB ¹ on December 31 2023	Compliance YES / NO	
<p>C.1. The company must publish the remuneration policy on its website and include a statement on the implementation of the remuneration policy in the annual report during the annual period which is subject of the analysis. Any essential change occurred in the remuneration policy must be published in a timely manner on the company's website.</p>	YES	www.antibiotice.ro/wp-content/uploads/2015/06/THE-REMUNERATION-POLICY-1.pdf
Section D - Adding value through investor relations		
<p>D.1. The company must organize an Investor Relations Service - indicating to the general public the responsible person(s) or the organizational unit. In addition to the information required by the law, the company must include on its website a section dedicated to Investor Relations, in Romanian and English, with all the relevant information of interest to investors, including:</p> <p>D.1.1. The main corporate regulations: the constitutive act, the procedures regarding the general meetings of shareholders;</p> <p>D.1.2. The professional CVs of members of the company's management bodies, other professional commitments of the Board members, including the executive and non-executive positions in boards of directors in companies or non-profit institutions;</p> <p>D.1.3. The current reports and periodic reports (quarterly, half-yearly and annual);</p> <p>D.1.4. Information concerning the general meetings of shareholders;</p> <p>D.1.5. Information concerning corporate events;</p> <p>D.1.6. The names and contact details of a person who will be able to provide relevant information upon request;</p> <p>D.1.7. The company presentations (e.g., investor presentations, quarterly results presentations, etc.), the financial situations (quarterly, half-yearly, annual), audit reports and annual reports.</p>	YES	<p>https://www.antibiotice.ro/en/contact-for-investor-relations/</p> <p>https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/</p> <p>https://www.antibiotice.ro/en/investors/corporate-governance/governance-structure/</p> <p>https://www.antibiotice.ro/en/investors/financial-information/financial-reporting/</p> <p>https://www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/</p> <p>https://www.antibiotice.ro/en/investors/financial-information/meeting-with-investors/</p> <p>https://www.antibiotice.ro/en/presentations/</p> <p>https://www.antibiotice.ro/en/investors/financial-information/</p>
<p>D.2. The company will have a policy on the annual distribution of dividends or other benefits to shareholders. The principles of the</p>	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/

annual distribution policy to shareholders will be published on the company's website.		
The state of compliance with the provisions of the new Corporate Governance Code of BVB ¹ on December 31 2023	Compliance YES / NO	
D.3. The company will adopt a policy regarding the forecasts, whether they are made public or not. The forecasting policy will be published on the company's website.	YES	https://www.antibiotice.ro/en/investors/corporate-governance/reference-documents/
D.4. The rules of general shareholders' meetings should not limit the participation of shareholders to general meetings and the exercise of their rights. The changes to the rules will enter into force at the earliest, starting with the following shareholders meeting.	YES	https://www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/
D.5. The external auditors will be present at the general shareholders' meeting when their reports are presented at these meetings.	YES	
D.6. The Board will provide the annual general meeting of shareholders with a brief assessment of the internal control and risk management systems as well as opinions on matters subject to the decision of the general meeting.	YES	https://www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/
D.7. Any specialist, consultant, expert, or financial analyst may attend the shareholders' meeting on the basis of a prior invitation from the Board. The accredited journalists may also participate in the general meeting of shareholders, unless the President of the Council decides otherwise.	YES	
D.8. The quarterly and half-yearly financial reports will include both Romanian and English information concerning the key factors that affect the changes in sales, the operating profit, the net profit and other relevant financial indicators from quarter to quarter, and from one year to another.	YES	https://www.antibiotice.ro/en/investors/financial-information/
D.9. A company will hold at least two meetings/teleconferences with analysts and investors each year. The information presented on these occasions will be published in the Investor Relations section of the company's website at the dates of the meetings/teleconferences.	YES	https://www.antibiotice.ro/en/investors/financial-information/meeting-with-investors/
D.10. If a company supports different forms of artistic and cultural expression, sporting activities, educational or scientific activities	YES	https://www.antibiotice.ro/en/responsibility/

and considers that their impact upon the innovative character and the competitiveness of the company is part of its mission and development strategy, it will publish the policy on the activity in this area.



ANTIBIOTICE S.A.

INDIVIDUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED ON DECEMBER 31, 2023

**prepared in accordance with
the International Financial Reporting Standards (“IFRS”)
adopted by the European Union**

INDEPENDENT AUDITOR'S REPORT

To ANTIBIOTICE S.A. shareholders

Report on the audit of Individual Financial Statements

Opinion

1. We audited the individual financial statements of Antibiotice S.A. ("The Company"), with its registered office in Iași, 1 Valea Lupului St., identified by the tax identification number RO1973096, comprising the financial position statement as of December 31, 2023 and statement of comprehensive income, statement of changes in equity and cash flow statement for the financial year ended on this date as well as notes to the individual financial statements that include material information on the accounting policies.
2. The individual financial statements as of December 31, 2023 are identified as follows:

• Net assets/ Total equity:	846,964,120 Lei
• Net profit of the fiscal year:	81,088,596 Lei
3. In our opinion, the attached individual financial statements give a true and fair view, in all material respects, of the financial position of the Company on December 31, 2023, as well as of its financial performance and cash flows for the fiscal year ended on the above-mentioned date in accordance with the Order of the Minister of Public Finance (OMPF) no. 2844/2016 for approving the Accounting Regulations in accordance with the International Financial Reporting Standards, with the subsequent amendments.

Basis for opinion

4. We conducted our audit in accordance with International Standards on Auditing ("ISA"), Regulation (EU) no. 537 of the European Parliament and of the Council (hereinafter referred to as the "Regulation") and Law no. 162/2017 on the statutory audit of annual financial statements and annual consolidated financial statements and amending some normative acts (hereinafter referred to as "Law 162/2017"). Our responsibilities under these standards are described in detail in our report section "Auditor's responsibilities in an audit of financial statements". We are independent of the Company, according to the International Code of Ethics for Professional Accountants issued by the Ethics Committee of the International Federation of Accountants (including the International Independence Standards) (IESBA code), according to the ethical requirements that are relevant for the audit of financial statements in Romania, including the Regulation and Law 162/2017, and we fulfilled our ethical responsibilities according to these requirements and according to the IESBA Code. We believe that the audit evidence we obtained is sufficient and appropriate to provide a basis for our opinion.

Other matters

5. The Antibiotice S.A.'s financial statements for the year ended December 31, 2022 were audited by another auditor who issued an unmodified opinion on those statements on March 17, 2023.

Highlighting some matters

6. As described in Note 23, during 2023 the Company restated the financial statements for 2022. Our opinion is not modified in respect of this matter.

Key audit matters

7. Key audit matters are those matters that, based on our professional judgment, were of greatest importance to the audit of the individual financial statements of the current period. These matters were addressed in the context of the audit of the individual financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key matters	How our audit addressed the key matter
<p>Revenue recognition, including discounts granted</p> <p>The revenues generated from the sale of finished products and traded goods represent the Company's core activity.</p> <p>Recognition of revenues resulting from the sale of finished products and goods depends on the appropriate assessment of the amount of the contractual counterperformance, including discounts granted in some sales transactions and their registration in the period to which they refer, in accordance with the commercial clauses of the contracts with customers.</p> <p>We believe that revenue recognition is a significant audit area, as the Company's management may incorrectly account the revenue from the sale of finished products and goods due to the nature of the sales transactions and contractual clauses regarding the manner and date when control over the sold goods is transferred.</p> <p>In addition, revenue is one of the Company's most important key performance indicators. The Company's presentations of revenue are included in the Note 3 to the individual financial statements.</p>	<p>Our audit procedures performed to address the risk of material misstatement of revenue recognition included the following:</p> <ul style="list-style-type: none"> • We evaluated the Company's accounting policies on revenue recognition, including discounts granted. • We assessed the development and implementation of existing key internal controls regarding the sales transactions of finished products, goods and discounts granted. • We confirmed the revenue and discounts granted to the customers selected on the basis of a random sample on December 31, 2023 in order to evaluate the completeness of the transactions made by the Company with them. • We selected a random sample of revenue including the discounts granted, which we compared with the relevant supporting documents to ensure the accuracy and completeness of the recorded transactions, also validating the financial period in which they had to be recorded depending on the date on which the transfer of control over the finished products or goods sold was made from the Company as the seller to the customer as the buyer. • We performed analytical procedures that consisted in the analysis of revenue and discounts granted, comparing the current period with the previous one for: sales, customer volumes and margin. • We evaluated whether the information presented in the Explanatory Notes is appropriate.

Other information

8. Administrators are responsible for the preparation and presentation of other information. That other information includes the Management Report and Remuneration Report, but does not include the individual financial statements and the auditor's report thereon, nor the non-financial statement, which is presented in a separate report.

Our opinion on the individual financial statements does not cover this other information and, unless expressly stated in our report, we do not express any assurance conclusion about them.

In connection with the audit of the individual financial statements for the financial year ended 31 December 2023, our responsibility is to read that other information and, in doing so, to consider whether that other information is materially inconsistent with the individual financial statements, or with our knowledge obtained during the audit, or if they appear to be materially misstated.

Other reporting responsibilities on other information – Management Report

Regarding the Management Report, we read it and report whether it was prepared, in all material respects, in accordance with the Order of the Minister of Public Finance no. 2844/2016, with the subsequent amendments, for the approval of the Accounting Regulations in accordance with the International Financial Reporting Standards, with the subsequent amendments.

Based exclusively on the activities to be carried out during the audit of the individual financial statements, in our opinion:

- a. The information presented in the Management Report and in the Remuneration Report for the financial year for which the individual financial statements were drawn up is consistent, in all material respects, with the individual financial statements;
- b. The Management Report was prepared in all material aspects, in accordance with the Order of the Minister of Public

Finance no. 2844/2016, for the approval of the Accounting Regulations in accordance with the International Financial Reporting Standards adopted by the European Union, with subsequent amendments.

In addition, based on our knowledge and understanding of the Company and its business environment, acquired during the audit of the individual financial statements for the financial year ended 31 December 2023, we are required to report whether we identified material misstatements in the Management Report and in the Remuneration Report. We have nothing to report on this matter.

Reporting responsibilities regarding other Information – Remuneration Report

As regards the Remuneration Report, we have read it to determine whether it presents, under all material respects, the information required by article 107, para. (1) and (2) of Law 24/2017 on issuers of financial instruments and market operations, as republished. We have nothing to report on this matter.

Responsibilities of the management and of the persons responsible for governance for the individual financial statements

9. The management is responsible for the preparation and fair presentation of the individual financial statements in accordance with the Order of the Minister of Public Finance no. 2844/2016 for the approval of the Accounting Regulations in accordance with the International Financial Reporting Standards, with subsequent amendments and for that internal control that the management considers necessary to allow the preparation of financial statements free of material misstatements, due to fraud or error.
10. In preparing the individual financial statements, the management is responsible for assessing the Company's ability to continue its activity, presenting, if necessary, the aspects related to the continuity of the activity and using the going concern accounting principle, unless the management either intends to liquidate the Company or cease operations, or has no other realistic alternative.
11. Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities in an audit of individual financial statements

12. Our objectives are to obtain reasonable assurance about whether the individual financial statements, taken as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement, if any. Misstatements can be caused either by fraud or error and are considered material if they can reasonably be expected, individually or cumulatively, to influence the economic decisions of users, taken on the basis of these individual financial statements.
13. As part of an audit in accordance with International Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. Also:
 - We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures in response to those risks, and obtain sufficient appropriate audit evidence to provide a basis for our opinion. The risk of not detecting a material misstatement due to fraud is higher than that of not detecting a material misstatement due to error, because fraud may involve collusions, forgery, intentional omissions, misrepresentations and avoidance of internal control.
 - We understand the internal control relevant to the audit, with a view to designing audit procedures appropriate to the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
 - We evaluate the appropriateness of the accounting policies used and the reasonableness of the accounting estimates and of the related information presentations made by the management.
 - We form a conclusion on the appropriateness of management's use of going concern accounting and determine, based on the audit evidence obtained, whether a material uncertainty exists regarding events or conditions that could cast significant doubt on the ability Company to continue its activity. If we conclude that a material uncertainty exists, we must draw attention in the auditor's report to the related presentations in the individual financial statements or, if those presentations are inadequate, we have to change our opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the Company to stop operating on a going concern basis.

- We evaluate the presentation, structure and overall content of the individual financial statements, including the information presentations, and the extent to which the individual financial statements reflect the core transactions and events in a manner that achieves fair presentation.
14. We communicate to those charged with governance, among other things, the planned scope and timing of the audit, as well as the main audit findings, including any significant deficiencies in the internal control, that we identify during the audit.
 15. We also provide those charged with governance with a statement that we complied with the relevant ethical requirements regarding independence and that we disclosed to them all the relationships and other matters that could reasonably be expected to affect our independence and, where applicable, the actions taken to eliminate risks or protective measures applied.
 16. Among the issues communicated with the persons responsible for governance, we determine which are the most important matters for the audit of the individual financial statements for the current period and which therefore represent key audit matters. We describe these matters in the auditor's report unless laws or regulations prohibit public disclosure of the matter or unless, in extremely rare circumstances, we determine that a matter should not be communicated in our report because it is reasonably expected that the public interest benefits are outweighed by the negative consequences of this communication.

Report on other legal and regulatory provisions

17. We were appointed by the General Meeting of Shareholders held on April 27, 2023 to audit the individual financial statements of Antibiotice S.A. for the financial year ending December, 31 2023. The total uninterrupted term of our commitment is 1 year, covering the financial year ending 31 December 2023.

We confirm that:

- Our audit opinion is consistent with the additional report submitted to the Company's Audit Committee, which we issued on the same date as this report. Also, in conducting our audit, we maintained our independence from the audited entity.
- Prohibited non-audit services referred to in Article 5 para.(1) of Regulation (EU) no. 537/2014 were not provided.

The engagement partner of the audit for which this independent auditor's report was prepared is Alina Mirea.

Report on compliance with Law no. 162/2017 on the statutory audit of annual financial statements and annual consolidated financial statements and amending some normative acts ("Law 162/2017") and Delegated Regulation (EU) 2018/815 of the Commission on the Regulatory Technical Standard regarding the European Single Electronic Format ("ESEF").

We performed a reasonable assurance mission on compliance with Law 162/2017 and Delegated Regulation (EU) 2018/815 of the Commission applicable to the individual financial statements included in the annual financial report of Antibiotice S.A. as presented in the digital files that include this audit report (**the "Digital Files"**).

(I) *Responsibility of the management and those charged with governance for the Digital Files prepared in accordance with the ESEF*

Management is responsible for the preparation of Digital Files in accordance with ESEF. This responsibility entails:

- designing, implementing and maintaining the relevant internal control for the application of ESEF;
- ensuring compliance between the Digital Files and the individual financial statements that will be submitted in accordance with the Order of the Minister of Public Finance no. 2844/2016 for the approval of the Accounting Regulations compliant with the International Financial Reporting Standards, with subsequent amendments.

Those charged with governance are responsible for overseeing the preparation of Digital Files in accordance with the ESEF.

(II) *Auditor's Responsibility for Auditing the Digital Files*

We have the responsibility to express a conclusion on the extent to which the individual financial statements included in the annual financial report comply with the ESEF requirements, in all material respects, based on the evidence obtained. Our reasonable assurance engagement was performed in accordance with International Standard on Assurance Engagements (ISAE 3000 Revised), Assurance Engagements Other Than Audits or Reviews of Historical Financial Information (ISAE 3000) issued by the International Auditing and Assurance Standards Board.

Our company applies the International Standard on Quality Management 1 ("ISQM 1") and, accordingly, maintains a comprehensive quality control system, including documented policies and procedures on the compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

A reasonable assurance engagement in accordance with ISAE 3000 involves performing procedures to obtain evidence about compliance with the ESEF. The nature, timing and extent of the procedures selected depend on the auditor's judgment, including the assessment of the risk of material deviations from the ESEF requirements, whether due to fraud or error. A reasonable assurance engagement involves:

- obtaining an understanding of the Company's process of preparing the Digital Files in accordance with ESEF, including the relevant internal controls;
- reconciliation of the Digital Files with the audited individual financial statements of the Company that will be submitted in accordance with the Order of the Minister of Public Finance no. 2844/2016 for the approval of the Accounting Regulations in accordance with the International Financial Reporting Standards, with subsequent amendments;
- evaluating whether the individual financial statements included in the annual report were prepared in a valid XHTML format.

We believe that the evidence obtained is sufficient and adequate to provide a basis for our conclusion. In our opinion, the individual financial statements for the financial year ended December 31, 2023 included in the annual financial report in Digital Files comply, in all significant matters, with the ESEF requirements.

Alina Mirea, Audit Partner

Registered in the Electronic Public Register of Financial Auditors and Audit Firms under number AF 1504

On behalf of:

DELOITTE AUDIT S.R.L.

Registered in the Electronic Public Register of Financial Auditors and Audit Firms under number FA 25

The Mark Building, 84-98 and 100-102 Calea Griviței, 9th floor, Sector 1
Bucharest, Romania
March 15, 2024

ANTIBIOTICE S.A.**THE INDIVIDUAL OVERALL RESULT STATEMENT****FOR THE YEAR ENDED ON DECEMBER 31, 2023****(all amounts are expressed in lei ("RON"), if not mentioned otherwise)**

	Note	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
Revenues from contracts with clients, of which:		600,780,825	483,724,186	483,724,186
<i>Revenues from the sale of finished products</i>	3	482,092,932	387,506,130	387,506,130
<i>Revenues from the sale of products made on other manufacturing sites</i>	3	117,383,457	95,160,681	95,160,681
<i>Revenues from the provision of services</i>	3	1,304,436	1,057,375	1,057,375
Other operating revenues	4	1,424,282	2,033,372	7,330,842
Revenues from subsidies	4	270,907	302,979	302,979
Changes in inventories of finished products and production in progress		13,408,502	11,689,110	11,689,110
The company's own work capitalized		13,381,851	13,779,091	13,779,091
Expenses with raw materials, used consumables and products made on other manufacturing sites	5	(218,168,457)	(177,117,257)	(177,117,257)
Employee benefit expenses	6	(156,053,526)	(122,940,724)	(125,766,529)
Shipping costs	7	(4,199,124)	(4,171,593)	(4,171,593)
Utility expenses	7	(25,334,283)	(22,026,479)	(22,026,479)
Net depreciation and adjustments for the depreciation of fixed assets, net	11.12	(27,875,560)	(22,269,554)	(25,307,276)
Net adjustments for depreciation of current assets		(426,963)	(20,328,387)	(1,058,801)
Net reversed provisions		-	(2,825,805)	-
Sponsorships, donations		(1,059,242)	(450,214)	(450,214)
Other expenses	7	(99,615,980)	(92,898,339)	(91,017,182)
Operational result		96,533,232	46,500,386	69,910,877
Net exchange rate differences	8	(945,157)	(797,515)	(797,515)
Net interest expense	8	(4,141,232)	(3,589,852)	(3,589,852)
Other financial expenses	8	77,403	(209,789)	(209,789)
Financial result	8	(5,008,986)	(4,597,156)	(4,597,156)
Pre-tax profit		91,524,246	41,903,230	65,313,721
Income tax expense	9	(10,435,650)	(3,389,803)	(13,841,684)
The profit of the financial year		81,088,596	38,513,427	51,472,037
Basic/diluted earnings per share		0,1208	0,0574	0,0767

* For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANIFinancial Director,
Ec. Paula Luminita COMAN

ANTIBIOTICE S.A.
THE INDIVIDUAL FINANCIAL POSITION STATEMENT
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), if not mentioned otherwise)

	Note	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
The profit of the financial year		81,088,596	38,513,427	51,472,037
<i>Other elements of the overall result</i>				
<i>Elements that will not be classified in profit or loss</i>				
<i>Revaluation of tangible assets</i>	11	35,964,800	-	103,085,549
<i>Deferred tax related to revaluations of tangible assets</i>	8	(5,754,368)		(16,491,168)
<i>Other elements of the overall result</i>		30,210,432	-	86,594,381
Total overall result		111,299,028	38,513,427	138,066,418

* For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANI

Financial Director,
Ec. Paula Luminita COMAN

ANTIBIOTICE S.A.

THE INDIVIDUAL FINANCIAL POSITION STATEMENT FOR THE YEAR ENDED ON DECEMBER 31, 2023

(all amounts are expressed in lei ("RON"), if not mentioned otherwise)

	Note	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
Assets				
Fixed assets				
Tangible fixed assets	11	692,361,541	496,810,361	599,898,910
Intangible fixed assets	12	45,526,698	35,795,943	32,758,221
Total tangible fixed assets		737,888,239	532,606,304	632,657,131
Current assets				
Inventories	13	160,214,484	122,494,428	142,659,974
Trade and similar receivables	14.15	235,771,990	196,402,918	204,033,217
Expenses registered in advance		3,489,615	3,243,331	3,243,331
Cash and cash equivalents	16	1,807,930	1,727,454	1,727,454
Total current assets		401,284,019	323,868,131	351,663,976
Total assets		1,139,172,258	856,474,435	984,321,107
Equity and liabilities				
Equity				
Subscribed capital	17	67,133,804	67,133,804	67,133,804
Revaluation reserves	17	225,417,959	111,164,239	197,758,620
Legal reserves and other reserves		324,877,598	305,594,766	305,594,766
Retained earnings		229,534,759	157,537,792	170,496,402
Total equity		846,964,120	641,430,601	740,983,592
Long-term liabilities				
Bank loans and debts	19	36,750,203	46,973,501	46,973,501
Subsidies for investments - non-current portion	20	1,586,415	1,857,322	1,857,322
Deferred tax liabilities	8	63,401,227	30,871,210	57,817,259
Total long-term liabilities		101,737,845	79,702,033	106,648,082
Current debts				
Trade and similar debts	18	150,780,362	86,067,391	99,391,828
Bank loans	19	29,552,092	34,008,116	34,008,116
Other debts	18	9,831,550	8,280,670	2,983,200
Subsidies for investments - current portion	20	306,289	306,289	306,289
Provisions		-	6,679,335	-
Total current debts		190,470,293	135,341,801	136,689,433
Total debts		292,208,138	215,043,834	243,337,515
Total equity and debts		1,139,172,258	856,474,435	984,321,107

* For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANI

Financial Director,
Ec. Paula Luminita COMAN

The attached notes are an integral part of these individual financial statements.

ANTIBIOTICE S.A.
THE INDIVIDUAL CHANGES IN EQUITY STATEMENT
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

DECEMBER 31, 2022	Share capital	Legal reserves and other reserves	Revaluation reserves	Cumulative reported result	Total equity
Balance on January 1, 2022	67,133,804	272,580,887	114,150,766	151,126,343	604,991,800
The result of the year	-	-	-	38,513,427	38,513,427
Other elements of the overall result	-	-	-	-	-
Total overall result	-	-	-	38,513,427	38,513,427
Reserves representing the surplus achieved from revaluation	-	-	(2,986,527)	2,986,527	-
Dividends paid in 2022	-	-	-	(2,074,626)	(2,074,626)
Other capital elements increases/(reductions)	-	33,013,879	-	(33,013,879)	-
Reported balance on December 31, 2022	67,133,804	305,594,766	111,164,239	157,537,792	641,430,601
Period corrections	-	-	86,594,381	12,958,610	99,552,991
Balance on December 31, 2022, restated *	67,133,804	305,594,766	197,758,620	170,496,402	740,983,592

During the year 2022, 33,013,879 RON were transferred from the result reported over to other reserves according to the decision of the GMS.

*For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANI

Financial Director,
Ec. Paula Luminita COMAN

The attached notes are an integral part of these individual financial statements.

ANTIBIOTICE S.A.
THE INDIVIDUAL CHANGES IN EQUITY STATEMENT
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

DECEMBER 31, 2023	Share capital	Legal reserves and other reserves	Revaluation reserves	Cumulative reported result	Total equity
Balance on January 01, 2023 reported	67,133,804	305,594,766	111,164,239	157,537,792	641,430,601
Corrections of the previous period	-	-	86,594,381	12,958,610	99,552,991
Balance on January 01, 2023 restated *	67,133,804	305,594,766	197,758,620	170,496,402	740,983,592
The result of the year	-	-	-	81,088,596	81,088,596
Other elements of the overall result	-	-	30,210,432	-	30,210,432
Total overall result	-	-	30,210,432	81,088,596	111,299,028
Reserves representing the surplus achieved from revaluation	-	-	(2,551,093)	2,551,093	-
Dividends distributed in 2023	-	-	-	(5,318,500)	(5,318,500)
The result reported over to other reserves	-	19,282,832	-	(19,282,832)	-
Balance on December 31, 2023	67,133,804	324,877,599	225,417,959	229,534,759	846,964,120

During the year 2023, 19,282,832 RON were transferred from the result carried over to Other reserves according to the decision of the AGM.

* For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANI

Financial Director,
Ec. Paula Luminita COMAN

The attached notes are an integral part of these individual financial statements.

ANTIBIOTICE S.A.
THE INDIVIDUAL CASH FLOW STATEMENT
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

Indirect method	Note	Period ended on December 31, 2023	Period ending on December 31, 2022 (restated)
Pre-profit tax		91,524,246	65,313,721
Adjustments for:			
Depreciation related to intangible assets		2,243,686	1,513,382
Depreciation related to tangible assets		25,686,248	21,052,424
Expenses related to inventory provisions		1,522,444	4,198,210
(Revenues) related to customer provisions and assimilated accounts		(1,095,480)	(3,139,409)
Expenses related to adjustments for the depreciation of fixed assets		-	3,037,722
The net loss from the disposal of tangible assets		(1,500)	2,753,525
Revenues from subsidies		(270,907)	(302,979)
Interest expenses		4,145,607	3,591,289
Interest revenues		(4,374)	(1,437)
Cash flow generated from operating activity before changes in working capital		123,749,970	98,016,448
(Increases) of stocks		(19,046,654)	(40,840,410)
(Increases)/Decreases in receivables		(30,643,294)	75,982,392
(Increases) of expenses in advance		(246,284)	(3,243,332)
Increases / (decreases) in debts		61,663,072	(10,357,574)
Income increases in advance		1,500	32,072
Interest collected		4,374	1,437
Profit tax paid		(13,023,231)	(3,929,305)
Net cash from operating activities		122,459,453	115,661,728
Cash flows from investment activities			
Purchases of tangible assets		(83,025,003)	(37,576,233)
Purchases of intangible assets		(15,012,163)	(7,469,561)
Net cash from investment activities		(98,037,166)	(45,045,794)
Cash flows from financing activities			
(Decreasing) the use of the credit line		(4,456,024)	(53,155,433)
(Repayment) long-term loan		(10,223,298)	(10,643,652)
Dividends paid		(5,433,706)	(3,426,840)
Interest paid		(4,088,957)	(3,529,553)
Net cash from financing activities		(24,201,985)	(70,755,478)
(Decrease)/Net increase in cash and cash equivalents		220,300	(119,541)
Cash and cash equivalents at the beginning of the financial year	16	1,727,454	2,111,377
The effect of the exchange rate on the movement of cash and cash equivalents		(139,824)	(264,382)
Cash and cash equivalents at the end of the financial year	16	1,807,930	1,727,454

* For more details on the 2022 restatements, see Note 23

Authorized by the Management Board on: 13.03.2024

General Director,
Ec. Ioan NANI

Financial Director,
Ec. Paula Luminita COMAN

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. GENERAL COMPANY INFORMATION

1.1. Brief company profile

Antibiotice S.A. ("ATB" - Bucharest Stock Exchange symbol, "The Company") is a commercial company established in Romania, with its registered office in Valea Lupului street no. 1, Iasi. The company is registered at the Trade Registry Office under no. J 22/285/1991 and has the unique registration code 1973096.

The object of activity of Antibiotice S.A. is the manufacture of basic pharmaceutical products, according to the Classification of Economic Activities in the National Economy, CAEN code 2110.

These financial statements are individual financial statements of Antibiotice S.A. drawn up on 31.12.2023, which were authorized on: 13.03.2024.

Antibiotice S.A.:

- is the most important producer of generics in Romania, with full Romanian capital;
- is the only Romanian company that produces active substances through biosynthesis processes;
- has been listed on the Bucharest Stock Exchange in the premium category, since 1997;
- has a product portfolio that includes generic drugs for human use (RX drugs and non-RX products), active substances based on biotechnologies derived from streptomycines noursei for pharmaceutical use (in the form of compacted Nystatin, micronized Nystatin and standard Nystatin), biocidal products for disinfecting surfaces and hands, veterinary medicines and biofertilizers. The product portfolio consists of over 160 products from 11 therapeutic classes. The prescription products are mainly grouped by ATC1 therapeutic classes and are intended for pathologies with increased incidence and the treatment of chronic conditions. The non-prescription products are grouped into portfolio concepts, for a more efficient communication to the target audience. The concepts include food supplements, medical devices, cosmetics, OTC drugs and OTX drugs (RX products with OTC behavior which are released from the pharmacy without a medical prescription). The products in the current portfolio are carefully monitored and action is taken to adapt to national requirements and international regulations, through the analysis of therapeutic trends, medical guidelines, new efficacy and safety studies. The expansion of the product portfolio makes a major contribution to the development of Antibiotice S.A. on the domestic market, as well as on the international markets, both through our own research and development activity, as well as through the assimilation of new products through business development (in-licensing contracts);
- has a diversified production capacity, organized on 3 production divisions as well as on 8 manufacturing flows on which: penicillin injectable powders are produced; penicillin capsules; non-beta-lactam capsules; cephalosporin capsules; tablets; ointments, creams, gels; suppositories; pessaries; active substances obtained through biosynthesis and 10 partner sites. All production capacities are the property of the company and they are located at the registered office. The company has the right of ownership over all fixed assets registered in the company's accounting;
- owns and operates a modern Research and Development Center;
- holds internationally recognized certifications and authorizations: authorization from the US Medicines Regulatory Agency (FDA) for Nystatin and injectable penicillin products, Certificate of Conformity with the European Pharmacopoeia (COS) for Nystatin, Certificate of Good Manufacturing Practice (GMP) for all manufacturing flows, TÜV Rheinland Certification for integrated management (quality, environment, occupational health and safety);
- is WHO prequalified and it has WHO certification for the range of essential antituberculosis drugs;
- is a traditional supplier of anti-infective drugs for hospitals in the U.S.A., Vietnam and European markets (the U.K., Denmark, The Netherlands, Serbia, Lithuania and Hungary);
- is the world market leader for the consumption of active substances based on biotechnologies derived from streptomycine noursei for pharmaceutical use (in the form of compacted Nystatin, micronized Nystatin and standard Nystatin). The superior quality of this product, recognized by the US authorities (FDA) as an international reference standard, is reflected in a continuous increase in the number of new customers in Europe, South America and North America.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. GENERAL COMPANY INFORMATION (continued)

1.2. Corporate Governance Structures

The structures on which the corporate governance system within Antibiotice S.A. is based can be found on the company's website at <https://www.antibiotice.ro/investitori-php/corporate-governance/>. These are:

- The General Meeting of Shareholders;
- The Management Board;
- The Advisory Committees;
- The Executive Management;
- The Corporate Governance Secretariat;
- The internal audit, financial management control and risk management.

The General Meeting of Shareholders

Antibiotice S.A. is organized on the principles of corporate governance, which regulates the selection and appointment procedure of administrators and directors, as well as the operation of the management system, seeking to strengthen the independence, accountability and professionalism of the management structures, the transparency and the quality of publicly presented information, as well as the protection of shareholders, including the minority shareholders. The management of the company is organized to meet the expectations of the shareholders in terms of ensuring competitiveness, profitability and the generation of long-term added value. A well-defined, traceable decision-making system is ensured and the delegation of duties and competences are proportional to the granted prerogatives and the existing control system.

The applying of the principles of good corporate governance practices with strict compliance with the recommendations of the Corporate Governance Code of the Bucharest Stock Exchange, ensures the transparency and efficiency of the company's activities and processes, thus providing the framework for maximizing the value of the Antibiotice S.A. shares in the long term, namely protecting the interests of interested parties and increasing the degree of trust in Antibiotice S.A.

The company's management considers the Corporate Governance Code to be an important tool for achieving sustainable performance for ensuring the accuracy and transparency of the company's decision-making process through the equal access of all shareholders to relevant information about the company.

The legal framework for ensuring the corporate governance system is:

- The Law no. 31/1990 on commercial companies, with subsequent amendments and supplements;
- The GEO no. 109/2011 regarding the corporate governance of public enterprises, with subsequent amendments and supplements;
- The Law no. 24/2017 regarding the issuers of financial instruments and market operations;
- The ASF Regulation no. 5/2018 regarding the issuers of financial instruments and market operations;
- The corporate governance code of Antibiotice S.A. which also includes the Regulation on Organization and Functioning of the Management Board and the Regulation on the Evaluation of administrators;
- The Code of Ethics

The General Meeting of Shareholders (GMS) represents the company's highest decision-making body, the place where shareholders participate directly and make decisions. Among other duties, the GMS decides on the distribution of the profit, elects the Management Board, appoints the auditors and it establishes the remuneration of the Management Board.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. COMPANY RELATED INFORMATION (continued)


The Management Board convened during the year 2023, 3 (three) Ordinary General Meetings and 2 (two) Extraordinary General Meetings, whose decisions can be found on the company's website at the address below:

<https://www.antibiotice.ro/investitori-php/financial-information/adunari-generale-ale-actionarilor/?raport=2023#>

The main shareholders of the company on 31.12.2023 (extract from the Register of Shareholders)

MINISTRY OF HEALTH (*)	53.0173%
INFINITY CAPITAL INVESTMENTS S.A. (*)	29.4153%
Other shareholders (44.174 shareholders)	17.5674%

NOTE: (*) - Significant shareholders, according to Law no. 297/2004 regarding the capital market, article 2, paragraph 1



Shareholding structure

MINISTRY OF HEALTH (*)

INFINITY CAPITAL INVESTMENTS S.A. (*)

Other legal entities (Pension Funds, Privately Administered Funds, domestic PJ/LP and foreign PJ/LP)

Natural persons

Classes of shareholders:

- Legal persons – 95.7240 %.
- Natural persons – 4.2760 %.

Antibiotice S.A. on the capital market

The securities issued by Antibiotice S.A. are listed in the PREMIUM category of the Bucharest Stock Exchange, under the symbol (ATB), starting with the year 1997.

The shares of Antibiotice S.A. are included in the BET-Plus index component, which includes Romanian companies listed on the BSE market that meet the minimum selection criteria with the exception of financial investment companies and the BET-BK, which was built to be used as a benchmark by fund managers and also by other institutional investors. This reflects the fact that Antibiotice S.A. is a solid company, developed on a lasting economic foundation.

The stock market capitalization of Antibiotice S.A. on December 31, 2023 was 936,517 thousand lei.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

During the year 2023, 49,531,258 shares were traded, worth 41,116,948.60 million lei (8,288,763.40 million EURO, 8,949,596.51 million USD), with an average price of 0.8301 lei /share.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. COMPANY RELATED INFORMATION (continued)

The corporate governance framework adopted and applied:

- protects the rights of shareholders;
- ensures the fair treatment of all shareholders;
- recognizes the role of third parties with interests in society;
- guarantees the provision of information and the transparency;
- ensures the responsibility of the Management Board towards the company and the shareholders.

On the Antibiotice S.A. company website at the address www.antibiotice.ro/investitori/informatii_actionari, there is a section dedicated to shareholders, where you can access and download documents related to the General Meetings of Shareholders: procedures regarding the access to and the participation in the meetings, the notices to attend, the agenda, the informative materials, the special powers of representation, the voting forms by mail, the draft decisions, the decisions and the voting results.

Investor relations

The investor relations activity supports the constant communication between the company and investors. This process allows the knowledge of the operational activity, the strategy and the perspectives of the business, with the aim of achieving, in the knowledge of the cause of a fair evaluation of the company. As a company listed on the stock exchange, we make available to the public and we send to the Financial Supervisory Authority (ASF) and the Bucharest Stock Exchange (BVB), annual, semi-annual, quarterly and current reports, as well as documents related to the smooth conduct of general meetings. Because we are oriented towards the development and increase of transparency towards the shareholders, immediately after the periodic financial reports (annual and semi-annual), we organize our own meetings and presentation events.

Interested investors and analysts participate in these events, who have the opportunity to send their questions, opinions and suggestions, thus ensuring a dialogue with the exponents of the capital market in Romania, so that they get a sufficient basis for the investment decision-making process.

The agenda of events, which aim to maintain a permanent dialogue among the company's management, investors and analysts, included during the year 2023, 4 (four) teleconferences for the presentation of individual financial statements, on March 2, May 15, August 23 and November 21.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. COMPANY RELATED INFORMATION (continued)

All the documents related to the smooth running of the events mentioned above, were published in accordance with the legislation in force, respectively: Law no. 31/1990 regarding commercial companies, republished, with subsequent changes and additions, the Government Emergency Ordinance no. 109/2011 regarding the corporate governance of public enterprises with subsequent amendments and supplements, the Law no. 24/2017 regarding the issuers of financial instruments and market operations, the Regulation no. 5/2018 regarding issuers of financial instruments and market operations.

The organization of the General Meetings of Shareholders, the changes in the structure of the company, the decisions of the general meetings, as well as the actions related to guaranteeing the rights of the shareholders - the distribution of dividends related to the financial year 2022, were carried out in accordance with the legal regulations.

The first place, for the best Company from the perspective of the activity in Investor Relations – Main Market – the vote of the public, awarded on November 17 by the Association for Investor Relations at the Romanian Stock Exchange during the ARIR Gala, as well as the scoring of grade 10, the highest grade for for the third consecutive year, when evaluating the VEKTOR indicator based on 15 criteria of good practices in the relationship with investors, motivates us to perform in the communication with them, to respect our mission to provide information in a transparent and responsible manner, so as to develop relationships based on ethics and trust with the current and potential investors.

This award recognition supports the company's trend towards a sustainable development, in accordance with the fairness of the company's activity in relation to the stakeholders.

The Management Board

Antibiotice S.A. is administered by a Management Board, which is responsible for the fulfillment of all the tasks necessary to achieve the object of the company's activity, with the exception of those provided by law for the General Meeting of Shareholders. There is a clear-cut distinction of duties between the Management Board and the Executive Management.

The Management Board ensures that its own decisions, those of the company's management, of the General Meeting of Shareholders, as well as the internal regulations, comply with the legal requirements and that they are adequately implemented. The Board is responsible for monitoring the company's management, on behalf of the shareholders.

The duties of the Management Board are described in the company's Statute and in the relevant internal regulations, available on the company's website, in the Corporate Governance section.

During the year 2023, the Management Board met in 11 (eleven) meetings and it adopted decisions that allowed it to fulfill its duties in an effective and efficient manner.

The membership of the Management Board of Antibiotice S.A. on December 31, 2023.

Ec. Ioan Nani

Vice-president of the Management Board and General Director

Fully qualified Executive Administrator

In the Ordinary General Meeting of Shareholders on May 20, 2020, Mr. Nani was reconfirmed as a member of the Management Board, for a mandate valid until 18.04.2024 and then Mr. Nani was elected by the members of the Management Board on 20.05.2020, in the position of vice-president.

Mr. Nani is an economist specialized in management and an accounting expert, he has been a member of the Management Board since 2009 and a General Director (1998 - 2008 and 2009 – present day).

Number of Antibiotice S.A. shares owned - 1.513*

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

Eng. Catalin Codrut Popescu

Mr. Popescu is a member of the Management Board and a representative of the INFINITY CAPITAL INVESTMENTS S.A shareholder.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. COMPANY RELATED INFORMATION (continued)

Fully qualified Non-Executive Administrator

At the Ordinary General Meeting of Shareholders on August 26, 2021, Mr. Popescu was elected to the Management Board, for a term valid until the date of 18.04.2024.

General Director of MEDIMFARM S.A.

Number of Antibiotice S.A. shares owned - 0*

Ec. Mihai Trifu

Member of the Management Board and representative of the INFINITY CAPITAL INVESTMENTS S.A shareholder.

Fully qualified Non-Executive Administrator

At the Ordinary General Meeting of Shareholders on August 26, 2021, Mr. Trifu was elected to the Board of Directors, for a term valid until the date of 18.04.2024.

Vice President and Deputy General Director of INFINITY CAPITAL INVESTMENTS S.A.

Number of Antibiotice S.A. shares owned - 0*

Physicist Lucian Timofticiuc

Member of the Administration Board and a representative of the Ministry of Health

Fully qualified Non-Executive Administrator

President of the Administration Board

In the Ordinary General Meeting of Shareholders of September 16, 2020, Mr. Timofticiuc was elected as a member of the Management Board for a term valid until April 18, 2024. Currently, Mr. Timofticiuc holds the position of administrator and General Director of Vremea Noua.

Number of Antibiotice S.A. shares owned - 0*

Legal Adviser Ionel Damian

Member of the Administration Board

Fully qualified Non-Executive Administrator

In the Ordinary General Shareholders' Meeting of November 2, 2020, he was elected as a permanent member of the company's Management Board, for a term valid until April 18, 2024.

Fiscal Audit Executive Director – Iasi County General Regional Directorate of Public Finance

Number of Antibiotice S.A. shares owned - 0*

(*) The number of Antibiotice S.A. shares owned on December 31, 2023, according to the latest database of Antibiotice S.A. for the year 2023.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

1. COMPANY-RELATED INFORMATION (continued)

The Corporate Governance Code

The basis of the good governance practices within the company is the Corporate Governance Code of Antibiotice S.A., which outlines the general framework for the activity of the Management Board. Built according to the principles and recommendations of the Corporate Governance Code of the Bucharest Stock Exchange (BVB), the corporate governance code of Antibiotice S.A., approved by the Management Board in January 2017 and updated in November 2021, includes, among other things, information about the duties of management structures, fair reward and motivation, investor relations, the risk management system and the internal control. The management of Antibiotice S.A. considers the Corporate Governance Code to be an important tool for achieving sustainable performance, ensuring the accuracy and transparency of the company's decision-making process, through equal access of all shareholders to relevant information about Antibiotice S.A.

The Code of Ethics

The Code of Ethics of Antibiotice S.A. is the basis of an organizational culture that respects the integrity standards and that complies with the specific legislation in force. The fundamental ethical values assumed by the company are the integrity, the professionalism, the responsibility and the transparency. Any violation of the code is considered to be an ethical incident, the failure to comply with the Code of Ethics may lead to disciplinary sanctions. The compliance with the provisions of the Code of Ethics is mandatory for all structures in the company's organizational chart (employees, executive management and members of the Management Board). The Code of Ethics is made known to every new employee or administrator and it can be consulted online.

The Advisory Committees

The Management Board exercises part of its responsibilities through the three advisory committees: the Audit Committee, the Commercial Policy Committee and the Nomination and Remuneration Committee. The specialized advisory committees carry out investigations, analyses, they elaborate recommendations and they periodically submit reports on their activity to the Management Board.

The membership of the Advisory Committees can be read at the address <https://www.antibiotice.ro/investitori-php/corporate-governance/structuri-de-guvernanta/>

The duties and responsibilities of the advisory committees can be found on the company's website at: <https://www.antibiotice.ro/wp-content/uploads/2015/06/Regulamentele-comitetelor-consultative-1.pdf>

The executive management

Antibiotice S.A. is represented by the General Director, according to the prerogatives established by law and by the company statute. The Management Board retains the authority to represent the company in relations with the directors it appointed. The management team membership of Antibiotice S.A., on 31.12.2023, can be read at the address: <https://www.antibiotice.ro/investitori-php/corporate-governance/structuri-de-guvernanta/>.

2. GENERAL INFORMATION

2.1. The drawing-up basis

The individual financial statements were drawn up in accordance with the provisions of O.M.P.F. no. 2844/2016 for the approval of the accounting regulations in accordance with the International Financial Reporting Standards with subsequent amendments and additions. These provisions comply with those of the International Financial Reporting Standards ("IFRS") and with the IFRIC interpretations, adopted by the European Union. The financial statements were drawn up on the basis of the going concern principle.

The accounting policies and the evaluation methods adopted for the preparation of the individual financial statements are consistent with those used for the preparation of the annual individual financial statements of Antibiotice S.A. on December 31, 2022. As described in Note 26, the company reopened the period ending on December 31, 2022 and it restated the comparative figures.

The company has drawn up individual IFRS financial statements that include the individual statement of the global result, the individual statement of the financial position, the individual statement of cash flows and the individual statement of changes in equity for the year ended on December 31, 2023.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

Starting with the period ending on June 30, 2023, the company prepared and presented the individual cash flow statement using the indirect method. For the period ending on December 31, 2023, in order to present some comparative information, the Company prepared the individual cash flow statement using the same method as on December 31, 2022.

These individual financial statements were prepared in accordance with IAS 1 Presentation of financial statements, as adopted by the European Union.

2.2. The bases of evaluation

The individual financial statements are drawn up based on the historical cost with the exception of land and buildings presented at revalued cost by using the fair value as assumed cost and the elements presented at fair value, that is the financial assets and liabilities at fair value, through the profit and loss account with the exception of those for which the fair value cannot be reliably established.

These individual financial statements have been drawn up for general purposes, for the use of people who know the provisions of the International Financial Reporting Standards, applicable to commercial companies whose securities are admitted to trading on a regulated market. Consequently, these financial statements should not be considered as the only source of information by a potential investor or other user.

2.3. Functional and presentation currency

The functional currency, as defined by IAS 21 "Effects of currency exchange rate variation", is the leu. The individual financial statements are presented in lei, the values being rounded to the nearest leu, that is the currency which the Company chose as the currency presentation.

The transactions made by the company in a currency other than the functional currency are recorded at the exchange rate in force on the date the transactions take place. The monetary assets and liabilities in foreign currency are converted at the exchange rate in force on the reporting date. The profit and loss resulting from exchange rate differences following the conclusion of these transactions and from the conversion to the exchange rate at the end of the reporting period of monetary assets and liabilities denominated in foreign currency are reflected in the individual statement of the overall result.

The foreign exchange differences are recognized in profit or loss in the period in which they occur, with the exception of the foreign exchange differences on foreign currency loans related to assets under construction for future productive use, which are included in the cost of those assets when they are considered as an adjustment of interest costs for those loans in foreign currency.

The exchange rates of the main foreign currencies according to the report of the National Bank of Romania are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
EUR	4.9746	4.9474
USD	4.4958	4.6346

2.4. Crucial accounting evaluations and estimates

The company makes certain estimates and assumptions regarding the future. The estimates and judgments are continually evaluated based on historical experience and other factors, including forecasting of future events that are believed to be reasonable under the existing circumstances. In the future, actual experience may differ from the present estimates and assumptions. Examples of evaluation, estimation, assumptions applied within the company are presented below:

- The evaluation of land investments and company owned buildings - based on the evaluations made by external appraisers, the fair value of real estate investments and company owned buildings is determined. These evaluations are based on assumptions that include future rental income, anticipated maintenance costs, future development costs and the discount rate. The evaluators also refer to the information on the market related to the prices of transactions with similar properties.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

- Adjustments for the impairment of receivables – For trade receivables, a simplified approach is adopted in which impairment losses are recognized based on the expected lifetime credit losses at each reporting date. If there are credit insurances or guarantees for the outstanding balances, the calculation of expected losses from receivables is based on the probability of non-repayment of the insurer for the insured part of the outstanding balance, and the remaining uncovered amount will have the probability of non-repayment of the counterparty. For trade receivables, the simplified model regulated by IFRS 9 is used.
- Adjustments for inventory impairment - The assessment for inventory impairment is performed on an individual basis and it is based on the management's best estimate of the present value of cash flows expected to be received. Each impaired asset is analyzed individually. The accuracy of the adjustments depends on the estimation of future cash flows. The adjustments regarding stocks are based on the calculation performed at the end of the financial year for the specific value adjustment related to stocks of raw materials, consumables and finished products that no longer correspond from a qualitative viewpoint. The calculation of the general adjustment for stock depreciation is made according to the validity period of the items in stock.
- Judicial proceedings - The company reviews the unresolved legal cases by following the developments in the judicial proceedings and the existing situation at each reporting date, in order to evaluate the provisions and presentations from its financial statements. Among the factors considered in making decisions related to provisions there are the nature of the litigation or claims and the potential level of damages in the jurisdiction where the litigation is adjudicated, the progress of the case (including progress after the date of the financial statements but before those statements are issued), the opinions of legal advisors, the experience in similar cases and any decision of the company's management related to how it will respond to the litigation, complaint or evaluation.
- Accounting estimates of expenses - There are objective situations in which until the closing date of some fiscal periods or until the closing date of a financial year the exact values of some expenses committed by the company are not known (e.g.: marketing campaigns - sales promotion of products and sales stimulus campaigns). For this category of expenses, the preliminary expenses will be made, which will be actually recorded in the following periods.
- Taxation - The taxation system in Romania is undergoing a phase of consolidation and harmonization with the European legislation. There are uncertainties regarding the interpretation of complex tax regulations, changes in tax laws and the amount and timing of future taxable income. Considering the diversity of business relationships and the longevity and complexity of the existing contractual agreements, the differences that appear among the actual results and the assumptions made or future changes to these assumptions could require future adjustments to the tax revenues and expenses already recorded. In Romania, the fiscal year remains open for fiscal verification for 5 years. The management of the company considers that the tax liabilities included in the financial statements are adequate.

2.5. Classification of short-term or long-term assets and liabilities

The company presents the individual financial position of assets and liabilities based on the short-term/long-term classification.

An asset is current when:

- it is expected to be achieved or intended to be sold or consumed within the normal operating cycle;
- it is held mainly for trading purposes;
- it is expected to be achieved within twelve months from the reporting period, or
- it constitutes cash and cash equivalents.

All the other assets are classified as fixed assets.

A debt is a short-term debt when:

- it is expected to be paid in the normal operating cycle;
- it is held mainly for trading purposes;
- it is about to be settled within twelve months from the reporting period;
- there is no unconditional right to postpone the settlement of the debt for at least twelve months after the reporting period.

The deferred tax assets and liabilities are classified as long-term assets and liabilities.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

2.6. Revenue recognition IFRS 15 - Revenue from contracts with customers

The revenues are increases in economic benefits recorded during the reporting period, in the form of incomes or increases in assets or reductions in liabilities, which materialize in increases in equity, other than those resulting from the shareholders' contributions.

The fair value is the value at which an asset can be traded or a debt settled, between interested parties and in good faith, in a transaction carried out under objective conditions.

The income assessment

The objective of IFRS 15 - Revenue from contracts with customers is to clarify the principles of revenue recognition. This includes eliminating inconsistencies and perceived weaknesses and improving the comparability of revenue recognition practices generated by companies, industries and capital markets. In this regard, IFRS 15 establishes a unique framework for revenue recognition. The basic principle of the framework is: an entity should recognize revenue to describe the transfer of goods or services promised to customers in an amount that reflects the consideration to which the entity expects to be entitled, in exchange for those goods or services. The revenue is recognized when or as the customer obtains control over the goods or services.

The revenues represent the gross inflow of economic benefits during the period generated within the normal activities of an entity, in the form of inflows of assets or increases in the value of assets, or decreases in liabilities, which result in increases in equity, other than those obtained through contributions from the capital holders. Revenues are increases in economic benefits recorded during the accounting period, in the form of incomes or increases in assets or reductions in liabilities, which materialize in increases in a company's own capital, other than those resulting from shareholders' contributions. The fair value is the value at which an asset can be traded or a debt settled, between interested parties and in good faith, in a transaction carried out under objective conditions.

IFRS 15 - Revenue from contracts with customers establishes a general framework that will be applied for the recognition of revenue from a contract concluded with a customer (with limited exceptions), regardless of the type of transaction or the industry. The standard establishes five steps to be followed for the revenue recognition:

- the identification of the contract/contracts with a client;
- the identification of performance obligations from a contract;
- the determination of the transaction price for the obligations in the contract;
- the allocation of the transaction price for the performance obligations;
- the revenue recognition when (or to the extent that) the entity fulfills a performance obligation.

IFRS 15 – The revenues from the contracts with customers focus on the identification of obligations and make a clear distinction between obligations that are satisfied "at a given point in time" and those that are satisfied "over a period of time"; this is determined by the manner in which the control of the goods or services is transferred to the customer. The principle underlying this standard is that the company should recognize and record revenues in a way that indicates the transfer of goods or services.

The revenues from the sale of finished products, of products made on other manufacturing sites and from other activities are recognized when there is an obligation to register a contract, i.e. all the following conditions were met:

- a) the parties to the contract have approved the contract (in writing, verbally or in accordance with other usual business practices) and they undertake to fulfill their obligations;
- b) the company can identify the rights of each party regarding the goods or services that will be transferred;
- c) the company can identify the payment terms for the goods or services that will be transferred;
- d) the contract has commercial content;
- e) it is likely that the Company will collect the counterperformance to which it will be entitled in exchange for the goods or services that will be transferred to the client.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The revenue from the sale of goods is recognized to illustrate the transfer of goods promised to customers at an amount that reflects the consideration to which they are expected to be entitled in exchange for those goods. The income is recognized when the Company fulfills a performance obligation by transferring some promised goods (an asset) to a customer. The asset is transferred when the customer obtains control over that asset. When the performance obligation is fulfilled, the value of the transaction price, which is allocated to that performance obligation, must be recognized as income. The company considers that the collection terms do not generate a financial component of the revenues invoiced to the distributors. The seller guarantees the quality of the delivered products for the entire period of validity under the condition that the customer complies with the legal rules and the written instructions received in advance from the seller regarding the transportation, handling and storage of the products.

In Romania, the standard terms agreed by the parties are as follows: 150 days from the invoice date for non-prescription products, medical devices, food supplements and products for the treatment of the tuberculosis and 180 days from the invoice date for prescription products. In foreign markets, the payment terms vary from the advance payment, before delivery to 90-120 days, depending on the volumes delivered, the customer and the market where the goods are transferred. The products will be sold by the manufacturer to the distributor at the list price in force on the invoicing date. The seller can grant the buyer commercial reductions/discounts, rebates and other commercial advantages provided by the legislation in force depending on the volume and structure of the sale made to the buyer, in accordance with the specific market conditions.

In accordance with IFRS 15, revenues are recognized in the amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services to a customer. According to IFRS 15, revenues will be recognized when a customer obtains control over the goods.

Revenues from the sale of finished products

The revenues obtained from the sale of products manufactured on our own manufacturing sites are recognized as revenues from the sale of finished products.

Revenues from the sale of products manufactured on partner sites

According to the requirements of Good Manufacturing Practices, the manufacturing of some products from the portfolio is carried out on partner manufacturing sites, the revenues from their sale are recognized as revenues from the sale of products manufactured on the partner sites.

Income from studies and research

The company is authorized to carry out clinical studies and laboratory analyzes for third parties, as the counterperformance is recognized as income from studies and research.

Income from various activities

The income from various activities includes the amounts obtained for the provision of wastewater collection services for economic agents in the vicinity.

Employee benefits – IAS 19

Current benefits granted to employees

The short-term benefits granted to employees include allowances, salaries and social security contributions. These benefits are recognized as expenses with the provision of services by employees.

Benefits after concluding the employment contract

Both the company and the employees have the legal obligation to contribute to the social insurance established at the National Pension Fund administered by the National Public Pensions House (contribution plan based on the "pay as you go" principle). The company has no other legal or implicit obligation to pay future contributions. Its obligation is only to pay the contributions when they become due. If the Company stops employing people who are contributors to the financing plan of the National Public Pensions House, it will have no obligation to pay the benefits earned by its own employees in previous years. The Company's contributions to the contribution plan are presented in the expenses chapter in the year to which it refers.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

2.7. Accounting policies – fixed tangible assets

Tangible assets are tangible elements that:

- a) are held in order to be used for the production or provision of goods or services, to be rented to third parties or to be used for administrative purposes;
- b) is expected to be used during several financial years.

Recognition:

The tangible assets, with the exception of land and buildings, are valued at net cost of accumulated depreciation and/or accumulated depreciation losses, if any.

The cost of an item of tangible assets must be recognized as an asset if and only if:

- a) it is probable that the entity will generate future economic benefits related to the asset;
- b) the cost of the asset can be reliably assessed.

Evaluation after recognition

After the recognition as an asset, an item of property, plant and equipment is accounted for at cost less the accumulated depreciation and the accumulated impairment losses.

After the recognition as an asset, an element of tangible assets whose fair value can be reliably assessed is accounted for at a revalued value and this is its fair value on the revaluation date. The revaluations are performed regularly enough to ensure that the book value does not differ significantly from what would have been determined by using the fair value at the end of the reporting period. The revaluation of tangible assets relates to buildings and land.

The fixed assets for production, supply or administrative purposes, or for purposes not yet determined, are recorded at cost minus any recognized impairment loss. The cost includes the professional fees and, for eligible assets, the costs of indebtedness capitalized in accordance with the accounting policy.

If an element of tangible assets is revalued, then the entire class of tangible assets to which that element belongs is revalued.

If the accounting value of a tangible fixed asset is increased as a result of the revaluation, then the increase is recognized in other elements of the overall result and accumulated in the equity as surplus from the revaluation. However, the increase must be recognized in profit or loss to the extent that it compensates for a decrease from the revaluation of the same asset previously recognized in profit or loss.

If the accounting value of an asset is reduced as a result of a revaluation, this reduction must be recognized in profit or loss. However, the reduction must be recognized in other elements of the comprehensive result to the extent that the revaluation surplus shows a credit balance for that asset. The reduction recognized in other elements of the global result reduces the amount accumulated in the equity capital as revaluation surplus.

The surplus from the revaluation included in the equity related to an element of tangible assets is transferred directly to the retained earnings when the asset is derecognized. The transfers from the revaluation surplus to the retained earnings are not made through profit or loss.

The effects of taxes on profit resulting from the revaluation of tangible assets are recognized and presented in accordance with IAS 12 Profit tax, if that is the case.

The company carried out the revaluation of immobilized assets such as land, buildings and special constructions existing in the heritage on 31.12.2023, for the purpose of accounting reporting.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The lands and buildings are provided in the Individual Statement of the financial position at their revalued amounts and it is the fair value on the revaluation date minus any accumulated depreciation and accumulated depreciation losses.

The revaluation was carried out by Darian DRS S.A., an authorized appraiser and an accredited member of ANEVAR. The revaluation of tangible fixed assets was carried out in accordance with the standards of practice in evaluation in compliance with the legislation in force on the date of the evaluation.

Basically, the evaluation approaches and applied methods relate to:

- In the cost approach, the cost of reconstruction or replacement of the building and land development is determined on the evaluation date, along with a value estimate of the losses that occurred due to physical wear, functional inadequacy and external conditions. To the estimated cost, after deducting the depreciation of the building, the real estate investor's profit and the estimated value of the land are added. The total represents the value indicated by the cost approach.
- In the income approach, the estimation of the value of the real estate property is sought through the perspective of the profitability it represents for the owner, based on the income from the rental. In the calculations to determine the value, an appropriate capitalization method and the appropriate capitalization rates are used.
- In the market approach, the aim is to estimate the value of the real estate property by analyzing the market for similar properties and by comparing these properties with the property subject to evaluation.
- In the direct comparison method, the market value is estimated by comparing the real estate with similar properties that have recently been sold, which are proposed for sale, or which are under contract.

The allocation of values for accounting purposes:

- in the case of land, the fair value was considered to be the market value obtained by the direct comparison method or the parceling and development analysis method;
- in the case of buildings and special constructions related to real estate, the fair value is equal to the value obtained under the cost approach - the net replacement cost;
- in the case of apartments, the fair value was assimilated to their market value.

The evaluation was based on the information regarding the price level corresponding to the month of December 2023. December 31, 2023 is the date on which the assumptions taken into account and the values estimated by the evaluator (evaluation date) are considered to be valid.

The revaluation results are detailed in Note 11 and the value after the revaluation on December 31, 2023 is 204,794,472 for land and 312,770,025 for buildings.

Due to the significant differences as a result of the revaluation, the company decided to reevaluate the land and constructions on December 31, 2022 and to correct the company's financial position on December 31, 2022.

Subsequent costs

The daily maintenance and repair expenses related to the tangible assets are not capitalized. They are recognized as costs of the period during which they are produced. These costs consist mainly of labor and consumables and they may also include the cost of low-value components. The expenses for the maintenance and repairs of tangible assets are recorded in the profit or loss account when they occur. The significant improvements brought to the tangible assets, which increase their value or life span, or which significantly increase their capacity to generate economic benefits are capitalized (increase accordingly the accounting value of that asset).

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

Depreciation of tangible assets

The depreciable value of an asset is allocated systematically over its useful life. The depreciation of an asset begins when it is available for use, that is, when it is in the location and condition necessary to be able to operate in the manner desired by management.

The company-owned lands are not depreciated.

For depreciable fixed assets, the company uses, from an accounting viewpoint, the straight-line depreciation method. The amortization periods are determined by an internal specialized committee according to the company's internal procedures. Below there is a brief presentation of the life spans of fixed assets by main categories:

Category	Lifetime
Buildings and constructions	24-40 years
Equipment and installations	7-24 years
Means of transport	4-6 years
Computing technology	2-15 years
Office furniture and equipment	3- 5 years

Depreciation of tangible assets

To determine whether an item of property, plant and equipment is impaired, an entity applies IAS 36 Impairment of Assets. At the end of each reporting period, the entity estimates whether there are indications of asset impairment. If such indications are identified, the entity estimates the recoverable value of the asset.

If and only if the recoverable amount of an asset is lower than its book value, the book value of the asset will be reduced to be equal to the recoverable value. Such a reduction represents an impairment loss. An impairment loss is recognized immediately in the profit or loss of the period, except when the asset is reported at the revalued value, in accordance with the provisions of another Standard (for example, in accordance with the revaluation model of IAS 16 Tangible assets). Any impairment loss in the case of a revalued asset is considered to be a decrease generated by the revaluation.

2.8. Intangible assets - accounting policies

Purchased intangible assets

The intangible assets are recorded according to IAS 38, "Intangible assets" and IAS 36, "Depreciation of assets". The externally acquired intangible assets are initially recognized at cost and subsequently amortized on a straight-line basis over their useful economic life.

The expenses related to the acquisition of patents, copyrights, licenses, brands and other intangible fixed assets recognized from an accounting viewpoint, with the exception of the costs of establishing, of the commercial fund, of intangible fixed assets with an indefinite useful life, thus classified according to the accounting regulations, it is recovered by means of straight-line depreciation deductions during the contract period or during the period of use.

Licenses

The licenses purchased separately are presented at historical cost. The licenses are capitalized based on the costs recorded with the acquisition and the commissioning. They have a fixed lifetime and they are subsequently accounted for at cost minus the accumulated depreciation and the depreciation losses.

Software

The licenses acquired separately are valued at historical cost. After the initial recognition, the software is accounted for at cost less any accumulated amortization and any impairment loss, if any.

The computer program maintenance costs are recognized at expense as they are achieved.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The depreciation of intangible assets

The computer programs are amortized linearly over a period of 3 years and the licenses are amortized during their validity, which cannot exceed 5 years.

The internally generated intangible assets (development costs)

To determine whether an internally generated intangible asset meets the recognition criteria, an entity divides the process of generating the asset into:

- (a) a research phase; and
- (b) a developmental phase.

The research expenses (or during the research stage of an internal project) are recognized as expenses of the exercise to which they relate.

The development expenses related to projects for new products intended for registration on the domestic and international markets, technological transfer projects are recognized as intangible assets. These consist of: the consumption of raw materials and consumables and the labor costs related to the hours worked for each project.

An internally generated intangible asset resulting from development (or from the development stage of an internal project) is recognized if and only if all the following conditions have been demonstrated:

- The technical feasibility of completing the intangible asset so that it is available for use or sale;
- The intention to complete the intangible asset and to use or sell it;
- The ability to use or sell the intangible asset;
- How the intangible asset will generate probable future economic benefits;
- The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset;
- The ability to reliably measure the expenses attributable to the intangible asset during its development.

The initially recognized amount for internally generated intangible assets is the amount of expenses incurred from the date on which the intangible asset meets the recognition criteria listed above for the first time. Where no internally generated intangible asset can be recognized, development expenses are recognized in profit or loss in the period in which they are incurred.

The recognition of costs in the accounting value of an intangible asset ceases when the asset is in the necessary condition to be able to function in the manner intended by the management. Thus, the costs of using or moving an intangible asset are not included in the accounting value of the asset in question.

The following costs are not included in the accounting value of an intangible asset:

- (a) the costs incurred when an asset capable of operating in the manner intended by the management has not yet been put into use; and
- (b) the initial operating losses, such as those borne as the demand for the production achieved by that asset takes shape.

After the initial recognition, the internally generated intangible assets are reported at cost less the accumulated amortization and the accumulated impairment losses, on the same basis as the intangible assets that are acquired separately.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The development expenses related to the projects for new products are recognized as intangible assets. These consist of: the consumption of raw materials and consumables, the labor costs related to the hours worked for each project, other fees paid to regulatory authorities in the pharmaceutical field with the amounts required for authorization.

Depreciation of intangible assets

An intangible asset is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. The gains or losses resulting from the derecognition of an intangible asset measured as the difference between the net proceeds from disposal and the accounting value of the asset are recognized in the profit or loss account when the asset is derecognised.

The impairment of non-financial assets (excluding stocks and deferred tax assets) - IAS 36 "Impairment of assets"

The assets owned by the company, as specified in IAS 36 "*Impairment of assets*", are subject to impairment tests whenever events or changes in circumstances indicate that it is possible that their accounting value cannot be fully recovered. When the book value of an asset exceeds the recoverable amount (that is, the highest amount between the value in use and the fair value minus the costs of sale), the asset is adjusted accordingly.

When it is not possible to estimate the recoverable amount of an individual asset, the impairment test is performed on the smallest group of assets to which it belongs, for which there are separately identifiable cash flows; its cash generating units (CGUs).

The depreciation expenses are included in the profit or loss account, except when they reduce previously recognized gains in other elements of the overall result.

The intangible assets are presented in detail in Note 12.

2.9. Stock accounting policies

According to the provisions of IAS 2, the stocks are assets:

- held for sale during the normal course of business;
- under production for such sale; or
- in the form of raw materials, materials and other consumables to be used in the production process or for the provision of services.

The valuation of inventories

The inventories are valued at the lower of cost and the net achievable value.

The raw materials and consumables are valued at the purchase price, including the transport, the handling costs and the net of commercial discounts, the disposal of raw materials and consumables inventories is done using the weighted average price method. The work in progress and the finished goods are valued at actual cost consisting of direct materials, direct labor and directly attributable production expenses and other costs incurred to bring them to their existing location and condition using the standard cost method. The standard costs take into account normal levels of consumption of raw materials and consumables, the labor, the efficiency and the capacity utilization. They are reviewed regularly and, if necessary, revised according to the current conditions.

The cost of inventories

The cost of inventories includes all acquisition costs, conversion costs, as well as other costs incurred to bring the inventories to their current condition and location.

The inventory purchase costs include the purchase price, import taxes and other taxes (except those that the entity can later recover from the tax authorities), transportation costs, handling and other costs that can be directly attributed to the purchase of finished products, materials and services. The trade discounts, rebates and other similar items are deducted to determine the purchase costs.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

Adjustments for inventory impairment - Inventory impairment assessment is performed on an individual basis and it is based on the management's best estimate of the present value of cash flows expected to be received. Each impaired asset is analyzed individually. The accuracy of the adjustments depends on the estimation of future cash flows. The adjustments regarding inventories are based on the calculation performed at the end of the financial year for the specific value adjustment related to inventories of raw materials, consumables and finished products that no longer correspond from a qualitative viewpoint. The calculation of the general adjustment for the depreciation of finished products and goods is made according to the period of validity of the items in stock.

2.10. Financial instruments

A financial instrument is any contract that gives rise to a financial asset for one entity and to a financial liability or equity instrument for another.

Financial assets

Recognition and initial evaluation

The financial assets are classified, upon the initial recognition, and subsequently evaluated at amortized cost, the fair value through other elements of the overall result.

The classification of financial assets at initial recognition depends on the contractual characteristics of the financial asset's cash flow and the company's business model for their management.

The financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows.

All the regular purchases or sales of financial assets are recognized and derecognized based on the date of the transaction. The purchases or sales in the usual way are purchases or sales of financial assets that require the delivery of the assets within the time frame established by regulations or conventions on the market.

With the exception of trade receivables that do not contain a significant financing component, the company initially evaluates a financial asset at fair value.

The receivables arise mainly through the provision of goods and services to customers (for example, trade receivables), but also they incorporate other types of contractual monetary assets (advances granted to suppliers of goods and services, commercial effects not yet due).

The adjustments for the impairment of commercial receivables include adjustments for receivables in litigation and adjustments established by applying the simplified analysis model provided by IFRS 9 Financial Instruments. The company applies the simplified approach of IFRS 9 for the measurement of expected credit losses, which aims at a reduction of expected loss (ECL) over the lifetime for all trade receivables. To measure the expected credit losses, trade receivables are grouped based on common credit risk characteristics and days past due.

The expected loss rates are based on the payment profiles of the sales for a period of 36 months before December 31, 2023 and January 1, 2023, and on the corresponding historical credit losses recorded during this period. Historical loss rates are adjusted to reflect the current and future information regarding the macroeconomic factors that impact the customers' ability to settle receivables.

The trade receivables are canceled when there is no reasonable expectation of recovery. The indicators showing that there is no reasonable expectation of recovery include, among others, the fact that a debtor does not commit to a repayment plan and that a debtor does not make contractual payments for a period of more than 90 days in arrears. The impairment losses on trade receivables are presented as net impairment losses within the operating profit. The subsequent recoveries of previously canceled amounts are credited to the same item.

Adjustments for the impairment of receivables – For trade receivables, a simplified approach is adopted in which the impairment losses are recognized based on expected lifetime credit losses at each reporting date. If there are credit insurances or guarantees for the outstanding balances, the calculation of expected losses from receivables is based on the probability of non-repayment related to the insurer for the insured part of the outstanding balance and the remaining uncovered amount will have the probability of non-repayment of the counterparty. For commercial receivables, the regulated simplified model is used of IFRS 9.

All the financial liabilities are subsequently valued at amortized cost using the effective interest method.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The effective interest method is a method of calculating the amortized cost of a financial debt and allocating interest expenses over the relevant period. The effective interest rate is the rate that accurately updates the estimated future cash payments (including all fees and points paid or received that are an integral part of the effective interest rate, the transaction costs and other premiums or discounts) over the estimated life of the financial debt, or (if applicable) a shorter period, at the amortized cost of a financial debt.

The company derecognizes the financial liabilities when and only when the company's obligations are honored, canceled or have expired. The difference between the accounting value of the derecognized financial debt and the consideration paid and to be paid is recognized in profit or loss.

The cash and cash equivalents

The cash from the individual statement of the financial position includes the cash at the banks and in the cash register. The company's exposure to the credit risk associated with the cash and cash equivalents is limited because it collaborates with solid financial institutions in terms of cash management and banking operations.

In the individual statement of cash flows, the cash and cash equivalents are included. The book value of these assets is approximately equal to its fair value.

2.11. The taxation

The income tax expense includes the current tax and the deferred tax.

The current tax

The current income tax assets and liabilities are valued at the amount expected to be paid or paid to the tax authorities. The tax rates and fiscal laws used to calculate the amount are those that are adopted or substantially adopted at the reporting date.

The current tax includes the tax to be paid or recovered related to the taxable profit or loss(es) of that particular year and any adjustment of the tax to be paid or recovered related to previous years. The amount of the current tax to be paid and recovered is the best estimate of the amount expected to be paid or recovered that reflects the uncertainty related to the profit tax. It is determined using the tax rates that have been adopted or largely adopted at the reporting date. The current tax credits and debts are offset only if certain criteria are met.

Taxation - The taxation system in Romania is undergoing a stage of consolidation and harmonization with the European legislation. There are uncertainties regarding the interpretation of complex tax regulations, changes in tax laws and the amount and timing of future taxable income. Considering the diversity of business relationships and the longevity and complexity of the existing contractual agreements, the differences that occur between the actual results and the assumptions made or future changes to these assumptions could require future adjustments to the tax revenues and expenses already recorded. In Romania, the fiscal year remains open for fiscal verification for 5 years. The management of the company considers that the fiscal obligations included in the individual financial statements are adequate.

The deferred tax

In calculating the deferred tax, the company will take into account the provisions of IAS 12 "Profit tax".

The deferred tax is recognized as the difference between the accounting value of assets and liabilities in the financial statements and the corresponding tax bases used to calculate the taxable income.

The deferred tax liabilities are generally recognized for all the taxable temporary differences, while the deferred tax assets are recognized for deductible temporary differences.

The current tax and the deferred tax are recognized in profit or loss, except in the case where they refer to elements that are recognized in other elements of the global result or directly in equity, in which case the current tax and the deferred tax are also recognized in other elements of the global result or, respectively, directly in equity.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The recognition of deferred tax assets is limited to those moments when it is possible that the taxable profit of the following period will be available.

The amount of the asset or liability is determined using tax rates that have been largely adopted up to the reporting date and are expected to be applied when the deferred tax liabilities/(assets) are settled/(recovered).

The company offsets the receivables and liabilities regarding the deferred tax if and only if it has a legally enforceable right to offset the assets and liabilities with the current tax and the assets and liabilities with the deferred tax refer to the profit tax levied by the same fiscal authority.

2.12. The provisions

The provisions are recognized when the Company has a present obligation (legal or implicit) as a result of a past event; it is probable that an outflow of resources incorporating economic benefits will be necessary to settle the obligation and a reliable estimate of the obligation's value can be made.

The provision is valued at the best estimate of the expenses necessary to settle the obligation at the reporting date, updated at a pre-tax rate that reflects the current market assessments of the value of money over time and the specific risks of the debt.

A provision is recognized if, as a result of a previous event, the Company has a current, legal or implied obligation, which can be reliably estimated and it is likely that an outflow of resources incorporating the economic benefit will be required to settle the obligation. The provisions are determined by discounting expected future cash flows using a pre-tax discount rate that reflects the current market assessments of the time value of money and specific debt risks.

According to IAS 37 "Provisions, contingent liabilities and contingent assets", a provision must be recognized if:

- a) The company has a current obligation (legal or implicit) generated by a past event;
- b) it is likely that for the settlement of the obligation an outflow of resources incorporating economic benefits will be necessary;
- c) a credible estimate of the value of the obligation can be made.

If these conditions are not met, a provision should not be recognized.

Judicial proceedings - The company reviews the unresolved legal cases following the developments in the judicial proceedings and the existing situation at each reporting date, in order to evaluate the provisions and the presentations from its individual financial statements. Among the factors considered in making decisions related to provisions are the nature of the litigation or claims and the potential level of damages in the jurisdiction in which the litigation is adjudicated, the progress of the case (including the progress after the date of the individual financial statements but before those statements are issued), the opinions or the opinions of legal advisers, the experience in similar cases and any decision of the company's management related to how it will respond to the litigation, complaint or assessment.

2.13. The recognition of expenses

The recognition of expenses constitutes reductions of the economic benefits recorded during the accounting period in the form of outflows or decreases in the value of assets or increases in liabilities, which materialize in reductions of equity, other than those resulting from their distribution to shareholders.

The accounting estimates of expenses - There are objective situations in which until the closing date of some fiscal periods or until the closing date of a financial exercise the exact values of some expenses committed by the company are not known (example-marketing campaigns-sales of product promotion and stimulation of sales). For this category of expenses, preliminary expenses will be made, which will be actually recorded in the following periods.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

2.14. The dividends

The dividends are recognized as a deduction from equity in the period in which their distribution is approved and are recognized as a liability to the extent that they are unpaid at the reporting date. The dividends are presented in the notes to the individual financial statements when their distribution is proposed after the reporting date and before the date of issuance of the individual financial statements.

The dividends are distributed from the net annual distributable profit based on the audited individual annual financial statements, after their approval by the Ordinary General Meeting of the Company and after the approval of the dividend proposal by the Ordinary General Meeting. The distributable profit represents the part of the net profit of the financial year that can be distributed in the form of a dividend after legal and statutory distributions have been made, such as the distribution for the legal reserve.

The shareholders receive dividends proportional to the ownership share of the paid-up social capital of the company and no right of priority or preference over the distribution of dividends in favor of any shareholder is applicable.

The proposal regarding the distribution of dividends made by the Management Board will be submitted to the vote of the General Meeting of Shareholders, as a rule, in the same meeting where the audited individual financial statements are approved.

When accounting for dividends, the provisions of IAS 10 "Events subsequent to the balance sheet date" are taken into account.

2.15. Capital and reserves

Capital and reserves (equity) represent the rights of the shareholders over the assets of an entity, after deducting all debts. The equity includes: capital contributions, reserves, retained earnings and financial year results.

Antibiotice S.A. was established according to Law no. 31/1990 on commercial companies, with subsequent additions and changes.

In the first set of individual financial statements prepared according to IFRS, the company applied IAS 29 "Financial reporting in hyperinflationary economies" for the shareholders' contributions obtained before January 1, 2004, namely they were adjusted with the corresponding inflation index.

2.16. Earnings per share

The company presents the basic and diluted result per share for ordinary shares. The result per basic share is determined by dividing the profit or loss attributable to the company's ordinary shareholders by the weighted average number of ordinary shares related to the reporting period.

The result per share is presented in detail in Note 10.

Segmented reporting

A segment is a distinct component of the company that provides certain products or services (activity segment) or which provides products and services in a certain geographic environment (geographic segment) and which is subject to risks and benefits different from those of the other segments. From the view point of the activity segments, the company does not identify distinct components from the viewpoint of the associated risks and benefits.

2.17. Affiliated parties

A person or a close member of that person's family is considered affiliated with a Company if that person:

- (i) has control or joint control over the company;
- (ii) has a significant influence on the company;
- (iii) is a member of the key management personnel.

The key management personnel represent those persons who have the authority and responsibility to plan, direct and control the company's activities directly or indirectly, including any (executive or non-executive) director of the entity.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The transactions with the key personnel include exclusively the salary benefits granted to them as presented in Note 7 - Expenses with employee benefits and the remuneration of the members of the Management Board.

An entity is affiliated to the company if it meets any of the following conditions:

- (i) the entity and the company are members of the same group (which means that each parent company, subsidiary and subsidiary in the same group is linked to the others);
- (ii) the entity is an associated entity or joint venture of the other entity (or an associated entity or joint venture of a member of the group of which the other entity is a part);
- (iii) both entities are participating associations of the same third party;
- (iv) one entity is a joint venture of a third entity, and the other is an associated entity of the third entity;
- (v) the entity is a post-employment benefits plan for the benefit of the employees of the reporting entity or of an entity affiliated with the reporting entity. If the reporting entity itself represents such a plan, the sponsoring employers are also affiliated with the reporting entity;
- (vi) the entity is controlled or jointly controlled by an affiliated person;
- (vii) the affiliated person who holds the control significantly influences the entity or the person is a member of the key personnel in the entity's management (or the entity's parent company).

The company does not carry out transactions with entities described in letters (i) - (vii) above.

2.18. Contingent assets and liabilities

A contingent liability is:

- a) a potential obligation arising as a result of previous events and whose existence will only be confirmed by the occurrence or the occurrence of one or more uncertain future events, which are not fully controlled by the company; or
- b) a current obligation arising as a result of previous events, but which is not recognized because:
 - it is not likely that resource outflows will be required to incorporate economic benefits for the settlement of this obligation; or
 - the value of the obligation cannot be assessed reliably enough.

The contingent liabilities are not recognized in the financial statements, but they are presented in the notes, with the exception of the case where the possibility of an outflow of resources incorporating economic benefits is remote.

A contingent asset is a potential asset that appears as a result of previous events and whose existence will only be confirmed by the occurrence or the non-occurrence of one or more uncertain future events, which are not fully controlled by the company. A contingent asset is not recognized in the financial statements, but it is presented when an inflow of economic benefits is probable.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

2.19. The risk management

The activities carried out by the company may give rise to various risks. The risk management monitors the impact of these risks and events that may have adverse effects on the company's operations.

The company is exposed through its operations to the following financial risks:

- The credit risk;
- The market risk, which includes the interest rate risk, currency risk and the instrument price risk;
- The liquidity risk.

Like all other activities, the company is exposed to risks arising from the use of financial instruments. This note describes the company's objectives, policies and processes for managing these risks and the methods used to assess them. Additional quantitative information regarding these risks is presented in these individual financial statements.

There have been no major changes in the company's exposure to risks regarding the financial instruments, its objectives, policies and processes for managing these risks or the methods used to evaluate them compared to previous periods, except as otherwise mentioned in this note.

The company is mainly exposed to risks arising from the use of financial instruments; the main financial instruments used by the company are:

- Trade receivables and other receivables;
- Cash and cash equivalents;
- Trade debts and other debts.

A summary of the financial instruments held by category is presented below:

Trade receivables, cash and cash equivalents at amortized cost	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)
Commercial and similar receivables	235,771,990	196,402,918	204,033,217
Cash and cash equivalents	1,807,930	1,727,454	1,727,454
Total	237,579,920	198,130,372	205,760,671

The values by maturity intervals of the financial assets are

Financial liabilities at amortized cost	Period ending on December 31, 2023 (audited)	Period ending on December 31, 2022 (audited)	Period ending on December 31, 2022 (restated) (restated)
Trade and similar debts	150,780,362	86,067,391	99,391,828
Bank loans	29,552,092	34,008,116	34,008,116
Total	192,993,444	120,075,507	133,399,944

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The values by maturity intervals of the financial debts are presented at the liquidity risk

The calculation and analysis of the net situation (equity)

Indicators (LEI)	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)
Short-term loans and credits	29,552,092	34,008,116	34,008,116
Long-term loans and credits	36,750,203	46,973,501	46,973,501
Cash and cash equivalents	(1,807,930)	(1,727,454)	(1,727,454)
Net liabilities	64,494,365	79.254,163	79.254,163
Total equity	846,964,120	641,430,601	740,983,592
Net debt in equity (%)	7.61%	12.36%	10.70%

The credit risk

The credit risk is the risk of financial loss for the company that occurs if a customer or counterparty to a financial instrument does not fulfill its contractual obligations. The company is exposed to the credit risk resulting from its operational activity, mainly from the collection of trade receivables.

Regarding the cash and cash equivalents, the company analyzed the credit risk and determined that it is not significant.

Receivables

The commercial receivables come from commercial relations with distributors in the national pharmaceutical market and from commercial relations with partners in the international market.

Within the company level, there is a Commercial Policy, in which the commercial conditions of sale are clearly presented and there are conditions imposed in the selection of clients.

Within the company, the exposure to credit risk is controlled. A specialized department permanently monitors each debtor in the commercial relations on the domestic market.

For the domestic and international receivables, the credit risk is constantly evaluated, taking into account the financial performance, the payment history and insurance policies are concluded.

The balance of receivables is monitored at the end of each month and any delay from a customer is analyzed.

The credit risk profile of the commercial receivables is presented according to their maturity, monitoring the receivables from the domestic market and from the international market separately. The historical non-payment rates are analyzed.

The trade receivables do not bear interest and they generally have payment terms that vary between advance payment and 180 days.

The trade receivables are considered in default when they are overdue for more than 90 days. The trade receivables are canceled when the management considers that there is no probability of collection.

In accordance with IFRS 9, the financial assets and liabilities of the company are valued at amortized cost.

The company has not included information regarding the fair value for financial assets and liabilities that are not valued at fair value if the accounting value represents a reasonable approximation of the fair value. The company used the simplified approach of IFRS 9 to determine the expected credit loss for trade receivables related to third parties that did not contain a significant financing component.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The methodology used by the company to evaluate the expected losses of trade receivables can be described as follows:

- determining an appropriate watch period for tracking the historical loss rate. The company selected 3 previous periods for data collection;
- collecting data on commercial receivables and grouping them according to maturity in each analyzed period;
- the analysis of the evolution of these balances over a period of 12 months and the determination of the unpaid amounts from each group of balances to determine the proportion of balances from each category of debt that was not collected in the end;
- the determination of the weighted average rate of losses (%) according to maturity for the 3 analyzed periods;
- the application of the loss rate thus determined for trade receivables on December 31, 2023.

The market risk

The market risk represents the possibility of recording losses or not achieving the estimated profits resulting, directly or indirectly, from fluctuations in the market price, interest rate or exchange rate related to the company's assets and liabilities.

The main subcategories of the market risk are the following:

The interest rate risk: the risk that the fair value of future cash flows or future cash flows related to financial instruments will fluctuate with the changes in interest rates.

The currency risk: The currency risk: the risk that the fair value of future cash flows or future cash flows related to financial instruments will fluctuate with changes in the exchange rates.

The company is mainly exposed to the currency risk in purchases made from external suppliers of raw materials, packaging materials and other materials. The suppliers from whom the company purchases these items necessary to support the production of medicines must have quality documents, provided in the European rules for the production and registration of medicines on the market.

On December 31, 2023, the company's net exposure to currency exchange risk was as follows:

Assets/liabilities in EURO equivalent to LEI	For the year ended on	
	31-Dec-23	31-Dec-22
Monetary financial assets	4,965,465	1,637,820
Monetary financial liabilities	(22,478,573)	(19,978,727)
Net financial assets	(17,513,109)	(18,340,906)
Variation RON/EUR	Gain/ Loss	
RON appreciation against EUR by 5%	(875,655)	(917,045)
RON depreciation against EUR by 5%	875,655	917,045
Impact on the result	-	-
Assets and liabilities in EURO		
Assets and liabilities in EURO	998,164	331,047
Assets and liabilities in EURO	(4,518,669)	(4,038,228)
Net financial assets	(3,520,506)	(3,707,181)

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

Assets/liabilities in USD equivalent LEI	31-Dec-23	31-Dec-22
Monetary financial assets	13,691,379	22,693,672
Monetary financial liabilities	(13,021,662)	(8,041,390)
Net financial assets	669,717	14,652,283
Variation RON/USD		
RON appreciation against USD by 5%	33,486	732,614
RON depreciation against USD by 5%	(33,486)	(732,614)
Impact on the result	-	-
Assets and liabilities in USD		
Monetary financial assets	3,045,371	4,896,576
Monetary financial liabilities	(2,896,406)	(1,735,077)
Net financial assets	148,965	3,161,499

The company's net exposure to foreign exchange risk, equivalent in lei, is presented in the following table:

Assets / Liabilities	31-Dec-23	31-Dec-22
LEI	82.609.998	88.021.883
EUR	(17.513.109)	(18.340.906)
USD	669.717	14.652.283
Other currencies (CAD, GBP)	(4.969)	(75.071)
Net exposure	65.761.638	84.258.188

The liquidity risk

The company's policy is to ensure that it will have enough cash to allow it to meet its obligations when they become due. To achieve this objective, it seeks to maintain the cash balances to meet the payment needs.

The liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The company prepares budgets, analyzes and estimates of cash flows, which allow the evaluation of the level of funding required in the following periods.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

The accounting values of monetary assets and liabilities are presented below:

The year 2023

December 31, 2023	Up to 3 months	Between 3 -12 months	Over 12 months	Total
Trade and similar receivables	113,909,596	106,711,418	15,150,976	235,771,990
Cash and cash equivalents	1,807,930			1,807,930
Total	115,717,526	106,711,418	15,150,976	237,579,920

December 31, 2023	Up to 3 months	Between 3-12 months	Over 12 months	Total
Trade and similar debts	82,696,971	68,083,391	-	150,780,362
Other debts	9,831,550	-	-	9,831,550
Short term loans	2,673,493	26,878,599	-	29,552,092
Long term loans	-	-	36,750,203	36,750,203
Total	95,202,014	94,961,990	36,750,203	226,914,207
Net position in 2023	20,515,512	11,749,428	(21,599,227)	10,665,713

The year 2022

December 31, 2022 reported	Up to 3 months	Between 3-12 months	Over 12 months	Total
Trade and similar receivables	111,039,321	70,198,778	15,164,819	196,402,918
Cash and cash equivalents	1,727,454	-	-	1,727,454
Total	112,766,775	70,198,778	15,164,819	198,130,372

31 decembrie 2022 raportat	Up to 3 months	Between 3-12 months	Over 12 months	Total
Trade and similar debts	85,426,642	640,749	-	86,067,391
Other debts	8,280,670	-	-	8,280,670
Short term loans	2,658,875	31,349,241	-	34,008,116
Long term loans	-	-	46,973,501	46,973,501
Total	96,366,187	31,989,990	46,973,501	175,329,678
Net position in 2022	16,400,588	38,208,788	(31,808,682)	22,800,694

The company's management closely monitors the situation and acts accordingly. The management believes that, based on the perspective of the cash flow and the support available from the shareholders, the Interval of more than 12 months the company should be in a negative position regarding the ability to pay. The management is confident that in 12 months there will be enough resources to cover the payment needs.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

2. GENERAL INFORMATION (continued)

2.20. New IFRS accounting standards and amendments to existing standards, which are in force this year

In the current year, the company applied a series of amendments to the IFRS Accounting Standards issued by the International Accounting Standards Board (IASB) and adopted by the European Union, which became mandatory for the reporting period starting on or after January 1, 2023. Their adoption did not have a significant impact on the presentation of information nor on the amounts reported in these individual financial statements.

-The new standard IFRS 17 "Insurance contracts" including amendments to IFRS 17 issued by the IASB in June 2020 and December 2021

-Amendments to IAS 1 Presentation of accounting policies

-Amendments to IAS 8 Definition of accounting estimates

-Amendments to IAS 12 Deferred tax related to receivables and payables arising from a single transaction

-Amendments to IAS 12 International tax reform — model rules regarding pillar II*

** the exception mentioned in the amendments to IAS 12 (for an entity not to recognize and not to provide information on deferred tax assets and liabilities related to deferred tax that is subject to OECD pillar two) is applicable immediately after the issuance of the amendments and retrospectively in accordance with IAS 8. The other presentation requirements are mandatory for annual periods beginning on or after January 1, 2023.*

New IFRS accounting standards and amendments to existing standards issued and adopted by the EU, but which have not yet entered into force

At the date of approval of these individual financial statements, the company did not apply the following modified IFRS Accounting Standards that were issued by the IASB and adopted by the EU, but they have not yet entered into force:

-Amendments to IFRS 16-Lease liabilities in a sale and leaseback transaction, effective date from January 1, 2024.

- The amendments to IAS 1-Classification of debts into short-term debts and long-term debts and long-term debts with financial indicators, effective date from January 1, 2024.

New IFRS accounting standards and amendments to existing standards issued but not yet adopted by the EU

Currently, the IFRS as adopted by the EU do not differ significantly from the IFRS adopted by the International Accounting Standards Board (IASB), with the exception of the following new standards and amendments to existing standards, which were not adopted by the EU at the date of authorization of these individual financial statements:

-Amendments to IAS 7 and IFRS 7 Financing agreements in relation to suppliers (date of entry into force established by the IASB: January 1, 2024)

They have not yet been adopted by the EU.

-The amendments to IAS 21 Lack of convertibility (effective date established by the IASB: January 1, 2025). They have not yet been adopted by the EU.

- IFRS 14 Deferral accounts related to regulated activities (date of entry into force established by: January 1, 2016). The European Commission decided not to start the approval process of this interim standard and to wait for the final standard.

- Amendments to IFRS 10 and IAS 28 Sale of or contribution of assets between an investor and its associated entities or joint ventures and subsequent amendments (the date of entry into force was postponed for an indefinite period by the IASB, but early application is allowed).

The approval process was postponed for an indefinite period until the completion of the research project on the equivalence method.

The company anticipates that the adoption of these new standards and the amendments to the existing standards will not have a significant impact on the individual financial statements of the company in the future.

The hedge accounting against the risks of a portfolio of financial assets and liabilities whose principles have not been adopted by the EU remains unregulated. According to the company's estimates, the use of hedge accounting for a portfolio of financial assets and

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

liabilities according to IAS 39: "Financial instruments: recognition and evaluation" would not significantly affect the individual financial statements, if it is applied at the balance sheet date.

3. OPERATING INCOME

An analysis of the revenues is presented below:

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Sales of finished products	572,102,283	481,986,592
Sales of products made on other manufacturing sites	134,284,838	103,496,897
Revenues from other activities	1,304,436	1,057,375
Commercial discounts granted	(106,910,732)	(102,816,678)
Total	600,780,825	483,724,186

According to the geographical distribution, the turnover is structured as follows:

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
On the Romanian market	382,398,442	299,195,890
On foreign markets	218,382,383	184,528,296
Total	600,780,825	483,724,186

4. OTHER REVENUES

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Revenues from revaluation of tangible assets	564,611	-	-
Revenues from compensations, fines and penalties	4,178	33,135	33,135
Revenues from the sale of tangible and intangible assets	1,500	103,545	103,545
Other operating revenues	853,993	1,896,692	7,194,162
Total	1,424,282	2,033,372	7,330,842
Revenues from subsidies	270,907	302,979	302,979
Total	1,695,189	2,336,351	7,633,821

5. EXPENDITURE WITH RAW MATERIALS, USED CONSUMABLES AND GOODS

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Raw material expenses	141,828,708	109,740,746
Consumables expenses	15,248,456	16,233,520
Freight charges	61,063,703	51,126,808
Consumed packaging	27,590	16,183

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

Total	218,168,457	177,117,257
--------------	--------------------	--------------------

6. EXPENSES WITH EMPLOYEE BENEFITS AND REMUNERATION OF THE MEMBERS OF THE MANAGEMENT BOARD

	Period ending on December 31, 2023	Period ending on December 31, 2022 (redported)	Period ending on December 31, 2022 (restated)
	RON	RON	RON
Wages	133,922,841	112,985,753	115,811,858
Labor insurance contribution	3,030,715	2,563,870	2,563,870
Meal vouchers and other benefits granted to employees	9,406,446	7,391,101	7,391,101
Total expenses with employee benefits	156,053,526	122,940,724	125,766,529

The remuneration granted to the Management Board and the Executive Management is presented in the following table:

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Wages	6,806,579	5,774,720
Civil contracts	901,685	914,091
Taxes and social contributions	216,331	154,855
Variable allowances	3,108,018	1,787,544
Total	11,032,613	8,631,210

7. OTHER EXPENSES

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Expenses with services performed by third parties	14,141,264	14,176,126	14,176,126
Repair expenses	2,545,491	1,959,716	1,959,716
Expenses with other taxes and fees*	47,588,521	38,256,584	38,256,584
Protocol, advertisement and publicity expenses	24,162,131	23,271,794	21,390,637
Insurance premium expenses	2,818,950	1,962,310	1,962,310
Consultancy expenses	106,912	-	-
Other general expenses	3,986,392	11,585,068	11,585,068
Rent expenses	595,149	293,025	293,025
Travel expenses	1,643,571	824,117	824,117
Expenses with postal and telecommunications fees	562,380	544,524	544,524
Expenses with compensations, fines and penalties	5,608	25,075	25,075
Expenses with the revaluation of tangible assets	1,459,611	-	-
Total	99,615,980	92,989,339	91,017,182

* For more details regarding the 2022 restatements, see Note 23

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

7. OTHER EXPENSES (continued)

Other general expenses in the amount of 3,986,392 lei recorded in 2023 include:

- environmental protection expenses in the amount of 1,485,956 lei;
- expenses for supporting the international sales, amounting to 1,039,541 lei;
- professional training expenses, in the amount of 955,676 lei;
- expenses with bank commissions in the amount of 504,921 lei;
- other operating expenses in the amount of 298 lei.

Other general expenses in the amount of 11,585,068 lei recorded in 2022 include:

- environmental protection expenses in the amount of 1,124,096 lei;
- expenses for supporting the international sales, amounting to 2,496,617 lei;
- professional training expenses, in the amount of 554,862 lei;
- expenses with bank commissions in the amount of 582,729 lei;
- losses from receivables and various debtors in the amount of 4,382,606 lei (related to the removal from the register of unpaid receivables from the period 2000-2017 from insolvent debtors, whose bankruptcy proceedings were closed by final court decisions);
- other operating expenses in the amount of 2,444,159 lei.

* For more details regarding the 2022 corrections, see Note 23

Expenses with other taxes and fees

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Expenses with the tax on buildings	1,523,139	1,399,608
Land tax expenses	570,498	535,211
Expenses with the tax on means of transport	38,606	41,922
Expenses with other taxes and fees	8,390,952	4,879,581
Expenses with the tax for the registration of licenses	6,672	-
Expenses regarding the environmental fund	40,522	62,378
Expenses with company taxes and advertising	5,472	5,232
Claw-back fee charges	37,012,660	31,332,652
Total	47,588,521	38,256,584

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

8. FINANCIAL RESULT

Financial income and expenses:

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Interest expenses	(4,145,606)	(3,591,289)
Interest income	4,374	1,437
Net interest expense	(4,141,232)	(3,589,852)
Income from exchange rate differences	11,456,207	10,696,832
Expenses from exchange rate differences	(12,401,364)	(11,494,347)
Net exchange rate differences	(945,157)	(797,515)
Other financial expenses	77,403	(209,789)
The financial result	(5,008,986)	(4,597,156)

The interest expenses refer to loans from banks, which are valued at amortized cost.

9. EXPENSES WITH CURRENT PROFIT TAX AND DEFERRED TAX

Amounts recognized in the profit or loss situation

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)
	RON	RON	RON
Current income tax expenses	10,606,050	3,929,305	3,929,305
The impact of deferred income tax	(170,400)	(539,502)	9,912,379
Total	10,435,650	3,389,803	13,841,684

Amounts recognized in other elements of the global result

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)
	RON	RON	RON
The reserve from the revaluation of tangible assets	(5,754,368)	-	(16,494,168)
Total	(5,754,368)	-	(16,494,168)

The profit tax

The current profit tax for the years 2023 and 2022 is determined at a statutory rate of 16% based on the adjusted accounting profit with the non-deductible expenses and non-taxable income. The final value of the profit tax is reduced by tax credits.

The deferred income tax on December 31, 2023 and December 31, 2022 is determined based on the tax rate of 16%, which is expected to be in effect when the temporary differences resume.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

9. EXPENSES WITH CURRENT PROFIT TAX AND DEFERRED TAX (continued)

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)
The accounting profit:	91,524,246	41,903,230
Tax at the Romanian corporate tax rate of 16% (2022: 16%)	14,643,879	6,704,517
Effect of non-deductible expenses	3,278,248	5,697,435
The effect of the non-taxable income	(2,520,784)	(2,847,492)
The tax related to the reinvested profit	(2,602,260)	(4,883,771)
Other tax effects	(2,363,432)	(1,335,975)
Income tax expenses	10,435,650	3,389,803

Modification of deferred tax balances

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)
	RON	RON	RON
Inventories	2,264,204	8,790,913	2,020,616
Employee benefits	2,619,657	-	1,068,694
Total deferred tax assets	4,883,864	8,790,913	3,089,310
Intangible assets	(68,285,091)	(39,662,234)	(60,906,569)
Total deferred tax liabilities	(68,285,091)	(39,662,234)	(60,905,569)
Net deferred tax liabilities	(63,401,227)	(30,871,210)	(57,817,259)

10. EARNINGS PER SHARE

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Net profit (A)	81,088,596	38,513,427	51,472,037
Number of ordinary shares (B)	671,338,040	671,338,040	671,338,040
Basic and diluted earnings per share (A/B)	0.1208	0.0574	0.0767

* For more details regarding the 2022 corrections, see Note 23

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

11. TANGIBLE FIXED ASSETS

	<u>Land</u>	<u>Buildings</u>	<u>Machinery and equipment, vehicles</u>	<u>Installation s and furniture items</u>	<u>In-progress fixed tangible assets</u>	<u>Total</u>
COST						
Balance on January 1, 2022	189,933,152	157,513,278	225,871,215	8,749,574	64,714,983	646,782,202
Increases:	-	-	-	-	37,576,233	37,576,233
Transfers to / from fixed assets in progress	-	54,141,612	37,931,262	1,130,587	(93,203,461)	-
Increase / (decrease) from revaluation	13,741,550	57,221,385	-	-	-	70,962,935
Disposals and other discounts	-	(901,646)	(2,434,289)	(40,719)	-	(3,376,654)
Balance on December 31, 2022 restated *	203,674,702	267,974,628	261,368,188	9,839,442	9,087,755	751,944,716
Balance on January 1, 2023	203,764,702	267,974,628	261,368,188	9,839,442	9,087,755	751,944,716
Increases:	-	-	-	-	83,025,003	83,025,003
Transfers to / from fixed assets in progress	-	21,432,297	27,448,395	560,988	(49,441,679)	-
Increase / (decrease) from revaluation	1,119,770	23,416,021	-	-	-	24,535,791
Disposals and other discounts	-	(52,921)	(2,573,774)	(165,743)	-	(2,792,438)
Balance on December 31, 2023	204,794,472	312,770,025	286,240,810	10,234,687	42,671,079	856,713,072

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

11. TANGIBLE FIXED ASSETS (continued)

	Land	Buildings	Machinery and equipment, vehicles	Installations and furniture items	In-progress fixed tangible assets	Total
CUMULATIVE AMORTIZATION						
Balance on January 1, 2022	-	23,591,076	135,912,271	6,438,037	-	165,941,384
Depreciation recorded during the year	-	8,881,920	11,872,360	298,144	-	21,052,424
Disposals and other discounts	-	(347,382)	(2,434,288)	(40,719)	-	(2,822,389)
Cumulative depreciation of revalued tangible assets	-	(32,125,614)	-	-	-	(32,125,614)
Balance on December 31, 2022 restated	-	-	145,350,343	6,695,462	-	152,045,805
Balance on January 1, 2023	-	-	145,350,343	6,695,462	-	152,045,805
Depreciation recorded during the year	-	10,705,925	14,571,307	409,016	-	25,686,248
Disposals and other discounts	-	(52,921)	(2,628,148)	(165,444)	-	(2,846,513)
Cumulative depreciation of tangible fixed assets revalued	-	(10,534,008)	-	-	-	(10,534,008)
Balance on December 31, 2023	-	118,996	157,293,502	6,939,034	-	164,351,532
NET ACCOUNTING VALUE						
Net book value on December 31, 2022 restated	203,674,702	267,974,628	116,017,845	3,143,980	9,087,755	599,898,910
Net book value on December 31, 2023	204,794,472	312,651,028	128,949,308	3,295,653	42,671,079	692,361,541

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO INDIVIDUAL FINANCIAL STATEMENTS
FOR THE YEAR ENDED ON DECEMBER 31, 2023
(all amounts are expressed in lei ("RON"), unless otherwise specified)

11. TANGIBLE FIXED ASSETS (continued)

The most important investment projects carried out in 2023 are the following:

1. The sewage system

The work on this investment began in 2019 and it will be completed in 2023. The current sewerage system is about 60 years old, showing advanced corrosion, due to the chemicals channeled and the mechanical action of the water. In the course of time, several major accidents occurred throughout the territory of the Antibiotice S.A. platform. Considering the high level of wear and tear, there is a risk of other damages occurring that could have had major implications on the company's activities and on the environment, which is why the creation of a new sewage system was imperatively necessary.

2. Photovoltaic plant of 2.5 MW

The achievement of this investment objective was based on the following prerequisites:

- the evolution of electricity prices;
- the growing forecast of the amount of energy purchased - the opportunity to finance energy capacities from renewable sources from the Romanian Recovery and Resilience Plan funds;
- the integration of sustainability principles in the company's development processes and strategies.

The expected results after the implementation of the investment are the following:

- reducing the amount of electricity purchased by about 3300 MWh per year, that is 26% compared to the level of consumption in 2021;
- the reduction of carbon dioxide emissions by about 558.5 tons/year;
- the development of the company's currently unused land.

The investment will be completed in 2024.

3. Photovoltaic plant of 1.2 MW

The photovoltaic panels related to this power plant will be placed on top of 13 buildings, for which, following technical expertise, it was found that the roofs bear additional loads. An annual production of about 1,840 MWh is estimated, representing about 15% of the annual electricity consumption of Antibiotice S.A. from 2021. The investment will be completed in 2024.

4. The outdoor lighting and the video surveillance

The outdoor lighting system on the Antibiotice S.A. platform was developed in several stages, always adapting to the changes brought by the demolition of some buildings and construction trestles or with the installation of video surveillance cameras.

Currently, most of the existing devices have functional deficiencies and do not ensure an optimal level of light flow, which leads to physical insecurity, the impossibility of monitoring perimeter areas both with human personnel and by taking images through video surveillance cameras, inadequate lighting of car and pedestrian traffic areas in the premises. The work on this investment objective started in 2023 and will be completed in 2024.

5. Drinking water supply system

The modernization works of the drinking water supply network began in 2017 and consisted in the replacement of steel pipes in various stages of wear with polypropylene pipes. Until now, sections representing about 50% of the total length of the drinking water supply network have been modernized. The remaining sections to be modernized will be completed in stages, until 2026.

ANTIBIOTICE S.A.**EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS****FOR THE PERIOD ENDING ON DECEMBER 31, 2023****(all the amounts are expressed in lei ("RON") unless provided otherwise)**

11. FIXED ASSETS (continued)**6. Warehouse for finished pharmaceutical products**

This investment meets the needs of Antibiotice S.A. to have a modern and efficient warehouse, capable of managing the planned future production. With a storage capacity adapted to the anticipated growth until 2030, this warehouse will serve as an essential hub for the storage and distribution of pharmaceuticals. Construction works began in August this year. Currently the resistance structure of the building has been completed. The construction works will be completed in 2024.

7. Other investments

Upgrading of production and utility distribution installations (steam, condensate, electrical, etc.), development of the product portfolio through in-house research and licensing, refurbishment of research and quality control laboratories, upgrading of information technology, for the integrated management system (quality, environment, sustainability and occupational health and safety), for upgrading the existing sites and equipment.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei (“RON”) unless provided otherwise)

12. INTANGIBLE ASSETS

	Disposals, patents and other similar rights (externally generated)	Other intangible assets (internally generated)	Other intangible assets (externally generated)	Development expenditure (internally generated)	Development expenditure (externally generated)	Total intangible assets
COST						
Balance on January 1, 2022	11,913,379	8,790,342	4,197,131	23,964,095	407,137	49,272,084
Increases	362,606	1,184,050	-	7,971,650	808,325	10,326,631
Disposals/reductions	-	-	-	(2,857,070)	-	(2,857,070)
Balance on December 31, 2022 corrected	12,275,985	9,974,392	4,197,131	29,078,675	1,215,462	56,741,645
Balance on January 1, 2023 restated	12,275,985	9,974,392	4,197,131	29,078,675	1,215,462	56,741,645
Increases	841,177	-	-	13,220,959	950,027	15,012,163
Transfers	-	10,700,896	764,071	(10,471,332)	(993,635)	-
Balance on December 31, 2023	13,117,162	20,675,288	4,961,202	31,828,302	1,171,854	71,753,808
Cumulative depreciation						
Balance on January 1, 2022	7,924,207	7,310,982	4,197,131	-	-	19,432,320
Depreciation expense	423,833	1,089,549	-	-	-	1,513,382
Impairment	3,037,722	-	-	-	-	3,037,722
Balance on December 31, 2022 restated	11,385,762	8,400,531	4,197,131	-	-	23,983,424
Balance on January 1, 2023 corrected	11,385,762	8,400,531	4,197,131	-	-	23,983,424
Depreciation expense	425,274	1,705,435	112,977	-	-	2,243,686
Balance on December 31, 2023	11,811,036	10,105,966	4,310,108	-	-	26,227,110
Net book value						
On December 31, 2022 corrected*	890,223	1,573,861	-	29,078,675	1,215,462	32,758,221
On December 31, 2023	1,306,126	10,569,322	651,094	31,828,302	1,171,854	45,526,698

* For more details on 2022 corrections, see Note 23.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)
13. INVENTORIES

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Finished products	77,950,369	67,319,987	67,319,987
Raw materials	68,605,059	47,011,753	55,538,012
Goods	21,176,967	27,243,090	27,243,090
Consumables	223,865	316,640	316,640
Inventory items	9,959	19,626	19,626
Waste products	3,743	4,111	4,111
Packages	74,492	78,647	78,647
Products in progress	6,321,323	4,768,710	4,768,710
Inventories - gross value	174,365,777	146,762,564	155,288,823
Value adjustments for raw materials and consumables	(1,964,160)	-	-
Value adjustments for finished products	(9,511,394)	(21,770,690)	(11,380,126)
Value adjustments for goods	(2,675,739)	(2,497,446)	(1,248,723)
Total value adjustments	(14,151,293)	(24,268,136)	(12,628,849)
Total inventories - net value	160,214,484	122,494,428	142,659,974

14. TRADE AND SIMILAR RECEIVABLES

	Balance on December 31, 2023	Balance on December 31, 2022 (reported)	Balance on December 31, 2022 (restated)*
	RON	RON	RON
Short term receivables			
Trade receivables	238,897,257	214,490,809	214,490,809
Clients - invoices to be drawn up	(7,528,379)	(438,682)	(438,682)
Trade effects	10,393,167	4,180,578	4,180,578
Advances paid to suppliers of fixed assets	410,546	888,436	888,436
Advances paid to suppliers of inventories and services	1,451,944	412,734	412,734
Advances paid to employees	126	154	154
Other receivables	12,776,201	6,223,542	6,223,542
Additional adjustments for impairment	(20,628,873)	(29,354,652)	(21,724,353)
Balance at the end of the period	235,771,990	196,402,918	204,033,217

* For more details on 2022 corrections, see Note 23.

Changes in impairment adjustments for receivables.

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Balance at the beginning of the period	(21,724,353)	(24,863,762)	(24,863,762)
Impairment adjustment recorded in the statement of comprehensive income in relation to trade receivables	(1,095,480)	(4,490,890)	3,139,409
Balance at the end of the period	(20,628,873)	(29,354,652)	(21,724,353)

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

15. TRADE AND SIMILAR RECEIVABLES

The impairment adjustments for receivables are set up/canceled by applying the simplified approach of IFRS 9, the historical loss rate is:

December 31, 2023

IFRS 9	0 days	Between 1-30 days	Between 31-60 days	Between 61-90 days	Between 91-180 days	Between 181-365 days	Over 365 days	Total
Receivables	224,613,037	12,044,450	2,115,191	4,470	-	120,109	-	238,897,257
Historical loss rate	1%	3%	10%	24%	100%	100%	-	

31.12.2022 restated

IFRS 9	0 days	Between 1-30 days	Between 31-60 days	Between 61-90 days	Between 91-180 days	Between 181-365 days	Over 365 days	Total
Receivables	186,961,913	19,896,913	5,439,986	829,650	508,131	854,216	-	214,490,809
Historical loss rate	0,25%	1%	2%	39%	100%	100%	100%	

16. CASH AND CASH EQUIVALENTS

The cash and cash equivalents at the end of the financial year, as presented in the cash flow statement, can be reconciled to the related items in the balance sheet as follows:

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
Liquid assets at bank	1,792,024	1,718,889
Cashing effects	-	-
Cash and cash equivalents	15,906	8,565
Total	1,807,930	1,727,454

The company has accounts with commercial banks in Romania that are part of European banking groups or with state banks.

17. SHARE CAPITAL

	Balance on December 31, 2023	Balance on December 31, 2022
	RON	RON
Fully paid ordinary shares	67,133,804	67,133,804

The subscribed registered capital of the company on December 31, 2023 is 67,133,804 lei, the nominal value of a share being 0,1000 lei/share. The company has a total of 671,338,040 shares, giving equal rights to the shareholders of the company. Antibiotice S.A. has not issued shares giving preferential rights to its shareholders. In accordance with the provisions of IAS 29 - hyper-inflationary economies, the registered capital has been restated taking into account the inflation index communicated by the National Statistical Commission. It was applied starting with the balance determined according to GD 500/1994, from the date of contribution until 31.12.2003, the date on which the national economy was considered to be no longer hyper-inflationary. Subsequently, the share capital increased according to the historical amounts registered at the Trade Register.

ANTIBIOTICE S.A.**EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS****FOR THE PERIOD ENDING ON DECEMBER 31, 2023****(all the amounts are expressed in lei ("RON") unless provided otherwise)****17. SHARE CAPITAL (continued)**

As of 31.12.2012, in the balance sheet of the company there is a loss carried forward from the first-time application of IAS 29 "Financial Reporting in Hyper-inflationary Economies" which is proposed to be covered by the amount resulting from the application of IAS 29 "Financial Reporting in Hyper-inflationary Economies" as follows:

Result carried forward, loss on first-time application of IAS 29	197,701,352
Share capital adjustments - first-time application of IFRS	197,701,352

Reserves

Reserves include the following components:

Description	December 31, 2023	December 31, 2022 (reported)	December 31, 2022 (restated*)
Fixed assets revaluation reserves	268,354,743	132,338,377	235,426,925
Legal reserves	13,426,761	13,426,761	13,426,761
Deferred income tax recognised on equity	(42,936,784)	(21,174,138)	(37,668,305)
Other reserves	311,450,837	292,168,005	292,168,005
TOTAL	550,295,557	416,759,005	503,353,386

Shareholding structure

	Balance on December 31, 2023		Balance on December 31, 2022	
	Number of shares	% holding	Number of shares	% holding
MINISTRY OF HEALTH	355,925,135	53.0173	355925135	53.0173
INFINITY CAPITAL				
INVESTMENTS S.A. *	197,475,826	29.4153	181,515,771	27.0379
Other natural and legal entities	117,937,079	17.5674	133,897,134	19.9448
Total	671,338,040	100.0000	671,338,040	100.0000

* On 31.12.2022, the company was called SIF OLTENIA

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

17. SHARE CAPITAL (continued)

Revaluation reserve

The reconciliation between the opening and closing balance of the revaluation reserve is as follows:

	Period ending on December 31, 2023	Period ending on December 31, 2022 (reported)	Period ending on December 31, 2022 (restated)*
	RON	RON	RON
Balance at the beginning of period for revaluation reserve	235,426,926	135,893,766	135,893,766
Balance at the beginning of the period for deferred tax relating to the revaluation reserve	(37,668,306)	(21,743,000)	(21,743,000)
Transfer of revaluation reserve to retained earnings as a result of depreciation and disposals of property, plant and equipment, net of tax	(2,065,204)	(3,555,389)	(3,555,389)
Revaluation of tangible fixed assets	34,993,022	-	103,088,549
Decrease in deferred tax on revaluation reserve	485,889	568,862	568,862
Corporation tax postponed	(5,754,368)	-	(16,494,168)
Balance at end of period for revaluation reserve	268,354,744	132,338,377	235,426,926
Balance at the end of the period for deferred tax relating to the revaluation reserve	(42,936,785)	(21,174,138)	(37,668,306)
Reconciliation of revaluation reserves	225,417,959	111,164,239	197,758,620

The following describes the nature and purpose of each reserve within the equity:

Nature of the reserve	Description and purpose of the reserve
Fixed assets revaluation reserves	If the carrying amount of an item of property, plant and equipment is increased as a result of revaluation, then the increase shall be recognized in other comprehensive income and accumulated in equity as revaluation surplus. The revaluation reserves cannot be distributed and cannot be used to increase the registered capital.
Legal reserves	According to Law 31/1990 each year at least 5% of the profit is taken to form the reserve fund, until it reaches at least one fifth of the registered capital.
Other reserves	Other reserves include reserves representing tax facilities that cannot be distributed with implications on the recalculation of corporate income tax. The difference represents reserves made up of profits.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

17. SHARE CAPITAL (continued)

The result carried forward includes the following components:

Description	December 31, 2023	December 31, 2022 (reported)	December 31, 2022 (restated)
Result carried forward - surplus obtained from revaluation reserves	29,247,881	26,400,236	26,400,236
Result carried forward from error correction	12,958,610	-	-
Result carried forward from the use, at the date of transition to IFRS, of fair value as deemed cost	122,851,143	123,147,695	123,147,695
Profit and loss for the year	81,088,596	38,513,427	51,472,038
Distribution of profit	(16,611,671)	(30,523,566)	(30,523,566)
Total	229,534,759	157,537,792	170,496,402

DISTRIBUTION OF PROFIT

On 31.12.2023 Antibiotice S.A. recorded a net profit of 81,085,595 lei, which is proposed for distribution as follows:

Description	December 31, 2023	December 31, 2022 (reported)	December 31, 2022 (restated)
Dividends	30,927,369	5,318,500	5,318,500
Other reserves	19,233,858	33,194,927	46,153,537
Company's own sources of funding	30,927,369	-	-
Total	81,088,596	38,513,427	51,472,037

18. TRADE AND SIMILAR DEBTS

The debts mainly include trade and other short-term financial debts (debts to employees, debts relating to taxes and duties, debts relating to short-term bank loans, debts to sundry creditors) which are initially recognized at fair value and subsequently carried at depreciated cost using the effective interest method.

	Balance on December 31, 2023 RON	Balance on December 31, 2022 (reported) RON	Balance on December 31, 2022 (restated)* RON
Trade debts	73,656,235	58,755,589	65,400,691
Effects to be paid	2,883,929	2,182,409	2,182,409
Debts from acquisition of fixed assets	40,406,065	12,839,306	12,839,306
Other current debts*	33,405,736	11,997,193	18,676,528
Advance payments received based on orders	428,397	292,894	292,894
Total	150,780,362	86,067,391	99,391,828

*Other current debts

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

18. TRADE AND SIMILAR DEBTS

	Balance on December 31, 2023	Balance on December 31, 2022 reported	Balance on December 31, 2022 (restated)*
	RON	RON	RON
Wage and salary debts to employees and social security debts**	29,726,847	8,284,752	14,964,087
Unclaimed employee rights	34,184	13,431	13,431
Other creditors	1,129,950	1,116,573	1,116,573
Interests payable	96,359	81,217	81,217
Other taxes payable	38,978	6,718	6,718
Dividends payable	2,379,418	2,494,502	2,494,502
Total	33,405,736	11,997,193	18,676,528

**these debts include:

- 2.865.047 lei remuneration due to employees representing the settlement of December 2023 paid in January 2024;
- 42.180 lei represent the amounts withheld from staff rights according to legal regulations, related to December 2023, which will be paid to third parties;
- 4.299.300 lei amounts owed to employees representing awards as well as debts to employees represented by guarantees withheld from employees as required by law;
- 3.476.901 lei represent the amounts withheld according to the legal requirements from the gross income of the employees representing the social security contribution;
- 1.367.942 lei represent the amounts withheld according to the legal requirements from the gross income of the employees representing the social security contribution;
- 310,710 lei represents the labor insurance contribution due by the unit for staff rights related to December 2023;
- 941,930 lei represents the income tax withheld as required by law from the gross income of employees for December 2023;
- 3.000.000 lei representing the amounts due for employee profit-sharing;
- 8.062.407 lei represent the management remuneration;
- 5.310.452 lei represent un-achieved rest leave;
- 49,978 lei personal material aid due.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

18. TRADE AND OTHER DEBTS (continued)

Value-added tax

The tax period for VAT is the calendar month, value added tax is accounted for on the basis of the VAT statement. The amount of VAT to be paid is due to the tax authorities by the 25th of the following month, irrespective of the level of debt recovery from customers. The tax authorities allow VAT to be settled on a net basis. If the deductible VAT is higher than the VAT collected, the difference is refundable at the request of the company. The VAT relating to sales and purchases that have not been settled at the end of the reporting period is recognized in the statement of financial position at net value and presented separately as a current asset or liability. In cases where adjustments for impairment of receivables have been recorded, the impairment loss is recorded for the amount of the receivable including VAT. The related VAT must be paid to the state budget and can be recovered only in the case of the debtor's statute of limitations, following the bankruptcy decision.

The claw-back tax

The claw-back tax regulated by the Emergency Ordinance no. 77/2011 on the establishment of some contributions for financing some health expenses, is paid quarterly to the State Budget for **prescription drugs**, included in the national health programs, with or without personal contribution, used in outpatient treatment on prescription through open circuit pharmacies, for those used in hospital treatment, paid from the Single National Health Insurance Fund and from the budget of the Ministry of Health.

Current taxes and duties payable

	Period ending on December 31, 2023	Period ending on December 31, 2022 reported (reported) RON	Period ending on December 31, 2022 restated* (corrected) RON
Claw-back tax	9,691,498	8,169,643	2,872,173
Other special funds	140,052	111,027	111,027
Total	9,831,550	8,280,670	2,983,200

19. BANK LOANS

The bank loans on December 31, 2023 and December 31, 2022 are as follows:

Financing bank	Type of financing	Date of granting	Balance on December 31, 2022	Balance on December 31, 2023	Short-term on December 31, 2023	Long-term on December 31, 2023	Period
Unicredit Bank	credit line - working capital	8/17/2016	34,008,116	29,552,092(*)	18,858,118	-	84 MONTHS
Unicredit Bank	investment credit	5/3/2018	46,973,501	36,750,203(**)	10,693,974(***)	36,750,203	120 MONTHS
TOTAL			80,981,617	66,302,295	29,552,092	36,750,203	

(*) working capital financing credit line and part of the short-term investment credit

(**) long-term investment credit

(***) short-term investment credit

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

20. INVESTMENT SUBSIDIES

	Period ending on December 31, 2023	Period ending on December 31, 2022
	RON	RON
January 1	2,163,611	2,466,590
Subsidy entries	-	-
Transferred to the statement of comprehensive income	270,907	302,979
On December 31, 2023/December 31, 2022	1,892,704	2,163,611
Current	306,289	306,289
Fixed	1,586,415	1,857,322

The amounts reflected in the investment grants account represent amounts received by the company in the form of grants over the last 10 years for investments in environmental protection as well as in increasing the competitiveness of products through funding from the Ministry of Economy, Ministry of European Funds, Ministry of Environment, Trade and Business Relations.

The objective of the subsidy received from the Ministry of European Funds for the Intelligent Energy Monitoring System is to reduce energy consumption by 1%. In 2023, there are no funding conditions that have not been met.

21. CONTINGENT LIABILITIES

Antibiotice S.A. has no contingent liabilities on December 31, 2023 and on December 31, 2022.

22. PRESENTATION OF AFFILIATED PARTIES

22.1 - Nature of relationships with related parties

For the purpose of presentation in the individual financial statements in accordance with IAS 24, the Company monitors its relationships with the related entities. During 2022 and 2023, the shareholder Infinity Capital Investments S.A. acquired shares of the Company, increasing its shareholding in the share capital of Antibiotice S.A. from 27.0379% to 29.4153%, thus becoming an associated entity with significant influence. The shareholder Infinity Capital Investments S.A. has two members in the Management Board of the Company.

22.2 - Amounts due and receivable from related parties

At the end of the financial years 2022 and 2023, the company had no receivables or debts to the related entity.

22.3 - Information on transactions with related parties

During the financial years 2022 and 2023, the Company did not enter into any commercial transactions with the related entity.

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

23. PRIOR PERIOD CORRECTIONS

- The Company recorded additional adjustments for inventories at selling price, these should have been recorded at cost of production; as a result, the Company recorded a correction on 31.12.2022, which increases the value of inventories and the result for 2022 by RON 11,639,287.
- The Company did not record the purchase of raw materials from certain suppliers according to the incoterm conditions; as a result, the Company recorded a correction on 31.12.2022, which increases the value of inventories and current liabilities by RON 8,526,259.
- Following the revaluation carried out on 31.12.2023 due to the significant value identified, the Company decided to revalue the land and buildings also on 31.12.2022; therefore the Company recorded a correction on 31.12.2022 which increases the value of land, buildings and revaluation reserve by RON 13,741,550 (land), RON 89,346,999 (buildings) as well as by RON 103,088,549 (revaluation reserve).
- The company has in the past incurred expenses related to new software. As the agreement with the supplier has been canceled, the Company has recorded an additional adjustment for the capitalization recorded for this software; as a result, the Company has recorded a correction on 31.12.2022, which decreases the value of intangible assets and the result for 2022 by RON 3,037,722.
- The Company has decided to apply the simplified approach of IFRS 9 "Financial Instruments" to calculate the additional adjustments for customers; as a result, the Company has recorded a correction on 31.12.2022, which increases the amount of receivables and the result for 2022 by RON 7,630,299.
- The Company has recorded debts to employees related to bonuses and unused leave as provisions and not as personnel related debts; therefore the Company has recorded a correction on 31.12.2022, which increases the value of current debts and decreases the value of provisions by RON 6,679,335.
- During the year 2023, the Company won the Claw-back tax lawsuit related to the year 2020, also during the year 2023 certain past debts related to invoices that never arrived were canceled; as a result, the Company recorded a correction on 31.12.2022, which decreases the value of current debts and increases the value of the result of the year 2022 by RON 7,178,627.
- After making the corrections described above, the Company also made corrections to the deferred tax arising both from the above corrections and from an error in the calculation of the deferred tax relating to the difference in the lifespan of the accounting fixed assets register and the tax register. As a result, the Company has recorded a correction on 31.12.2022, which increases the amount of deferred tax by RON 26,946,049, decreases the amount of the revaluation reserve by RON 16,494,168 and increases the 2022 expense by RON 10,451,881.

ANTIBIOTICE S.A.**EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS****FOR THE PERIOD ENDING ON DECEMBER 31, 2023****(all the amounts are expressed in lei ("RON") unless provided otherwise)****23. CORRECTIONS OF THE PREVIOUS PERIOD (continued)**

The effect of the correction of accounting errors on the comparative amounts in the individual statement of comprehensive income and the individual statement of financial position as of the date of this report are summarized below:

	Period ending on December 31, 2022 (reported)	Adjustments	Period ending on December 31, 2022 (restated)
Income from the agreements with customers, of which:	483,724,186	-	483,724,186
<i>Income from the sale of finished products</i>	387,506,130	-	387,506,130
<i>Income from the sale of products made on other manufacturing sites</i>	95,160,681	-	95,160,681
<i>Income from the provision of services</i>	1,057,375	-	1,057,375
Other operating incomes	2,033,372	5,297,470	7,330,842
Subsidy income	302,979	-	302,979
Changes in inventories of finished products and work in progress	11,689,110	-	11,689,110
Income from fixed asset projects	13,779,091	-	13,779,091
Expenditure on raw materials, consumables used and products made at other manufacturing sites	(177,117,257)	-	(177,117,257)
Expenditure on employee benefits	(122,940,724)	2,825,805	(125,766,529)
Transport costs	(4,171,593)	-	(4,171,593)
Expenditure on utilities	(22,026,479)	-	(22,026,479)
Depreciation and impairment adjustments for fixed assets, net	(22,269,554)	(3,037,722)	(25,307,276)
Adjustments for impairment of current assets, net	(20,328,387)	19,269,586	(1,058,801)
Reversed provisions, net	(2,825,805)	(2,825,805)	-
Sponsorships, donations	(450,214)	-	(450,214)
Other expenditure	(92,898,339)	1,881,157	(91,017,182)
Operating result	46,500,386	23,410,491	69,910,877
Exchange rate difference, net	(797,515)	-	(797,515)
Expenditure for the interests, net	(3,589,852)	-	(3,589,852)
Other financial expenses	(209,789)	-	(209,789)
Financial result	(4,597,156)	-	(4,597,156)
Pre-tax profit	41,903,230	23,410,491	65,313,721
Expense for the corporate tax	(3,389,803)	(10,451,881)	(13,841,684)
Profit for the financial year	38,513,427	12,958,610	51,472,037
Total overall result	38,513,427	12,958,610	51,472,037
Result per basic and diluted share	0.0574		0.0767
Profit for the financial year	38,513,427	12,956,610	51,472,037
Other elements of the overall result			
Items that will not be classified to profit or loss			
Revaluation of tangible fixed assets	-	86,594,381	86,594,381
Other elements of the overall result	-	86,594,381	86,594,381
Total overall result	38,513,427	99,550,991	138,066,418

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

23. CORRECTIONS OF THE PREVIOUS PERIOD (continued)

	Period ending on December 31, 2022 (audited)	Adjustments	Period ending on December 31, 2022 (restated)
Assets			
Non-current assets			
Tangible assets	496,810,361	103,088,549	599,898,910
Intangible assets	35,795,943	(3,037,722)	32,758,221
Total fixed assets	532,606,304	100,050,827	632,657,131
Current assets			
Inventories	122,494,428	20,165,546	142,659,974
Trade and similar receivables	196,402,918	7,630,299	204,033,217
Expenses registered in advance	3,243,331	-	3,243,331
Cash and cash equivalents	1,727,454	-	1,727,454
Total current assets	323,868,131	27,795,845	351,663,976
Total assets	856,474,435	127,846,672	984,321,107
Equity and debts			
Equity			
Subscribed capital	67,133,804	-	67,133,804
Reevaluation reserves	111,164,239	86,594,381	197,758,620
Legal reserves and other reserves	305,594,766	-	305,594,766
Carried forward result	157,537,792	12,958,610	170,496,402
Total equity	641,430,601	99,552,991	740,983,592
Long-term debt			
Bank loans and debts	46,973,501	-	46,973,501
Investment subsidies - non-current portion	1,857,322	-	1,857,322
Debts on deferred taxes	30,871,210	26,946,049	57,817,259
Total long-term debts	79,702,033	26,946,049	106,648,082
Current liabilities			
Trade and similar debts	86,067,391	13,324,437	99,391,828
Bank loans	34,008,116	-	34,008,116
Other debts	8,280,670	(5,297,470)	2,983,200
Investment subsidies - current portion	306,289	-	306,289
Provisions	6,679,335	(6,679,335)	-
Total current debts	135,341,801	1,347,632	136,689,433
Total debts	215,043,834	28,293,681	243,337,515
Total equity and debts	856,474,435	127,846,672	984,321,107

ANTIBIOTICE S.A.
EXPLANATORY NOTES TO THE INDIVIDUAL FINANCIAL STATEMENTS
FOR THE PERIOD ENDING ON DECEMBER 31, 2023
(all the amounts are expressed in lei ("RON") unless provided otherwise)

24. EVENTS AFTER THE REPORTING PERIOD

There are no significant subsequent events not disclosed in these individual financial statements.

25. OTHER INFORMATION

At the date of these financial statements Antibiotice S.A. has not prepared a non-financial statement. For the year 2023 the Company will issue by 30.06.2024 the sustainability report prepared in accordance with GRI standards.

26. INFORMATION RELATING TO THE AUDIT OF INDIVIDUAL FINANCIAL STATEMENTS

A fee of 424,887 RON (85,900 EUR) was charged for the audit of individual financial statements, of which:

- The fee for the audit of the individual financial statements as of 31.12 2023 is 340,798 RON.
- The fee for the review of the interim financial statements is 84,089 RON.

Authorized by the Management Board on: 13.03.2024.

General Director
Ec. Ioan NANI

Financial manager,
Ec. Paula Luminita COMAN

Report date: **16.04.2024**

Name of issuing company: **Antibiotice SA**

Headquarters: **Iași, 1 Valea Lupului St., postal code 707410, <http://www.antibiotice.ro>**

E-mail: **relatiicuinvestitorii@antibiotice.ro**

Telephone/fax no. **0232.209.000 / 0232.209.633**

Unique registration code in the Trade Register Office: **RO1973096**

Order number in the Trade Register: **J22/285/1991**

Subscribed and paid-up capital: **67.133.804 lei**

Regulated market on which the securities issued are traded: **Bucharest Stock Exchange**

Notice of availability - 2023 Annual Report

Antibiotice Iași informs the investors that the **Report at 31.12.2023**, is available through the *Bucharest Stock Exchange, Financial Surveillance Authority* as well as through its website: www.antibiotice.ro (Investors/Financial Information /Annual Report 2023).

We mention the fact that the above-mentioned report can also be obtained from our company's headquarters (Investor Relations, fax no. 0372. 065.633, e-mail: relatiicuinvestitorii@antibiotice.ro).

General Director,
ec. Ioan NANI

Financial Director,
ec. Paula-Luminița COMAN